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Abstract
Inflammation is the response of higher multicellular animals to injury and noxious pathogens
and is followed by the remodeling of damaged tissues to their previous healthy state. Many
specialized cells are recruited to orchestrate the inflammatory response but these cells must
be removed to allow the restoration of normal tissue structure and function. Some recruited
cells leave inflamed tissues by emigration to lymph nodes whilst others, having served their
purpose, die by 'apoptosis' or programmed cell death. Apoptotic 'corpses' are removed by
phagocytosis, a process by which cells or similar particles, are captured, engulfed and
ingested by other cells. In higher animals, 'professional' phagocytes, such as Macrophages
(Mcp), are primarily responsible for the removal of apoptotic cells from inflamed tissues.
The removal of apoptotic cells prevents their inner contents from being released and
inflicting secondary damage upon healthy cells. Furthermore, the act of phagocytosis of an
apoptotic cell induces an anti-inflammatory, reparative phenotype in Mcp. It has now
become clear that human diseases can arise from, or be exacerbated by defective clearance of
apoptotic cells by Mcp. The processes by which Mcp remove apoptotic cells is clearly of
importance in our understanding of inflammatory disease.
I began this thesis by examining the rate at which Mcp phagocytosed apoptotic cells in vivo
using the murine peritoneal cavity as a model system. I noted that the number of Mcp
recovered from the peritoneal cavity fell dramatically as apoptotic cells were phagocytosed.
This disappearance of Mcp was not merely a non-specific effect of manipulating the
peritoneal cavity but was a consequence of the phagocytosis of apoptotic cells. The
mechanism underlying this 'Macrophage Disappearance Reaction' (MDR) was investigated
and two manipulations - the instillation of hyularonidase enzyme or unfractionated heparin -
respectively increased or decreased the magnitude of the MDR without affecting the rate of
apoptotic cell clearance.
I then turned my attention to the fate of the disappearing Mcp, focusing on the omentum, an
organ within the peritoneal membrane highly adapted for the initiation of acute inflammatory
reactions and innate immunity. A series of adoptive transfer experiments showed that, after
phagocytosing apoptotic cells, intraperitoneal Mcp migrated to specialized coelomic-
associated lymphoid tissue (CALT) called 'Milky Spots' within the omentum. Further
experiments showed that some Mcp subsequently left the peritoneal cavity and migrated to
parathymic lymph nodes, a known destination for inflammatory peritoneal Mcp during the
resolution of peritonitis. I then returned to the starting point of this thesis, ie the rate of
phagocytosis of apoptotic cells in vivo, and developed a powerful new in vivo phagocytosis
assay using omental milky spots as the experimental model.
This thesis has contributed to a wider and deeper understanding of the clearance of apoptotic
cells by Mcp and the fate of phagocytic peritoneal Mcp. The hitherto unrecognized role of the
omentum in the clearance of peritoneal apoptotic cells and Mcp emigration should increase
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CHAPTER 1 - INTRODUCTION
1.1 Inflammation
Inflammation is the response of tissues to injury, the classical injury being bacterial
infection. There are four cardinal clinical signs of inflammation - reddening, heat,
swelling and pain, often Latinised to rubor, calor, tumor and dolor. These clinical
features reflect the typical physiological changes that occur during acute
inflammation. An increased blood supply causes reddening and warmth of inflamed
tissue. Local vessels also become permeable to leukocytes and plasma which enter
the inflamed tissue causing swelling. Noxious chemicals and other molecules
stimulate local nerve fibres, causing the sensation of pain.
In the early stages of inflammation vast numbers of blood borne neutrophils (PMNs)
enter injured tissue. The vascular endothelium upregulates adhesion molecules -
selectins immediately followed by integrins and immunoglobulin-like cell adhesion
molecules (ICAMs) - which allow anchorage ofPMNs to the endothelium, a process
called tethering. Marginated PMNs then cross the endothelium and migrate
following a chemokine gradient to the nidus of injury. In bacterial infections, PMNs
phagocytose pathogens opsonised with complement or antibody. Phagocytosed
bacteria are killed by exposure to intracellular granules containing bacteriocidal
substances including proteases, myeloperoxidase, hydrolase enzymes, lysozymes and
defensins. PMNs may also degranulate releasing their bacteriocidal contents into the
injured tissue. Unfortunately, the contents of PMN granules may damage and kill
bystander resident cells as well as bacteria. Whilst these bystander cells may be
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replaced in time, the tissue's capacity for regeneration may be exceeded by a very
large loss of resident cells. In such circumstances, cells may be replaced by acellular
scar tissue with a consequent loss of tissue function. Therefore, successful resolution
of inflammation demands that PMN activity is limited to that required for pathogen
removal with minimal resident cell damage. PMNs do not emigrate from sites of
inflammation so they must be deactivated and removed within inflamed tissues. This
is effected by a form of programmed cell death called apoptosis.
1.2 Apoptosis
The word 'apoptosis' translates from ancient Greek as 'leaves falling from the tree'.
Apoptosis was first described by Kerr et al in a seminal 1972 paper (Kerr et al.,
1972). The authors' choice of name for their discovery reflected their belief that
apoptosis was a physiologically and immunologically silent form of cell death. Over
the last three decades, it has become apparent that apoptosis is involved in a wide
variety of biological processes in multicellular organisms. During embryogenesis,
organ development produces unwanted cells which are removed by apoptosis, the
classical example being loss of interdigital web spaces during vertebrate limb
development (Zakeri and Ahuja, 1994). Apoptosis is also involved in post-
embryonic tissue remodeling, such as regression of the tadpole tail (Kerr et al., 1974)
or deletion of autoreactive thymocytes during T cell maturation (Wyllie, 1980).
Apoptosis is an important way of deleting irreparably damaged cells too. This is
3
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especially important for the removal of cells which have sustained chromosomal
DNA damage and are at risk of malignant transformation (Danilevicius, 1973).
Cells undergo a well-defined sequence ofmorphological changes during apoptosis
(Kerr et ah, 1972). The first stage involves the dissociation of the cell from its
neighbours. Then specialised organelles become tightly packed together as the
cytoplasmic volume decreases. Next come changes in the nucleus. Chromatin
condenses to the peripheral region, the nucleolus disintegrates and finally fragments
in a process called karyorrhexis. Lastly the cytoplasmic membrane loses its
connections with the underlying cytoskeleton and apoptotic blebs are formed. These
blebs may contain fragments of the nucleus or cell organelles and are potentially
autoantigenic (Casciola-Rosen et ah, 1994).
Apoptosis is executed by a specialised sequence of biochemical events. The
molecular components of these pathways are pre-formed and present within all cells
in an inactive state. This allows the swift execution of the apoptotic program
following the addition of a death signal or the removal of a survival signal (or both).
The key players in apoptosis are a family of enzymes known as the caspases (Miura
et ah, 1993). Caspases are so called as they are cysteine proteases that cleave
proteins at sites following aspartate residues (hence c-asp-ase). One particular
unusual feature of some caspases is their ability to activate each other when brought
into close proximity - the so called 'induced-proximity' phenomenon. This
adaptation aids the rapid activation of the apoptotic program following an
4
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appropriate stimulus. Caspases show high evolutionary conservation and most family
members play direct roles in apoptosis (Hengartner, 2000).
The initiating pathways can be broadly divided into a 'death receptor' and
'mitochondrial' pathways; both converge on a common execution pathway. The
detailed biochemistry of these pathways is complex and further reading is
recommended (Hengartner, 2000). What follows is a simplified version of the
current biochemical model of apoptosis.
5
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Schematic diagram of Fas-induced apoptosis. Extracellular fas-ligand binds to Fas (CD-95) which
associates to form trimers. Fas associated death domains (FADD) are recruited to Fas trimers and
they in turn recruit pro-caspase-8 molecules to the FADD death effecter domain (DED). Proximity
activation of pro-caspase 8 results in the formation of caspase-8 hetero-tetramers which activate
caspase-3, the trigger for the final pathway of apoptosis.
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Fas-ligand binds to Fas and promotes the formation of Fas trimers. Fas trimers then
recruit Fas associated death domains (FADD) which in turn recruit multiple pro-
caspase-8 molecules to the FADD death effector domain (DED). The aggregation of
procaspase-8 molecules causes induced proximity activation and the formation of
caspase-8 hetero-tetramers. Caspase-8 hetero-tetramers induce the activation of
caspase-3 which initiates execution of the final pathway of apoptosis.
The second major pathway which initiates apoptosis is the intracellular
mitochondrial pathway. Mitochondria contain pro-apoptotic molecules that, whilst
harmless within the mitochondrion, induce apoptosis if released into the cytoplasm.
Certain injurious stimuli, including DNA damage, oxidative stress or hypoxia cause
mitochondrial membrane pores to open allowing cytochrome c and other pro-
apoptotic mediators to enter the cytoplasm. Cytoplasmic cytochrome c associates
with pro-caspase-9 and Apaf-1 to form the so-called apoptosome. The apoptosome
promotes the conversion of pro-caspase-3 to caspase-3 which then induces the
execution phase of apoptosis.
The final execution pathway caspases (3, 7 and 10) cleave specific protein targets
within the cell, in some cases destroying them, in other cases causing activation of
other enzymes. One of the enzymes activated is the caspase-activated DNAse
(CAD) which causes the cleavage of chromosomal DNA; a process long identified as
a hallmark of apoptosis (Enari et al., 1998, Wyllie, 1980). Other enzymes cause the
breakdown of proteins responsible for cytoskeletal and nuclear structural integrity.
7
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Though the effects of the caspases are observed throughout the cell, it would be a
mistake to think they were random or imprecise. Unlike necrosis, cell death resulting
from a failure of cell membrane integrity, apoptosis is an ordered and controlled
form of cell death.
1.3 Apoptosis, macrophages and phagocytosis
Apoptosis alone does not remove PMNs from inflamed tissue though it does prevent
further degranulation (Whyte et al., 1993). However, apoptotic cells can themselves
induce inflammation or auto-immunity, a subject covered later in this chapter.
PMNs must be removed in order for the successful resolution of inflammation and
this removal is achieved by phagocytosis.
Phagocytosis is the process by which cells engulf and digest other cells, cellular
debris and other cell-sized particles. Most cells can perform phagocytosis but higher
organisms have 'professional phagocytes'; cells specialised for efficient
phagocytosis and to effect appropriate immune responses to the material they engulf.
In vertebrates these cells are the macrophages (Mcp).
Mcp develop in the bone marrow from CD34+ progenitor cells and enter the
circulation as monocytes (Jandl James, 1996). Starting in the later stages of
embryonic development, monocyte-derived Mcp take up residence in all tissues
where they act as sentinels for infection and injury. The functions ofMcp can be
8
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broadly categorised as phagocytosis, cell killing, cytokine production and antigen
presentation. Their defining function in relation to apoptotic cells is phagocytosis
however M(p are also involved in tissue repair. For example, in a carbon
tetrachloride (CCI4) induced reversible model ofmurine hepatic injury, Mcp persist
within scars throughout the recovery phase (Duffield et al., 2005). The changing role
ofMcps at different phases of the reparative process was illustrated by M(p depletion
experiments. These experiments used transgenic mice in which Mcp expressed the
human heparin binding EGF protein (hb-EGF - the diphtheria toxin receptor)
(Duffield et al., 2005, Cailhier et al., 2005). Mips were selectively depleted
following the administration of diphtheria toxin, whereas other murine cells were
unharmed by diphtheria toxin. After the induction of CCI4 hepatic injury, the
depletion ofMcp at the height of the injurious phase results in reduced hepatic
scarring when compared with Mcp-replete controls (Duffield et al., 2005).
Conversely, Mcp depletion during the later recovery phase resulted in failed matrix
degradation (Duffield et al., 2005).
Before phagocytosis can occur, a Mcp must come into direct contact with apoptotic
cells. Unlike apoptotic cells, Mcp are highly motile and migrate through tissues under
the influence of chemokines. Recruited inflammatory Mcp traffic through injured
tissues in hours or days (Melnicoff et al., 1989). In contrast, resident tissue Mcp
remain in non-inflamed tissue for much longer periods; up to 49 days in the
peritoneal cavity (Melnicoff et al., 1988a) and for many months or years in the case
of osteoclasts (Vaananen et al., 2000). Chemokines, released by injured or
9
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bystander resident cells or by leukocytes, recruit Mcp to sites of injury. It has recently
been shown that apoptotic cells also secrete chemokines. Smooth muscle cells
conditionally over-expressing FADD were shown to synthesise and secrete the PMN
and monocyte chemokines IL-8 and MCP-1 during apoptosis (Schaub et al., 2000).
Following in vivo transplantation and the induction of apoptosis, these same smooth
muscle cells produced IF-8 and MCP-1 initiating monocyte-derived M(p and PMN
recruitment. Whilst the release of chemokines may exacerbate inflammation, it may
also increase the clearance of apoptotic cells via the recruitment ofMcp.
Once Mcp and apoptotic cells are in direct contact, the process of phagocytosis proper
can begin. This can be divided into two stages; the tethering of the apoptotic cell and
its ingestion and digestion in a phagosome.
10
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Figure 2. Schematic diagram ofphagocytosis of an apoptotic cell
Stage 1 Tethering and engulfment
Molecular bridges tethering
Stage 2 Ingestion into phagolysosome
Schematic diagram of phagocytosis. Initial stage involves the tethering of the apoptotic cell within a
pseudopodial extension of the Mcp. Tethering is mediated by molecular bridges of apoptotic cell
ligands to receptors on the M(p (upper figure). Cytoskeletal rearrangements within the M<p result in
pseudopodial fusion and the engulfment of the apoptotic cell within a phagolysosome where
'digestion' of the apoptotic cell can occur.
11
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Apoptotic cells display a number of different motifs on their outer cell membrane
which are recognised by receptors on the Mcp. These apoptotic cell motifs are
sometimes called 'eat me' signals (Savill and Fadok, 2000). One of the most
extensively studied of the 'eat me' signals is the aminophospholipid molecule
phosphatidylserine (PS). PS is a normal component of the cell membrane but it is
usually localised to the inner cell membrane leaflet by the action of the enzyme
aminophospholipid translocase (Bretscher, 1972). During apoptosis scramblase
enzymes facilitate the translocation of PS to the outer cell membrane leaflet (Fadok
et al., 1992b). This appears to be an event unique to apoptosis and occurs in vivo in a
wide variety of vertebrates and invertebrates (van den Eijnde et al., 1998) and
implies a very important role for PS in apoptosis.
A large body of experimental data indicates that PS is a key player in the
phagocytosis of apoptotic cells. Early evidence for this came from Fadok, who
studied the phagocytosis of apoptotic cells by different populations ofMcp (Fadok et
al., 1992a). Fadok demonstrated that the the phagocytosis of apopotic cells by
murine peritoneal Mcp was inhibited in the presence of PS liposomes. This implied
the existence of a Mcp-borne receptor which recognized PS on the surface of target
apoptotic cells. Fadok also observed that bone marrow-derived murine Mcp used a
different, PS-independent mechanism to phagocytose apoptotic cells (Fadok et al.,
1992a). Further evidence for the role of PS in phagocyte-apopotic cell interaction
came from a later observation that annexin V (which binds to and obscures PS on
12
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the surface of apoptotic cells (Koopman et al., 1994)) significantly inhibits the
engulfment of apoptotic cells by phagocytes (Krahling et ah, 1999).
The identification of the receptor for PS has been the subject ofmuch investigation
and controversy. Fadok concluded that 'stimulated' peritoneal Mcp expressed a
receptor for PS whereas unstimulated (bone marrow derived) Mcp did not (Fadok et
al., 1992a). Fadok then created a monoclonal antibody (mAb 217) which bound to
the surface of stimulated Mcp, binding which was inhibited by PS vesicles (Fadok et
al., 2000). Furthermore, mAb 217 also inhibited the phagocytosis of apoptotic cells
(Fadok et al., 2000). These strands of evidence suggested that the antigenic target of
mAb 217 was the PS receptor. Later experiments by the same group offered insights
into the function of this putative PS receptor. The presence of PS on the surface of
surrogate particles did not affect their tethering to Mcp but was required for later
engulfment (Hoffmann et al., 2001). The presence ofmAb 217 triggered the
phagocytosis of bound, previously unphagocytosed cells (Hoffmann et al., 2001).
These observations were interpreted as indicating that the PS receptor was not
involved in the tethering of apoptotic cells but instead triggered a signaling cascade
resulting in the engulfment of tethered apoptotic cells by Mcp.
Fadok's group then investigated potential antigens for mAb 217 and identified a
47kDa protein as the most likely candidate (known henceforth as the PS receptor
(PSR)) (Fadok et al., 2000). Genes encoding the PSR in humans and C. elegans were
also identified. Transfection of human or nematode PSR genes into cells lacking
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phagocytic capacity conferred a new, albeit inefficient, ability to phagocytose
apoptotic cells (Hoffmann et al., 2001, Wang et al., 2003). Furthermore, the
transfection ofPSR-expressing cells with small inhibitory RNA (siRNA)
corresponding to the PSR gene product lead to reduced binding ofmAb 217 and
reduced phagocytosis of apopotic cells (Hoffmann et al., 2001).
The sum of these data offered compelling evidence that the true PSR had been
identified. However, more recent work has cast significant doubt on this. Knock out
mice and zebrafish lacking the PSR gene have been created. These animals display
similar patterns of abnormal embryonic development with brain, lung (in mice) and
cardiovascular development most severely affected (Hong et al., 2004, Bose et al.,
2004, Kunisaki et al., 2004). These groups reported contradictory findings with
regard to the clearance of apoptotic cells; Kunisaki et al. identified defective
phagocytosis whereas Bose et al. did not (Kunisaki et al., 2004, Bose et al., 2004).
The mice used to generate these knock out animals had different genetic
backgrounds which could have explained the different observations regarding
phagocytosis. However Bose et al. also demonstrated identical binding ofmAb 217
to M(p derived from PSR -/- knockout mice and PSR +/+ wildtype controls, strong
evidence against a link between the PSR gene and the molecule identified by mAb
217 as the receptor for PS on apoptotic cells (Bose et al., 2004).
The identification of the sub-cellular localization of the PSR gene protein has cast
further doubt on its role as the true PS receptor. Cells transfected with genes
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encoding PSR linked to GFP produced GFP tagged PSR protein in both a vertebrate
cell line (Cui et al., 2004) and invertebrate hydra cells (Cikala et ah, 2004). In both
cases the GFP-tagged PSR protein clearly localized to the nuclear membrane, not
the outer cell membrane. Detailed examination of the DNA sequences of the
vertebrate and hydra PSR genes identified five potential nuclear localization signals
(Cui et ah, 2004, Cikala et ah, 2004). Cikala et ah also identified a highly conserved
central Jumanji domain within the PSR protein (Cikala et ah, 2004). This domain
and others indicated that the PRS protein is not a receptor but instead part of a family
of transcription factors that includes hypoxia-inducible factor with no known or
likely role in the recognition and phagocytosis of apoptotic cells (Hewitson et ah,
2002). If the PSR encoded protein really is a transcription factor, not a PS receptor,
this could explain the extreme developmental abnormalities and mild or absent defect
in phagocytosis of apoptotic cells observed in PSR -/- knock out mice.
This remains a controversial area of research in the field of apoptotic cell clearance.
At the present time, there remains little doubt as to the importance of PS in the
recognition of apoptotic cells by M(p. However there are now grave concerns that
the product of the PSR gene has been mis-identified as the PS receptor.
Investigations that re-evaluate other targets ofmAb 217 are eagerly awaited.
Mcp exhibit other receptors that recognise 'eat me' signals on apoptotic cells directly
or through bridging molecules, such as Clq (Korb and Ahearn, 1997), mannose
binding lectin (Ogden et ah, 2001) or milk fat globule-EGF-factor 8 (Hanayama et
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al., 2002) that bind eat me signals on the apoptotic cell surface. Some of these
receptors, such as the scavenger receptors, are homologues ofmolecules the
nematode Caenorhabditis elegans (C. elegans) uses to phagocytose apoptotic cells
during embryonic development (Horvitz, 2003). C. elegans has a rigid, predictable
and well-characterised pattern of development. Newly hatched worms all have 556
cells and fully mature adults 959. During development, 131 cells will die by
apoptosis in a highly predictable spatial and temporal fashion. All of this is readily
observed by microscopy. Mutations of single genes (known as the central cell death
or CED genes) can result in deficient clearance of apoptotic cells from the
developing worm (Ellis and Horvitz, 1986). C. elegans has proved an ideal model in
which to study apoptotic cell clearance and many other aspects of biology (Horvitz,
2003).
Unsurprisingly, phagocytosis of apoptotic cells is more complicated in mammals
than C. elegans. Many molecules have been shown to participate in the clearance of
apoptotic cells in vitro (see table 1.3). Confirmatory in vivo studies using targeted
deletion strategies are ongoing but the evidence to date suggest that there is
considerable inbuilt redundancy in mammalian phagocytosis. Targeted deletion of a
single gene often produces either no failure of phagocytosis or partial inhibition,
often confined to specific tissues. For example, antibody-mediated blockade of
scavenger receptor A (SRA) in murine M(p caused a 50% reduction in the
phagocytosis of apoptotic thymocytes in vitro (Piatt et al., 1996). Many T-
lymphocytes undergo apoptosis within the thymus and it was hypothesised that the
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absence of SRA would result in defective phagocytosis of T-lymphocytes within the
thymus. However this is not the case. Experimental mice in which the SRA gene
was deleted showed entirely normal phagocytosis of apoptotic T-lymphocytes (Piatt
et al., 2000). It was concluded that other mediators of phagocytosis were able to
compensate for the absence of SRA, illustrating inbuilt redundancy in mammalian
phagocytosis of apoptotic cells.
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Table 1 Molecules mediating the phagocytosis of apoptotic cells in C.
elegans and humans
C. elegans Function Human homologue(s) Function























p2 integrin 8 Binds
phosphatidylserine




Phosphatidlyserine 9,10 Mediates the
engulfment of
apoptotic cells
Calreticulin " Binds Clq and
mannose binding
lectin on AC
p2 glycoprotein 1 receptor 12 Binds p2 glycoprotein
1 on AC
avp3 integrin' Binds bridging TSP
avp5 integrin'3 Binds PS via milk fat
globulin epidermal
growth factor
CD-31 14 Binds disabled CD-31
on AC





Mer receptor tyrosine kinase21 Unknown
References
'(Ellis et al., 1991) 2(Savill et al., 1990) 3 (Oka et al, 1998) "(Piatt et al., 1996) 5(Wu and Horvitz,
1998b) 6(Becq et al., 1997) 7 (Savill et al., 1992) 8(Mevorach et al., 1998) 9"'°(Fadok et al., 1992a,
Fadok et al., 1993) "(Ogden et al., 2001) 12(Rovere et al., 1998) 13(Akakura et al., 2004) '"(Brown et
al 20(P) 15'20(Gregory et al., 1998, Devitt et al., 1998, Gregory and Devitt, 1999, Moffatt et al., 1999,
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Devitt et al., 2003, Devitt et al., 2004) 21(Scott et al., 2001)
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Clq, the first component of the classical complement activation pathway, also
mediates the phagocytosis of apoptotic cells. Its globular heads bind motifs on the
surface of apoptotic cells whilst its stalk binds to calreticulin on Mcp (Ogden et ah,
2001). Both in vitro and in vivo studies demonstrated slower phagocytosis of
apoptotic cells by peritoneal Mcp from Clqa knockout mice compared to wild-type
controls (Taylor et al., 2000). However, in vivo phagocytosis of apoptotic cells was
delayed, rather than arrested completely, further evidence for inbuilt redundancy in
the phagocytosis of apoptotic cells.
M(p produce pseudopodia which engulf tethered apoptotic cells. Pseudopodia are
formed by localised actin rearrangement in the cytoskeleton and changes within the
cell membrane itself. The intracellular events resulting in apoptotic cell engulfment
are complex and further reading is recommended (Castellano et al., 2001). However,
studies on C. elegans identified CED 2, 5, 10 and 12 as genes encoding intracellular
signaling proteins which modulate the engulfment of apoptotic cells (Wu et al., 2001,
Reddien and Horvitz, 2000, Wu and Horvitz, 1998a, Wu and Horvitz, 1998b).
Interestingly, these genes were also required for embryonic cell migration. Crkll,
dock-180 and rac are mammalian homologues of CED 2, 5 and 10 and it is
speculated that they perform similar functions.
Eventually the engulfing pseudopodia fuse and the apoptotic cell is trapped within an
intracellular vesicle called a 'phagosome'. The phagosome is moved into the interior
of the Mcp where it fuses with endosomes and lysosomes (Iger et al., 1994). This
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fusion adds digestive enzymes to the phagosome (now called the phagolysosome)
causing destruction of the apoptotic cell. The processes occurring within the
phagolysosome are poorly understood. However recent studies have provided new
insights into the composition and maturation of phagolysosomes (Garin et ah, 2001)
and further developments in the field are anticipated.
Recently work has shown that healthy, non-apoptotic cells actively inform Mcp of
their viability in order to avoid capture and phagocytosis, the previous dogma being
that Mcp passively 'ignored' viable cells. This was elegantly demonstrated by Brown
and colleagues who used a flow chamber system to assess tethering of viable and
apoptotic cells to Mcp or Mcp cell lines (Brown et al., 2002). Both viable and
apoptotic cells firmly adhered to Mcp at 20°C under shear force. However, when the
temperature was raised to 37°C, only viable cells detached from Mcp whilst apoptotic
cells remained firmly attached. The requirement for a physiologically appropriate
temperature implied that the detachment of viable cells was dependent upon active,
metabolic processes. The precise mechanisms underlying this phenomenon are the
subject of ongoing investigations. However, membrane bound CD-31 appears to
play a role as CD-31 blocking antibodies inhibited the detachment of viable cells
from Mcp. CD-31 is not expressed by all tissues so other mechanisms must be
involved in the discrimination of viable cells by Mcp.
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1.4 Phagocytosis ofapoptotic cells and the modulation of
inflammation
Mcp assist the resolution of inflammation by removing apoptotic PMNs from
inflamed tissue. The phagocytosis of apoptotic PMNs and other cells by Mcp further
contributes to the resolution of inflammation in other ways. Firstly, production of
anti-inflammatory cytokines by Mcp, secondly the removal of apoptotic cell derived
auto-antigens and finally prevention of phagocytosis by dendritic cells.
The en masse apoptosis of PMNs can be seen as the beginning of the resolution
phase of acute inflammation. However, at this stage Mcp, which remove the
apoptotic PMNs, are producing a variety of pro-inflammatory cytokines. It is now
known that the act of phagocytosis of an apoptotic PMN, or apparently any apoptotic
cell, will halt the production of pro-inflammatory cytokines and induce a new Mcp
phenotype characterised by the production of anti-inflammatory cytokines including
transforming growth factor-(31 (TGF-pi), interleukin-10 and prostaglandin^ (Voll
et al., 1997, Fadok et ah, 1998).
Much attention has been focused on the production ofTGF-pi by Mcp following
apoptotic cell phagocytosis. TGF-pi has several functions including downregulation
of the acute inflammatory response (Letterio and Roberts, 1998) and scar formation
during wound healing (Border and Noble, 1994). In a seminal paper (Huynh et ah,
2002), Huynh and colleagues beautifully demonstrated the link between PS-receptor-
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mediated apoptotic cell phagocytosis and TGF-pi production by Mcp in vivo.
Apoptotic cells instilled intra-tracheally into inflamed murine lungs were
phagocytosed by Mcp. Significantly more TGF-pi and accelerated resolution of the
lung injury was subsequently observed in the lungs of animals receiving apoptotic
cells compared to controls. However, these effects were lost when non-PS exposing
apoptotic cells (the PLB-985 cell line) were instilled. The increase in TGF-pi levels
seen with PS exposing apoptotic cells was re-established when PLB-985 cells were
instilled together with PS but not with control phospholipids. Furthermore, the
instillation of liposomes bearing PS resulted in accelerated resolution of
inflammation and increased Mcp production of TGF-pl. Apoptotic cells opsonised
with antibody (hence phagocytosed via Mcp borne Fc receptors rather than the PS-
receptor) did not induce TGF-pi production. Similar results were observed in a
second model of inflammation, thioglycollate-induced peritonitis. However, recent
work has cast doubt on the role of PS in the phagocytosis of apoptotic cells, as
previously discussed (Bose et ah, 2004).
Certain autoimmune diseases, such as systemic lupus erythematosis (SLE), are
characterised by autoantibodies; antibodies targeted against self antigens. Self
antigens targeted by classical SLE autoantibodies have been identified at the exposed
surface of apoptotic cells. Keratinocytes undergoing apoptosis display autoantigens
concentrated in blebs of cell membrane where they are highly visible to the immune
system (Casciola-Rosen et al., 1994). These antigens include Ro, La, nucleosome
components and snRPNPs. It is also worth noting that antibodies against
23
CHAPTER 1 - INTRODUCTION
phospholipids such as PS are also common in SLE. Many such antigens found on
apoptotic blebs are constituent cell peptides which were altered by caspase and other
enzymic degradations during apoptosis. The presentation of'altered self is believed
to be an important mechanism leading to autoantibody generation. Mcp express Class
II MHC and can present antigen to T-cells. It has generally been accepted that Mcp
have a lesser ability to present antigen to T-lymphocytes compared to another type of
phagocyte, the dendritic cell (DC) (Janeway, 2001c). However, Pozzi et al. recently
showed that peptide pulsed Mcp can prime T cells in vivo (Pozzi et al., 2005).
Furthermore, the abundance of Mcp in inflamed tissue may compensate for their
lower antigen presentation capacity. The DC has a lower capacity for phagocytosis
than the Mcp but a much greater ability to present antigen and activate T-
lymphocytes. However, dendritic cells (DCs) can phagocytose apoptotic cells and
then activate T-lymphocytes with apoptotic cell-derived antigens (Albert et al.,
1998). This is a somewhat controversial area as other data suggests that DCs that
phagocytose apoptotic cells contribute to the maintenance of immunological
tolerance (Huang et al., 2000, Ma et al., 2005). Furthermore, other studies suggest
that immature DCs which phagocytose apoptotic cells have impaired maturation,
defective interleukin-12 production and a lower ability to stimulate T-lymphocytes
(Stuart et al., 2002). Clearly further work is needed to establish how the context in
which DC phagocytose apoptotic cells alters their immune response.
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Whilst the phagocytosis of apoptotic cells is generally considered to have neutral or
anti-inflammatory consequences in the modulation of inflammation, the phagocytosis
of bacteria and other invading pathogens typically has the opposite effect and initates
or exacerbates an inflammatory response. Work by Blander and Medzhitov has shed
new light on important differences in the mechanisms used by M(p and dendritic cells
to phagocytose and process apoptotic cells and bacteria (Blander and Medzhitov,
2004).
Phagocytosis is a vital process in host defence against invading microbial pathogens.
Microbes are removed by phagocytosis and then killed within phagolysosomes by
chemical and enzymic degradation (Janeway, 2001c). The discovery of a novel
mechanism by which the innate immune system mounted specific and rapid
responses to microbes began with the identification of a new role for the 'Toll' genes
(which had known functions in embryonic development) in anti-fungal immunity in
Drosophila melanogaster (Lemaitre et ah, 1996). A human homologue for Toll was
soon identified (Taguchi et al., 1996) and a year later it was shown that a human Toll
protein could activate inflammation through the NF-kB pathway (Medzhitov et al.,
1997). The wide expression of Toll proteins across both invertebrate and vertebrate
species and the remarkable conservation of their structure and function suggested key
roles in innate immunity. It is now accepted that Toll proteins - commonly referred
to as Toll-like Receptors (TLRs) - recognize specific pathogen-associated molecular
patterns (PAMPs) not expressed by the host. The TLR identified by Medzhitov and
Janeway in 1997 is now designated TLR-4 and is a crucial part of the leukocyte
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receptor complex for lipopolysaccharide (LPS), a key player in the endotoxin-
mediated toxic shock syndrome (Poltorak et al., 1998).
Recent work from Medzhitov's group has shed new light on the role TLR-4 plays in
the processing of phagocytosed bacteria and apoptotic cells. Blander and Medzhitov
showed that murine Mcp lacking TLR-4 or its adaptor protein MyD88 phagocytosed
bacteria at a slower rate that wild type control M(p (Blander and Medzhitov, 2004).
furthermore the rate at which phagolysosomes containing bacteria matured to their
full killing potential was significantly slower in M(p lacking TLR-4 or MyD88
(Blander and Medzhitov, 2004). Finally, dendritic cells (DCs) lacking MyD88
demonstrated delayed antigen presentation and T cell activation than wildtype
control DCs (Blander and Medzhitov, 2004), presumably a consequence of delayed
upstream pathogen processing.
Blander and Medzhitov also studied the effect of TLR-4/MyD88 on the phagocytosis
of apoptotic cells (Blander and Medzhitov, 2004). Intriguingly they found no
difference in either the rate of engulfment or the rate of phagolysosome maturation
following the phagocytosis of apoptotic cells in either TLR-4 or MyD88 deficient
Mcp. The overall rate ofmaturation and processing of ingested apoptotic cells was
considerably slower that for bacteria and not altered by the simultaneous
phagocytosis of apoptotic cells and bacteria (Blander and Medzhitov, 2004). This
suggests that TLR-4 is a key player in directing bacteria and apoptotic cells through
distinct processing pathways within phagocytes. This may help to explain some of
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the differences in the inflammatory responses that follow the phagocytosis of
bacteria or apoptotic cells.
1.5 The consequences of failed apoptotic cell clearance
The presence of so much redundancy is a testament to the importance of
phagocytosis of apoptotic cells. The ways in which apoptotic cells might induce or
exacerbate inflammation have already been outlined. So what is the evidence that
defective phagocytosis of apoptotic cells induces inflammation in vivo?
Some of the most compelling evidence comes from the study of humans and
experimental animals completely deficient in Clq. Clq is the first component of the
classical complement activation pathway which acts as a bridging molecule to effect
phagocytosis of apoptotic cells (Ogden et al., 2001). Mcp phagocytosis of apoptotic
cells in vivo is deficient in the absence ofClq (Taylor et al., 2000).
In humans, homozygous Clq deficiency is the strongest predictor for the
development of SLE (Botto and Walport, 2002). Some of the evidence for a link
between defective apoptotic cell clearance and SLE is circumstantial, namely the
presence of autoantibodies targeting apoptotic cell-derived 'altered self. More direct
evidence for the link comes from animal models of immune mediated inflammatory
disease. Mice (and humans) have three genes encoding Clq protein - Clqa, Clqb
and Clqc (Petry et al., 1996). Targeted deletion of the Clqa gene resulted in a
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viable and fertile mouse completely lacking Clq protein - 'Clqa -/- mice' (Botto et
al., 1998). Clqa -/- Mcp exhibit defective phagocytosis of apoptotic cells in vivo
(Taylor et al., 2000).
Botto and colleagues characterised the autoimmune phenotype of Clqa-/- mice and
made the following observations. A significant proportion ofClqa -/- mice
spontaneously develop anti-nuclear, anti-histone and anti-sm antibodies typical of
those found in SLE. They also developed autoimmune glomerulonephritis (GN), an
inflammatory renal injury, with similar histological features to SLE-associated GN.
A large number of free apoptotic cells were seen within the inflamed glomeruli
implying a failure ofMtp to phagocytose the apoptotic cells.
These autoimmune phenomena were more pronounced when the C1 qa -/- mice were
bred onto a hybrid 129/Ola x C57BL/6 background rather than either pure 129/Ola or
C57BL/6 backgrounds suggesting that other genetic modifiers were influencing the
autoimmune phenotype (as is also thought to be the case in humans).
A separate study examined the effect ofClq deficiency in accelerated nephrotoxic
nephritis, an experimentally induced immune-mediated form ofGN (Robson et al.,
2001). Induction ofNTN injury resulted in more severe glomerular damage and
greater loss of kidney function in Clqa -/- mice compared to control animals. As in
spontaneous SLE-like GN, many free apoptotic cells were observed in the inflamed
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glomeruli ofClqa -/- mice during NTN. These data suggested that Clq was
protective against severe NTN-induced GN.
Mice lacking components of the alternative complement pathway or components of
the classical pathway downstream from Clq did not develop the severe GN seen in
Clqa-/- mice following the induction ofNTN. This indicated that Clq itself, rather
than other components of the complement cascade, was preventing the development
of a more severe GN following the induction ofNTN. Clq also mediates the
phagocytosis of apoptotic cells by Mcp independently of other complement molecules
in vivo (Taylor et al., 2000). Taken as a whole, the data from Clq deficient humans
and mice provide the most compelling evidence that failed Mcp phagocytosis of
apoptotic cells can induce immune-mediated inflammatory diseases.
Deficiency in the clearance of apoptotic cells from tissues in itself does not
necessarily generate inflammatory or autoimmune disease. CD-14 is a pattern
recognition receptor expressed on the outer cell membrane ofMcp in mammals
including humans and mice. It is perhaps best known as a co-receptor (with Toll-like
receptor 4 (TLR-4) and MD-2) for LPS but it also plays an important role in the
phagocytosis of apoptotic cells. Apoptotic cells bind to CD-14 on human Mcp and
this triggers their phagocytosis (Devitt et al., 1998). Although the precise ligand for
this interaction remains unknown, the region ofCD-14 that apoptotic cells bind is
very closely related to the region which interacts with LPS (Devitt et al., 1998). This
is a fascinating observation given that interactions between LPS and the CD-14/TLR-
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4/MD-2 receptor trigger a strong pro-inflammatory response (Chow et al., 1999,
Kawasaki et al., 2000, Paik et al., 2003) whereas the phagocytosis of apoptotic cells
is typically anti-inflammatory (see Chapter 1.4 and 1.5). Later work by Devitt and
Gregory has shown that CD-14 -/- mice (completely lacking CD-14) demonstrate
defective clearance of apoptotic cells in vivo (Devitt et al., 2004). Thymic, splenic,
pulmonary and intestinal tissues from normal CD-14 -/- mice all contained
significantly more free apoptotic cells than tissues from CD-14 +/+ controls (Devitt
et al., 2004). Furthermore, CD-14 -/- mice also showed defective clearance of
additional apoptotic cells introduced either by direct injection (peritoneal cavity) or
generated indirectly following the systemic administration of dexamethasone
(thymus) (Devitt et al., 2004). However, the presence of excess apoptotic cells
within tissues of normal CD-14 -/- mice did not result in autoimmunity, as evidenced
by normal serum auto-antibody levels and the absence of histological evidence of
inflammation. This might be explained by the ability of apoptotic cells to retain their
ability to confer an anti-inflammatory phenotype to CD-14 -/- M(p despite defective
phagocytosis (Devitt et al., 2004).
1.6 Macrophage emigration in the resolution of inflammation
The inflammatory response is characterized by the recruitment of inflammatory Mcp
as well as PMNs. Inflammatory Mcp initiate and sustain inflammation by the
secretion of cytokines, in particular tumour necrosis factor-a (TNF-a), a- and P-
interferons (IFN-a and IFN-P), and the interleukins (IL) -1, -6, -10, and -18. These
cytokines have a variety of effects on other cells involved in the inflammatory
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response which are discussed in detail elsewhere (Janeway, 2001b). In cases of
bacterial infection, the primary role ofM(ps is to phagocytose bacteria and kill them
within phagolysosomes. Mcps also kill non-phagocytosed bacteria by secreting
bacteriocidal substances including nitric oxide, various oxygen-containing free
radical species and proteases (Albina and Reichner, 1998, Shapiro, 1999). However,
these substances not only kill pathogens as resident healthy cells may be
inadvertently killed too. For this reason, the successful resolution of inflammation
requires the deactivation and removal of inflammatory Mcp as well as PMNs.
M(p are deactivated in several ways. One is the phagocytosis of apoptotic cells (as
outlined in chapter 1.4). Other important deactivating events are the cessation of
IFN-y production by Thl CD4+ T-lymphocytes and the production of anti¬
inflammatory cytokines by Th2 CD4+ T-lymphocytes (Janeway, 2001b). Unlike
PMNs, the deactivated Mcp do not usually undergo apoptosis within inflamed tissues.
As the phagocytosis of apoptotic cells is crucial to their safe disposal, it would make
little sense for professional phagocytes to undergo apoptosis en masse. The final fate
of inflammatory Mcp is poorly understood and some may undergo apoptosis within
inflamed tissue (Lan et ah, 1997). However, some inflammatory Mcps do leave
inflamed tissues and migrate to lymph nodes (Bellingan et ah, 1996).
Much of our understanding of Mcp emigration to LNs comes from the investigation
of peritoneal Mcp (Bellingan et ah, 1996, Bellingan et ah, 2002). Peritoneal
inflammation in mice can be reliably initiated by the intraperitoneal injection of
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brewers thioglycollate (TG) (Melnicoff et al., 1989). TG-induced peritonitis is
characterised by an almost immediate influx ofPMNs (peaking after 8 hours) and
M(p (peaking after 5 days) (Melnicoff et al., 1989). Intraperitoneally injected
phagosome specific dyes, such as PKH-2 (green) and PKH 26 (red) (Melnicoff et al.,
1988a), are specifically taken up by peritoneal Mcp and are excellent tracker dyes for
these cells (Melnicoff et al., 1988a). By employing PKH-dye labeling, it was shown
that inflammatory peritoneal Mcp leave the peritoneal cavity during peritonitis and,
over the course of 4 days, emigrate to parathymic lymph nodes (Bellingan et al.,
1996). The points ofMcp departure from the peritoneal cavity were identified as
milky spots, a type of coelom-associated lymphoid tissue (CALT). Mcp binding to
milky spots and subsequent emigration to parathymic lymph nodes were partially
mediated by VLA-4 and VLA-5 integrins (Bellingan et al., 2002).
1.7 The M<p disappearance reaction
Peritoneal Mcp also exhibit a very rapid local migratory or redistribution phenomenon
known as the 'Macrophage disappearance reaction' (MDR). Peritoneal Mcp are
generally harvested by a lavage procedure involving the intra-peritoneal instillation,
agitation and recovery of a physiological solution. The recovered suspension
contains many peritoneal leukocytes, including Mcp. In the 1960s, it was noticed that
the intraperitoneal injection of Bacillus Calmette-Guerin (BCG) into previously
immunised guinea pigs resulted in a dramatic reduction in the number of peritoneal
Mcp recoverable by peritoneal lavage (Nelson and Boyden, 1963). Similar
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phenomena were described in other animals after a variety of stimuli all of which
could be considered pro-inflammatory (see Table 2).
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Table 2 Published experimental reports of the MDR
1stAuthor Year Species model Agent inducing MDR
Nelson 1963 Guinea Pig BCG
Gillissen 1970 Guinea Pig Mycobacterium bovis
Bultmann 1971 Rat Streptococcus
Schimke 1977 Guinea Pig Bovine IgG
Tomazic 1977 Mouse Mycobacterium tuberculin
Shannon 1980 Mouse BCG
Ochiya 1982 Guinea Pig Mcp migration inhibitory factor
D'Silva 1983 Guinea Pig Haemocyanin
Ochiya 1983 Guinea Pig Ovalbumin (IP and intradermal)
Melnicoff 1989 Mouse Brewers thioglycollate
(Gillissen and Bubenzer, 1970, Bultmann et al., 1971, Schimke et al., 1977, Tomazic
et al., 1977, Shannon and Love, 1980, Ochiya et al., 1982, D'Silva et al., 1983,
Ochiya et al., 1983, Melnicoff et al., 1989, Nelson and Boyden, 1963)
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The MDR has also been observed in the pleural cavity (Sultan et ah, 1978). A
number ofmolecules that may mediate the MDR have been suggested including
thrombin (Jokay and Karczag, 1973), Tymphokines' (Sipka et ah, 1977), fibrin
(Sultan et al., 1978) and hyaluronic acid (Shannon and Love, 1980). It is fair to say
that no agreement has been reached upon which, if any, of these molecules is
predominant. There is also uncertainty as to whether the MDR represents the
beginning ofMcp emigration from the peritoneal cavity or local sequestration ofM(p.
One study employed selective labeling to demonstrate that some Mcp reappeared
within the peritoneal cavity a week after the induction of a MDR (Haskill and
Becker, 1985). It was also suggested that these Mcp had undergone cell division prior
to their reappearance. Nonetheless, only a small fraction of the original
'disappeared' population reappeared within the peritoneal cavity.
For the past 30 years, the MDR has remained an immunological curiosity, with no
explanation for how, where or why peritoneal Mcp disappear.
1.8 The peritoneal cavity, milky spots and omentum
The peritoneal cavity is a serosal cavity whose main function is to protect the organs
contained within from damage by external injury or friction (Mutsaers and Wilkosz,
2007). Single cell thick layers ofmesothelial cells form the outer and inner epithelial
surfaces of the peritoneal membrane which encloses the peritoneal cavity. Although
the mesothelial cells are the most abundant cell type within the peritoneal membrane,
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there are also significant numbers of fibroblasts and leukocytes all of which play
important roles in peritoneal immunity (Faull, 2000). The fibroblasts are located
within the interstitial connective tissue that lies below the mesothelial epithelial layer
of cells and the deeper network of capillaries (Faull, 2000). Both fibroblasts and
mesothelial cells are able to generate cytokines and chemokines during immune
responses (Loghmani et al., 2002, Witowski et ah, 2001, Topley et al., 1993). The
peritoneal blood circulation arises from the systemic, rather than portal, circulation
and mostly comprises capillaries arising from the superior and inferior epigastric
vessels. These capillaries are accompanied by lymphatic vessels concentrated within
the omentum and sub-diaphragmatic area often accompanying milky spots
(Goldsmith et al., 1990). During inflammation a great proliferation of lymphatic
vessels and milky spots is seen (Dux et al., 1986).
Bellingan and colleagues identified the milky spots as sites ofMcp emigration from
the inflamed peritoneum (Bellingan et al., 1996). Milky spots were first described by
the great German pathologist Friedrich Daniel von Recklinghausen who gave them
the name 'pus balls' (von Recklinghausen, 1863). However pathologists eventually
adopted the more appealing, if less accurate, 'milky spots'.
Milky spots appear to be found in all vertebrates. In humans, they first develop in
the middle trimester of gestation (Krist et al., 1997). It is often reported that milky
spots are most abundant at birth and their number decreases with increasing age.
However, the only study to address this in humans examined diseased omentum and
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was possibly confounded by the increasing omental adiposity associated with aging
(Shimotsuma et al., 1993). Milky spots are unevenly distributed throughout the
peritoneal cavity being most abundant within the omentum but also concentrated on
the sub-diaphragmatic and peri-uterine regions of the peritoneal membrane
(Shimotsuma et al., 1993). Similar structures are found within the pleural and
pericardial membranes (Pereira Ade et al., 1994).
Milky spots are aggregations of leukocytes - mostly M(p and lymphocytes-
surrounding a central blood vessel and often a lymphatic vessel (Lenzi et al., 1996).
They arise between the two mesothelial cell layers of the peritoneal membrane. The
architectural arrangement ofM(p reflects their maturity. Immature monocyte-derived
Mcp are found at the innermost aspect of the milky spot close to the central vessels.
Further from the central blood vessel, the maturity ofMcp increases with the
outermost layer being the most mature (Krist et al., 1995). It is suspected but not
demonstrated that similar principles apply to the arrangement of lymphocytes.
Fibroblasts and connective tissue are found between the tightly packed leukocytes
(Krist et al., 1995). There is a discontinuation of the peritoneal mesothelial cell
lining of the interior of the peritoneal cavity associated with milky spots (Mironov et
al., 1979). This affords mature Mcp direct contact with the peritoneal fluid which
they continuously sample and survey for pathogens (Krist et al., 1997). The break in
the peritoneal membrane also assists the seeding of leukocytes into the peritoneal
cavity during peritoneal inflammation (Dux et al., 1986).
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Peritoneal milky spots increase dramatically in number and cellularity during
peritonitis (Dux et al., 1986, Beelen et al., 1988). This is due to a recruitment of
PMNs and monocyte-derived Mcp, facilitated by the production of chemokines
including SDF-1 (Pinho Mde et al., 2002) and the proliferation ofM(p under the
influence of GM-CSF (Koenen et al., 1996, Zhu et al., 1997). Milky spot Mcp and
nearby mesothelial cells upregulate a large number of molecules involved with cell
adhesion and migration including LFA-1, Mac-1, VLA-4, ICAM-1 and VCAM-1
further facilitating leukocyte trafficking through milky spots (Cui et al., 2002).
Blood vessels within milky spots are fenestrated and have a characteristic high
endothelial phenotype, further enhancing leukocyte recruitment (Krist et al., 1995).
Milky spots contain an unusually high proportion ofB-l lymphocytes (Kasaian and
Casali, 1993). These evolutionarily primitive lymphocytes produce so-called
'natural' antibodies with a low affinity against many (usually bacterial) antigens
(Kasaian and Casali, 1993). They are almost exclusively found within the peritoneal
cavity and play an important role in the innate immune response to bacterial
infections (Boes, 2000). The low specificity of natural antibodies means that they
can bind to self- as well as bacterial antigens. Consequently, natural antibodies have
been shown to participate in auto-immune diseases (Bell, 1993).
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1.9 The Omentum
Most peritoneal milky spots are found within the omentum. The omentum comprises
a double fold of peritoneal mesothelium containing adipose tissue and milky spots.
The omentum first appears during the 8th week of gestation, arising from the dorsal
mesogastrium (Krist et al., 1997). Milky spots appear later, during the middle
trimester. The omentum is found in the right hypochondrial abdominal region of
mammals and is attached to the stomach, small intestine and, in mice, the pancreas
(Goldsmith et al., 1990). The omentum receives a large blood supply from the
gastroepiploic vessels and its lymphatic drainage is to the coeliac lymph nodes.
Whilst the basic structure of the omentum is similar amongst all vertebrates, there are
species variations. In humans, the omentum is apron-like in appearance with milky
spots arranged within a lacy network of adipose-rich tissue. This structure is best
appreciated in neonates as with increasing age the milky spots are obscured by
adipose tissue. In mice, milky spots are organised within fatty ribbon-like structures
called omental lymphoid organs (OLOs) (Dux et al., 1986). An individual mouse
may have one or more OLOs and their precise architecture varies between strains
(Goldsmith et al., 1990). A branch of the gastro-epiploic vessels run along the length
of the OLO sending marginal branches to the milky spots. Lymphatic vessels follow
similar routes to the blood vessels and eventually drain into the coeliac, pancreatic
and ultimately the parathymic lymph nodes.
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The omentum has been known to physicians since ancient times and there have been
a number of historical theories regarding its function. Galen performed a partial
omentectomy on an injured gladiator who recovered but thereafter was greatly
intolerant of cold weather. Galen's report of this gave rise to the popular theory that
the omentum's purpose was to warm the intestines. Soothsayers believed that
examination of animal omenta could foretell future events. The word omentum is in
fact derived from omen, reflecting this ancient belief.
The modem view of the omentum as an organ of immunity began in 1896 (reported
by Rothenberg and Rosenblatt, 1942) when Stichler placed snails into the peritoneal
cavity of dogs and observed their subsequent encasement by the omentum
(Rothenberg and Rosenblatt, 1942). The belief that the omentum actively patrolled
the peritoneal cavity caused surgeons to nickname the omentum the 'abdominal
policeman'. However, in 1926 Florey showed that the movement of the omentum
was entirely passive (Florey et ah, 1926). Sir Charles Sherrington, Nobel Laureate
and George Holt Professor of Physiology at Liverpool University 1895-1913, first
pointed out that the 'doubled-up' posture associated the acute abdomen is ideal for
moving the omentum to the farthest regions of the lower abdomen.
Significant changes occur within the omentum during peritonitis. Its blood supply
dramatically increases and it is the principal site ofPMN extravasation during
peritonitis (Fukatsu et ah, 1996, Doherty et ah, 1995). The omentum becomes
adherent to sites of inflammation and produces a layer of fibrin which may
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eventually organise into a walled off collection (Konturek et al., 1994). The changes
occurring within omental milky spots have already been discussed.
These functions of the omentum suggest that it is an important 'engine' of peritonitis.
Omentectomy renders experimental animals increasingly susceptibile to fatal
peritoneal infections (Agalar et al., 1997). Moreover, peritoneal PMNs harvested
from such animals were found to have reduced chemotactic ability. A retrospective
study compared 406 human patients who had proctocolectomy with omentectomy
with 239 patients who had undergone a proctocolectomy without omentectomy. The
rate of post operative sepsis was significantly higher in patients who underwent the
additional omentectomy compared to those who had not (10% Vs 4%, p=0.01)
(Ambroze et al., 1991). A similar increase in peritoneal sepsis requiring re-operation
(8% Vs 3%, p=0.01) was also observed. These data suggest that the omentum is
important but not vital for peritoneal immunity. It is likely that activity in other
milky spots compensates in individuals lacking an omentum.
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1.10 The murine omentum as a model forM<p interactions with
apoptotic cells in vivo
The peritoneal cavity has many features favorable for the study ofMcp interactions
with apoptotic cells. Cells can be readily recovered from the peritoneal cavity by a
simple lavage procedure. Apoptotic cells and other phagocytosable particles can be
readily injected into mice without the requirement for general anaesthesia. Taylor
and others have shown that the in vivo rate of phagocytosis of labeled apoptotic cells
can be measured within the peritoneum (Taylor et al., 2000, Scott et ah, 2001).
However studies to date on the phagocytosis of apoptotic cells within the peritoneal
cavity have focused on M(p that can be recovered by lavage. It seems likely that such
an approach will only allow the investigation of the subset of less adherent Mcps.
The phagocytosis of large numbers of apoptotic cells in vivo is likely to involve the
recruitment and emigration of Mcp, phenomena best appreciated within the omentum,
the major site of peritoneal leukocyte trafficking.
42
CHAPTER 1 - INTRODUCTION
1.11 Aims of this study
• To determine the influence of the administration of apoptotic cells upon
peritoneal and milky spot M(p.
• To determine whether the omental milky spot M(p phagocytose intra¬
peritoneal apoptotic cells.
• To determine the relative contribution the omentum makes to apoptotic cell
clearance within the peritoneal cavity.
• To investigate the mechanisms influencing apoptotic cell clearance by milky
spots.
• To develop an in vivo assay of apoptotic cell phagocytosis based upon the
omentum and explore the interaction of the omentum with other bioparticles.
• To investigate whether the phagocytosis of apoptotic cells stimulates the
emigration ofM(p from the peritoneal cavity and, if so, which mechanisms
govern Mcp emigration.
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2.1 List of reagents used in experiments and suppliers
Reagent Supplier
2pm fluorescent latex beads Sigma-Aldrich Co Ltd, UK
CMFDA dyes Molecular Probes, Netherlands
DMSO Sigma-Aldrich Co Ltd, UK
FACS Flow sheath solution BD Biosciences, UK
FACS Lysis solution BD Biosciences, UK
FITC-Annexin V Sigma-Aldrich Co Ltd, UK
Flowcheck Microspheres Beckman-Coulter, UK
Foetal calf serum Invitrogen, UK
Hanks Buffered Salt Solution Sigma-Aldrich Co Ltd, UK
Hoescht 33342 Sigma-Aldrich Co Ltd, UK
Human Clq Advanced Research Technologies, CA, USA
Hyularonidase enzyme Sigma-Aldrich Co Ltd, UK
Liberase enzyme Roche, UK
PBS Sigma-Aldrich Co Ltd, UK
Propidium Iodide Sigma-Aldrich Co Ltd, UK
Rat anti-mouse B220 antibody Pharmingen, San Diego, USA
Rat anti-mouse CD3 antibody Pharmingen, San Diego, USA
Rat anti-mouse GR1 antibody eBiosciences, UK
Rat-anti-mouse F4/80 antibody Caltag Medsystems, UK
RPMI 1640 culture medium Invitrogen, UK
RPMI culture medium Sigma-Aldrich Co Ltd, UK
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2.2 Lavage ofperitoneal cells
Mice were sacrificed by cervical dislocation in accordance with the Centre for
Inflammation Research and Home Office guidelines for the care of experimental
animals. After 45-60 seconds agonal breathing, cardiac and muscle activity ceased
and dissection could begin.
Deceased animals were placed in the supine position on a polystyrene dissection
board and secure by placing a single securing pin through each of the four limbs into
the dissection board. Fur was removed carefully removed from the lower abdomen
using close cut electic shaving clippers. The underlying skin was then cleaned by
applying 70% ethanol solution with sterile skins wipes; the skin was then allowed to
air dry (approximately 15 seconds). The skin was lifted using rat-toothed forceps
and a midline incision from just below the xiphisternum to the pubic area was made
using dissection scissors. This incision went through the skin and subcutaneous
tissues but did not breach the underlying peritoneal membrane. The skin and the
underlying parietal peritoneum were separated by careful blunt dissection of the sub-
dermal fascia using curved-ended forceps. Transverse incisions through the skin
were made and further blunt dissection performed allowing it to be reflected
completely away from the underlying peritoneal membrane. With practice, this
procedure could be completed in 15-20 seconds.
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The peritoneum membrane was carefully lifted with curved forceps and PBS (kept
cold by storage in an ice bucket) was injected from a 5ml syringe through a 19 guage
needle. The needle breached the peritoneal membrane at the anterior midline in the
lower part of the abdomen. The needle was only advanced a few milimetres into the
abdominal cavity. Extreme care was take to ensure that the needle did not breach or
damage the internal abdominal organs.
The bevel of the needle was positioned above the internal abdominal organs
approximately 2-3 mm below the inner peritoneal membrane. With the instilling
needle remaining in situ, the lavage fluid was agitated by gentle, rhymic squeezing of
the fluid-filled peritoneal cavity for about 10 seconds, taking care not to breach the
membrane with the needle tip. The peritoneal lavage fluid was then carefully
withdrawn from the cavity into the syringe. Intra-abdominal fluid pressure was
maintained during the withdrawal of fluid by applying gentle pressure to the lateral
walls of the peritoneal cavity using the thumb and index finger of the hand not
holding the syringe (eg right handed experimenters use right hand to handle syringe
and left to apply pressure to peritoneal cavity). Particular care was taken to ensure
that the opening of the needle was kept clear of underlying fat and mesenteric
structures. These structures floated freely within the abdominal cavity and could
become caught up or sucked into the needle during aspiration of fluid. This could be
avoided by fastidious positioning and handling of the needle within the abdominal
cavity. The volume of peritoneal fluid withdrawn was noted and was typically in
the range of 4.0-4.5 mis (i.e. 80-90% of that injected). The entire procedure, once
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learned correctly, took approximately 60 seconds to perform. Recovered peritoneal
fluid was then placed in sealed 15 ml plastic tubes and stored at 4°C until labeled and
analysed.
2.3 Development and improvement of the peritoneal lavage
technique
The technique used to instill material IP and subsequently recover peritoneal cells by
lavage evolved from the method described by Taylor and Thomas (Taylor et ah,
2000). Dr Graham Thomas (University of Edinburgh) kindly demonstrated the
technique, highlighting important practical points. It soon that the technique was
very technically demanding and prone to error, particularly the leakage of IP instilled
material, heavily blood stained lavages and recovery low volume lavages.
Refinements and new steps were incorporated into the Taylor and Thomas technique
and these lead to the final method described in section 2.2 (above). During this
development process, it became clear that the success of the entire technique was
largely dependant on the initial IP injection of apoptotic cells or other experimental
materials. For this reason, the major methodological refinements focused on
improving the initial IP injections; these were:-
• A Pre-loading of all injection and lavage syringes prior to experiment.
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• B Use of orange (25 gauge needles) for IP injection instillation of cells
or other experimental materials prior to lavage (Taylor and Thomas used 21
gauge green needles).
• C Shaving of fur and cleaning of skin with ethanol soaked wipes prior to
initial IP injection
• D Limitation of initial injection of IP cells or other experimental needles
to a maximum of 0.5ml (previously 1ml).
• E Use of Vaseline gel to seal IP puncture point
• F Positioning ofmice 'head down' during IP injection of apoptotic cells
The combination of acquired experience and technical refinements lead to major
improvements in overall performance, demonstrated in figure 3. The top and middle
figures show the rates of complications - bloody lavages and leaks of IP injection
fluid- as percentages of all the total number of procedures performed in each
experiment. The bottom figure shows the mean volume of lavage fluid recovered per
experiment (in all cases 5ml were instilled). The data are displayed as Shewhart run
chart format with the major protocol changes highlighted with arrows. The letters A-
F indicating major changes in technique correspond to those listed in the preceding
paragraph.
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Figure 3. Improvements in the performance of the peritoneal
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Top figure - Y-axis = blood-stained lavages as a percentage of all lavages performed in the
experiment. Middle figure - Y-axis = visible leak of IP injected fluid prior to lavage as a percentage
of all IP injections performed in the experiment. Bottom figure - Y-axis = mean volume of instilled
peritoneal lavage fluid (5ml) recovered by aspiration. All figures - X-axis=chonological order of
experiments, annotated arrows indicate change in experimental protocol (see section 2.3 for key) and
experiment in which change was introduced.
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Great care was taken to ensure that this was achieved. The accuracy of the time
intervals between the initial IP instillation of experimental material and the final
lavage of peritoneal cells. All timed lavages were within ± 3 seconds of the time
stated in minutes, including those performed 1 minute after the initial IP injection.
This was achieved by careful planning and preparation of experiments including a
written schedule of desribing the start and finish times for all individual animals.
The importance of thorough preparation when performing this technique on multiple
animals cannot be over emphasized.
The choice of the number of cells to instill was made after considering both scientific
and ethical issues. It was decided at an early stage to use apoptotic murine cells for
most experiments. The major reason behind this was to avoid perturbation of the
recipient's immune system by cross-species reactivity. The most readily available
and reliable source of apoptotic cells were murine thymocytes. The number of
apoptotic cells generated by a single murine thymus was approximately 5-10xl06
depending upon the age of the donor animal and other variables. Empirical data
from early developmental work showed that it took approximately 30 minutes for
0.5x106 apoptotic cells to be cleared from the peritoneal cavity. The technical
performance of the peritoneal installation-lavage technique tended to deteriorate if
shorter time points were used in experiments involving large numbers of animals.
Longer timepoints would have been valid scientifically but would have also
demanded larger quantities of apoptotic cell feed. This in turn would have
significantly increased the number of experimental animals used per experiment for
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no obvious scientific gain. Such an action would have been against the important
principal of 'reduction' in in vivo experimentation. Therefore, for most experiments
that examined the kinetics of intraperitoneal leukocytes, 0.5-1.0xl06 apoptotic cells
were instilled IP and recovered by peritoneal lavage 30 minutes later.
It was clear that large scale experiments in the clearance of apoptotic cells IP could
be reliably performed using 0.5-1.0xl06 apoptotic cells and a 30 minute interval. It
was decided that to use longer time intervals and larger cell feeds was unlikely to add
significant scientific value but would require larger numbers of animals. As such,
this was against the important principle that all experiments involving animals should
use the minimum possible number of animals and strive to reduce this number in the
future. Hence for most experiments, the 'just right' conditions of 30 minute time
intervals from initial IP injection of cells to lavage and 0.5-1.0xl06 IP injected cells
were used.
2.4 Immunolabelling of lavaged peritoneal cells
400pl of well-mixed peritoneal fluid was transferred to a flow cytometry tube using a
calibrated pipette and placed in an ice bucket which was covered with aluminium foil
to limit unwanted light exposure. 50pl ofmouse serum (Serotec) was then added to
the tube and the solution thoroughly mixed and left for 30 minutes. 50pl of a
mixture of lpl antibody solution (see below), 9pl mouse serum and 40pl PBS was
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then added, thoroughly mixed with the periteonal cell suspension and incubated for a
further 30 minutes. Two washing steps were performed in which 2 mis ofPBS were
added to the tube which was then securely placed in a Sigma centrifuge and spun at
300G for 5 minutes. The excess supernatant fluid was carefully removed by
decanting after each centrifugation step and the remaining cell pellett resuspended by
5 seconds of agitation on a bench vortex.
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Figure 4. Antibodies used for immunolabeling ofperitoneal cells
































CHAPTER 2 - METHODS
2.5 Analysis of lavaged peritoneal cells by flow cytometry (M<p,
neutrophils, lymphocytes)
Suspensions of labeled peritoneal cells were identified by flow cytometry using a
Coulter Excel cytometer using Expo 32 software. 200pl of flow cytometry buffered
solution was added to each sample and thorough mixing was achieved by repeated
use of a 200pl calibrated pipette. A representative FSC/SSC dot plot of lavaged
resident peritoneal cells is shown below (Figure 5)
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Figure 5. Typical FSC/SSC plot of lavaged peritoneal cells
M(p and monocytes (within red line) are larger and more granulated than
lymphocytes (within blue line). This explains the higher FSC & SSC values of
M(p/monocyte populations. Mature M(p have higher SSC & FSC values than
immature M(p.
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For each experiment, fine adjustments to the thresholds for the fluorescent channel
detectors were made in order for unlabeled cells to have a peak fluorescence at the
midpoint between 10° and 101 on the logarithmic scale. The FL-3 channel was
reserved for Flowcheck™ microspheres, when utilised.
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Figure 5. Typical FSC/SSC plot of lavaged peritoneal cells
Mcp and monocytes (within red line) are larger and more granulated than
lymphocytes (within blue line). This explains the higher FSC & SSC values of
M(p/monocyte populations. Mature Mcp have higher SSC & FSC values than
immature M(p.
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2.6 Analysis of flow cytometry data
The LMD files generated by flow cytometry were analysed using WinMDI software
(WinMDI 2.8 freeware, Scripps Institute, CA, USA). The most basic data was a 2-
dimensional (2D) dot plot of the entire peritoneal cell population show by ungated
FSC (Y-axis) and SSC (X-axis). In most experiments, cell populations of interest
were identified by immunofluorescent labeling. Furthermore, the cells of interest -
primarily Mcps, apoptotic and other lymphocytes - and Flowcheck™ microspheres
differed significantly in size. FSC is a recognised surrogate marker for the size of a
cell. Therefore, a population of interest was usually identified by plotting a 2D dot
plot of FSC (X-axis) with the appropriate fluorescent channel on the Y-axis. Given
the specificity of the immunolabeling, it was not strictly necessary to use a 2D plot.
However, this was used as a contingency against the theoretical possibility of
adherant fluorescent labeling of other particles within a sample. It also made it easier
to identify Flowcheck™ microspheres which, by design, were fluorescent in all
detector channels.
2.7 Haemocytometry-based counting ofperitoneal cells
The number of a particular population of cells within a peritoneal lavage sample
could be calculated using a combination ofmicroscopic counting with a
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haemocytometer and flow cytometry analysis. Firstly, the absolute number of cells
was estimated using a haemocytometer. The mixture was mixed well then a 10pl
aliquot removed and placed under a coverslip on a haemocytometer grid. The slide
was examined under light microscopy and the total number of cells within a grid
counted. The haemocytometer is calibrated such that the concentration of cells per
ml of fluid can be calculated by multiplying the number of cells in one large grid by
104:-
eg 100 cells per grid = lOOxlO4cells/ml = 1x106 cells/ml.
Then, by separately analysing the sample using flow cytometry, the proportion of a
particular cell of interest can be determined as described above. The absolute
number of a particular cell type per ml of lavage fluid can thus be easily calculated
using the following formula:-
Population A (cells/ml) = Total Concentation (cells/ml) * x (percentage
A/100)**
*=Measured by haemocytometry **=Measured by flow cytometry
For example, the number ofMtps in 1 ml of lavage fluid can be calculated from the
following data set:-
Total cells/ml by haemcytometry = lxl07 cells/ml
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Number of flow cytometry events in Mcp gate = 2,500
Total number of flow cytometry events = 15,000
Percentage Mcp events = (2,500/15,000) x 100
= 16.7%
Macrophages/ml lavage = lxl07x (16.7/100) cells/ml
= 1.67xl06 cells/ml
2.8 Bead-based counting ofperitoneal cells by flow cytometry
Whilst the so-called 'dual platform' technique described above is a well-recognised
method for determining the absolute cell number within a sample, it has certain
drawbacks. Firstly, it is slow and laborious and secondly, for samples containing
small numbers of cells, the haemocytometry estimation of total cell number may be
inaccurate and thirdly, it is assumed (perhaps incorrectly) that microscopic and flow
cytometric analyses identify the same objects as 'cells'. Both microscopy and flow
cytometry will mis-identify a small number of non-cellular objects as 'cells'.
However, when both microscopy and flow cytometry are used in combination, such
errors are combined. Therefore for reasons of speed and accuracy, a robust, flow
cytometry based method for counting specific cell populations was desirable. Such a
method required a standard reference point from which an exact number of cells
within a sample could be determined. This was achieved by 'spiking' each sample
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with a known quanitity of Flowcheck™ synthetic polystyrene beads which have a
highly uniform size and fluorescence (Flowcheck™ Beckman Coulter ref. 6605359).
In each experiment, 25ul of beads from a stock suspension of lxlO6 beads per ml
were added to each sample (ie 2.5xl04 beads). The beads were added immediately
before flow cytometric analysis and the sample mixed thoroughly. This was
necessary as prolonged co-incubation might have resulted in binding of beads to
peritoneal lavage cells - especially M(ps. The fluorescence of the beads was
considerably greater than any of the labeled cell populations and they fluoresced in
all channels from FL1-FL4. None of the cellular fluorescent labeling techniques
required the FL3 channel so this was reserved for the beads. The flow cytometer was
adjusted such that the beads had FL3 fluorescence around 10 on the log scale. With
these settings, other cells had FL3 fluorescence of 101 or less and hence could be
easily excluded from any analyses.
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Figure 7. Flow cytometry plot of flowcheck microspheres
"te?. jr
"SS LOG
Flow cytometry plot showing Flowcheck ™ microspheres of uniform size with high
fluorescence in FL3 channel (points within red line). In contrast, virtually all
peritoneal lavage cells (including F4/80-PE/Cy5 labeled Mcp) have virtually no FL3
fluorescence and only a few appear on the positive side of the Y-axis (points within
blue line). This demonstrates how effectively Flowcheck™ beads can be separated
from peritoneal cells using flow cytometry.
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To calculate the number of cells in a particular sample, gates are placed around the
cell population of interest and a second gate around the 'spiked' beads. 15000 events
are then collected by the flow cytometer. The number of cells per ml is determined
using the following equation:-
Cells/rnl — (Cell events counted x Number ofbeads in sample) / (Bead events counted
x volume oflavage)
For example,
Cell events counted = 16,000 cells
Bead events counted = 1,000 beads
Number of beads in sample = 25,000 beads
Volume of lavage analysed = 0.4 ml
Cells/ml = (16,000 x 25,000) / (1,000 x 0.4ml)
Cells/ml = 1,000,000 cells/ml
A comparison of the two methods was performed and showed a high degree of
correlation between the results obtained. However, the single platform beads-based
system proved to be much faster and was used in all experiments unless otherwise
stated.
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2.9 Intraperitoneal instillation of substances
Substances were instilled IP according to the terms and conditions of the relevant
Research Project Licence, my own Personal Licence and the Home Office general
guidelines for the use of experimental animals. Unaesthetised animals were scruffed
and held in the non-dominant hand and fur was removed from the lower right
quadrant of the abdomen using close cutting electric clippers held in the dominant
hand. The underlying skin was cleaned by applying 70% ethanol using an anti-septic
wipe. The cleaned skin dried within 15 seconds. Then a maximum of 0.5mls of
fluid was injected IP using a 21 gauge (orange) needle. During injection the animal
was held in a 'head down' position for 5 seconds. Experience showed that this
minimized the leakage of IP injected fluid. A small amount of Vaseline was applied
to the puncture site whist the needle was being withdrawn to help prevent leakage of
fluid after injection - this often required the help of an assistant. The procedure was
generally done without general anaesthesia.
2.10 In vivo labeling ofperitoneal M(ps with PKH-2 and PKH-26 dyes
The phagocyte-specific dyes PKH-2 and PKH-26 are sold in a kit form complete
with instructions. The techniques for PKH-2 and PKH-26 labeling differ only in
respect of the dye used and PKH-2 is referred to only in this description. The dyes
are equally effective at labeling resident or recruited inflammatory peritoneal Mcps.
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In some experiments, PKH dye was injected following the IP injection of brewers
thioglycollate.
0.05ml PKH-2 were removed from the kit and mixed thoroughly with 0.95mls of
absolute ethanol, providing 50pM working stock dye solution. The metal tab of one
diluent bottle was lifted and 0.05ml of the dye into the diluent injected into 10 mis of
diluent. The bottle and dye were vigorously mixed and allowed to stand for at least
15 minutes prior to use. 0.5mls of the diluted dye were injected IP into each
experimental animal using a fresh needle for each injection. Labeled peritoneal M(p
were harvested 24 hours after IP injection using the peritoneal lavage technique
previously described.
2.11 Preparation and labeling of viable thymocytes
Young mice (less than 7 weeks old) were sacrificed by cervical dislocation and the
limbs pinned to a polystyrene board as previously described. Fur was removed from
the abdominal wall and thorax using close cutting electic clipplers. The skin was
cleaned with 70% ethanol solution applied with a sterile wipe. The skin was opened
at the midline on the anterior wall at the level of the lower abdomen. A midline
incision through the underlying skin and peritoneal membrane was made using
dissection scissors. The incision was extended through the thoracic cage to the level
of the neck. Extreme care was taken to avoid damage to the underlying blood
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vessels, heart and lungs. The thoracic subcutaneous tissue was dissected by lateral
thoracotomy scars to expose the internal structures of the thorax. The thorax was
opened with lateral thoracotomy incisions and the thoracic cage reflected superiorly.
This allowed the passive deflation of the lungs which were not punctured. The
thymus was thus exposed and carefully dissected from underlying with a single cut at
its root with a sterile scalpel.
Whole thymocytes were then disaggregated by gentle agitation between sterilised
frosted glass slides whilst submerged within RMPI 1640 tissue culture medium under
sterile conditions within a negative pressure tissue culture hood. For experiments
requiring the cells to be labeled with a fluorescent dye, lpl ofCMFDA green or red
tracker dye (lug/ml in DMSO) was added for every lxl06 cells within the
suspension and the suspension incubated for 15 minutes at 37°C in a light-proof
incubator. Following incubation, 1ml of FCS was added to the suspension to remove
any unused dye. The cell suspension was washed by two centrifugations at 4°C,
250G with decanting of supernatant and replacement with fresh PBS.
2.12 Preparation and labeling of apoptotic thymocytes
Thymocytes were harvested from whole thymi and labeled with fluorescent dye as
described above. Apoptosis was induced by prolonged serum starvation and
exposure to dexamethasone using the following method. A suspension of
9 . • .
thymocytes was transferred to a 75cm tissue culture flask containing RPMI medium,
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lpM dexamethasone and 1% FCS. This suspension was then incubated at 37°C for
15 hours. Following incubation, the cell suspension was washed by two
centrifugations at 4 °C, 250G with decanting of supernatant and replacement with
fresh PBS. Finally, the cells were resuspended to the desired concentration and
checked for viability, apoptosis and necrosis as described below.
2.13 Quantification of apoptosis and necrosis in thymocyte
suspensions (Annexin V, PI, Hoescht 333342)
The percentage of apoptotic thymocytes in a cell suspension was determined either
by a) binding of FITC-conjugated annexin V to the external cell membrane leaflet
(demonstrating phosphatidylserine translocation to the outer membrane) or b)
pyknotic nuclear morphology (identified by the nuclear dye Hoescht 33342).
2.14 FITC-Annexin V labeling
lxlO6 cells were removed from the cell suspension and lul of 1:5000 Annexin-V-
FITC in (Hanks Balanced Salt Solution with 5pM CaCh) within a flow cytometry
tube. 1 Oul of the suspension was then placed in a haemocytometer and examined by
fluorescence and light microscopy. Annexin-FITC+ cells were apparent by their
green fluorescence under fluorescence microscopy; the total number of cells was
established by examination under light micrscopy. By dividing the number of
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apoptotic cells by the total number of cells in a field the percentage of apoptotic
thymocytes within a cell preparation was determined. Typically, a total of 250 cells
were counted.
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2.15 Hoescht 333342 labeling
The labeling of thymocytes with Hoescht 333342 differs from Annexin-FITC
labeling only in the substitution of 1 gil of 1:1000 Hoescht 333342 for lpl Annexin-
FITC. Cells were examined under light microscopy to determine the total number of
cells in a field as described above. Apoptotic cells were identified by the presence of
condensed, pyknotic nuclei, highlighted by Hoescht 333342 which is a DNA-binding
nuclear dye. The percentage of apoptotic cells was determined by dividing the
number of apoptotic cells by the total number of cells - typically 250 cells were
counted in total.
2.16 Propidium iodide (PI) labeling of necrotic cells
PI is a so-called 'vital dye' - ie excluded by cells with proper metabolism and an
intact cell membrane. Necrotic cells retain propidium iodide and hence have red
fluorescence under fluorescence microscopy. The method for identifying necrotic
cells within a sample of thymocytes is identical to that for those for identifying
apoptotic cells, as described above. The only difference being the substitution of 1 ul
of 1:1000 propidium iodide for either annexin-V or Hoescht 333342.
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2.17 Preparation and labeling of apoptotic Jurkat T-lymphocytes
The human leukaemic Jurkat T-cell line was maintained in long term culture in 10%
FCS/RPMI-1640 medium. Apoptosis was induced and assessed using the methods
previously described for apoptotic T-lymphocytes.
2.18 Opsonisation of apoptotic thymocytes with C1q (and BSA)
Apoptotic thymocytes were prepared as previously described. They were then
resuspended at 5x107 cells/ml in RMPI culture medium with 10% murine serum from
Clqa -/- mice. The cells were then split and either purified human Clq or bovine
serum albumin (control) added to a final concentration of 1.5pg/ml. The suspension
was then incubated at 37°C for 60 minutes after which the cells were washed twice
by centrifugation and resuspension in PBS as previously described.
2.19 Analysis ofwhole blood for labeled peritoneal Mcps
Experimental mice had previously received IP injections ofCMFDA-green labeled
apoptotic cells. The peritoneal Mcp which had phagocytosed these cells were thus
expected to have acquired the green fluorescent cell tracker dye. 25pi of whole
blood was obtained by cardiac puncure and added to 1ml of 3.9% sodium citrate.
lOOpl of the mixture was aliquoted into flow cytometry tubes. 2 ml of FACSLysis
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buffer (BD, UK) was then added to lyse erythrocytes and samples were spun,
resuspended and analysed for the presence of green fluorescent apoptotic cell-
bearing Mcp using flow cytometry.
2.20 Dissection of the omental lymphoid organ for fluorescence
microscopy
Mice were sacrificed by cervical dislocation in accordance with the Centre for
Inflammation Research and Home Office guidelines for the care of experimental
animals. After 45-60 seconds agonal breathing, cardiac and muscle activity ceased
and dissection could begin.
Deceased animals were placed in the supine position on a polystyrene dissection
board and secure by placing a single securing pin through each of the four limbs into
the dissection board. Fur was removed carefully removed from the lower abdomen
using close cut electic shaving clippers. The underlying skin was then cleaned by
applying 70% ethanol solution with sterile skins wipes; the skin was then allowed to
air dry (approximately 15 seconds). The skin was lifted using rat-toothed forceps
and a midline incision from just below the xiphisternum to the pubic area was made
using dissection scissors. This incision went through the skin and subcutaneous
tissues but did not breach the underlying peritoneal membrane. The skin and the
underlying parietal peritoneum were separated by careful blunt dissection of the sub-
dermal fascia using curved-ended forceps. Transverse incisions through the skin
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were made and further blunt dissection performed allowing it to be reflected
completely away from the underlying peritoneal membrane. With practice, this
procedure could be completed in 15-20 seconds.
The exposed peritoneal membrane was opened using dissection scissors by means of
a longitudinal midline incision. The root of the coeliac mesentary was clamped with
a pair of curved forceps and the attached block of tissue comprising the stomach,
spleen, part of the small intestine together with the omentum was removed as a single
structure by cutting the mesenteric root with dissection scissors. The block was the
placed in large petri dish containing cold PBS. Suspension in PBS caused the spleen,
stomach and small bowel to sink wheras the omentum floated above these organs, by
virtue of it's high fat content. The omentum was then carefully separated from the
other organs using dissection scissors and spread on a glass microscope slide. A few
drops of PBS were placed over the omentum to assist spreading on the slide and a
cover slip placed over the lymphoid organ. Excess fluid was carefully removed with
tissue paper and the slide taken for microscopic examination. The process of
removing the block of abdominal organs took only 1-2 minutes but the separation of
the omentum was an intricate process that took inexperienced operators 10-15
minutes though with experience this operation could be completed within 2-3
minutes.
2.21 Dissection of the omentum for fluorescence microscopy
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The abdominal cavity was opened and the omental lymphoid organ and its associated
visceral peritoneal membrane recovered as previously described. Other samples of
peritoneal membrane were harvested prior to disposal of the carcass. Sections of
anterior abdominal wall peritoneal membrane were harvested from the anterior
midline region where the abdominal musculature was least abundant. Sub¬
diaphragmatic peritoneal membrane was removed by careful dissection of the central
region of the diaphragm. These samples of peritoneal membrane were mounted on
glass slides and covered as described in the previous section. The samples varied
somewhat is size but were typically 5x5 mm square sections.
2.22 Quantification of fluorescent cells within the omental lymphoid
organ and other regions of the peritoneal membrane
Labeled cells attached to the omental lymphoid organ were readily seen under
fluorescence microscopy. To directly compare the number of labeled apoptotic cells
attached to the omental lymphoid organ and other regions of the peritoneal
membrane, six randomly selected regions of the lymphoid organ were examined
2.23 Digestion of cells from the omental lymphoid organ and lymph
nodes
The omentum or parathymic lymph node was identified, dissected and incubated in 1
ml RPMI 1640 medium with 2.5% liberase (Roche) [1.67 Wunsch El/ml] and 1%
DNAse (Roche) for 30 minutes at 37°C. The partially digested lymphoid organ or
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lymph node was then disagregated by passed through a 40pm sieve using the plunger
from a 1ml sterile syringe. The disagregated cells were resuspended in cold PBS
with 5mM EDTA.
2.24 Preparation of a) resident and b) inflammatory M<ps for adoptive
transfer
Donor resident peritoneal macrophages were labeled in situ with PKH-26PCL dye
and peritoneal cells recovered 24 hours later by peritoneal lavage. Peritoneal cells
from several donor mice were pooled and resuspended with a macrophage
concentration of lxl 06 cells/ml. 0.5 ml of donor peritoneal cells were injected into
recipients either with 5x106 apoptotic cells (Hoescht 33342 labeled) or PBS. An
identical process was followed for the adoptive transfer of inflammatory Mcp except
that 0.5 mis of 3% brewers thioglycollate was injected IP 4 days prior to the injection
ofPKH-26PCL.
The concentration of Mcp was determined by manual counting on a haemocytometer
under fluorescent microscopy (red channel). At least 200 cells were counted to
determine the final concentration ofMcp.
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2.25 Preparation of mixed populations of cells for intraperitoneal
injection
Cells of interest were prepared as outlined earlier. Appropriate fluorescent labeling
was used to distinguish the populations of cells of interest (as discussed in Results
Chapters). Unless otherwise stated, all cells were resuspended to a final
concentration of lxlO10 cells/ml. Cells were differentially labeled to enable
identification by microscopy and/or flow cytometry (as discussed in Results
Chapters). Equal volumes (and hence equal numbers and concentrations) of cells
were mixed to create a 50:50 mixture of cells - no other proportion was used in any
experiments. Prior to IP injection, the cells were counted on a haemocytometer to
determine a) the presence of fluorescent label and b) the actual mixture of cells in the
suspension. An arbitrary tolerance of 50% ± 2% was allowed for each mixture
though in fact 50% ± 1% was achieved in practically all experiments. Flow
cytometry was used to determine the exact ratio of cells in some early experiments
until it became clear that the fluorescence microscopy technique was satisfactory.
The following mixtures of cells were used in the work described in this thesis:-
• Viable and apoptotic thymocytes from C57BL/6 mice
• C1 q +/+ and C1 qa -/- apoptotic thymocytes
• CD-31 +/+ and CD-31 -/- apoptotic thymocytes
• CD-31 +/+ and CD-31 -/- viable thymocytes
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2.26 Analysis of data
Experimental data were expressed descriptively as mean values with standard error
ofmean demonstrated using error bars or preceded by ± symbol. Experimental data
were compared using Student's t-test for comparison of two variables. In cases where
multiple variables were tested, ANOVA was utilised.
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3.1 Introduction
The first part of this study involved establishing a murine peritoneal in vivo assay for
the phagocytosis of apoptotic cells. We took the model employed by Taylor et al. for
their work on Clq in the phagocytosis of apoptotic cells (Taylor et al., 2000). This
involved the intraperitoneal instillation of apoptotic Jurkat cells - a human T-cell
lymphoma derived cell line - which were phagocytosed by either resident or
thioglycollate elicited inflammatory Mcp. The rate of phagocytosis of apoptotic cells
was determined by measuring the loss of free apoptotic cells and the uptake of
apoptotic cells by peritoneal Mcp. We elected to use murine thymocytes as our
source of apoptotic cells. These cells die in vivo by apoptosis and are cleared by
phagocytic Mcp (Surh and Sprent, 1994), though they are not naturally found within
the peritoneal cavity. As syngeneic cells, it seemed less likely that they would elicit
unwanted immunological or inflammatory responses as a result of cross-species
reactivity.
Mcp and apoptotic cells recovered from the peritoneal cavity can be analysed
microscopically eg cytospin analysis or by flow cytometry. Flow cytometry has the
advantages of speed and objectivity when compared with microscopy and these were
the principal reasons why flow cytometry was the preferred method for assessing the
phagocytosis of apoptotic cells from peritoneal lavage fluid. Methods to identify
Mcp, instilled apoptotic cells and other leukocytes within the peritoneal lavage fluid
were developed and validated. This work was then extended to develop a 'single
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platform' technique for counting cells within peritoneal lavages using only the flow
cytometer, rather than a combination of flow cytometry and microscopy. This
required the establishment of an internal standard to convert numbers of flow
cytometer recorded events into absolute numbers of target cells per ml of fluid.
Fluorescent beads, designed specifically for the calibration of flow cytometers,
provided the internal standard required for counting, based on an established
technique used to count human blood lymphocyte subpopulations (Nicholson et al.,
1997). The assay was then used to determine the kinetics of apoptotic cell clearance
from the peritoneal cavity ofC57BL/6 mice. A number of genetically manipulated
mice lacking genes encoding molecules believed to be important for the phagocytosis
of apoptotic cells were bred onto this background and comparative assays were
intended to be performed to establish whether knockout mice had in vivo defects in
the phagocytosis of apoptotic cells.
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3.2 Recovery and labeling ofperitoneal cells
Peritoneal cells were recovered by the instillation of PBS. The total number of cells
recovered from each lavage varied but was typically in the range of 0.5-1.0 xlO6
cells/ml in the non-inflamed peritoneal cavity. Flow cytometry with fluorescent
immunophenotyping was the principal technique used to identify and quantify
peritoneal Mcp. The labels used to identify the principal cell populations within the
peritoneal cavity are shown in Figure 8. Representative flow cytometry histogram
plots of major peritoneal cell populations are shown in Figure 9. A representative
forward versus side scatter dot plot of peritoneal lavage cells is shown in Figure 10.
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Figure 8. Immunolabeling markers forperitoneal leukocytes






Dendritic cell LO HI
HI=highest possible expression ofmarker; LO=Marker expressed, but at a significantly lower level
than HI; Blank box=marker not expressed.
'(Kishimoto et al, 1997)
Populations ofM(p, B- and T-lymphocytes were all identified amongst cells lavaged from the non-
inflamed peritoneal cavity. Neither DCs nor PMNs were found in non-inflamed, resident peritoneal
lavages. Bone marrow derived dendritic cells were used as a positive internal control for CD1 lc.
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Figure 9. Flow cytometric analysis of peritoneal leukocytes
Histograms showing fluorescence in FL2 channel. Faint line represents labeled cells whilst heavy line
represents isotype controls. Labels are rat anti-mouse B220-RPE (top), rat anti-mouse CD3-RPE
(middle) and rat anti-mouse F4/80-RPE. B220 labeled distinct HI and LO populations. B220-HI are
B-l lymphocytes whereas B220-LO are B-2 lymphocytes and M(p
83
CHAPTER 3 - RESULTS SECTION A
Figure 10. M<p and lymphocytes further defined by distinct










Mcp were clearly and specifically identified by F4/80 fluorescent immunolabeling. Furthermore,
applying a coloured gate to F4/80 HI cells identified Mcp as a population of cells with distinct forward
(FSC) and side-scattering (SSC) properties (purple events within R2). Similar gating by fluorescence
identified lymphocytes within a separate population with lower forward and side scattering properties
(blue events within Rl). In general terms, forward scatter approximately reflects the size of cells
whereas side scatter reflects their granularity. Mcp are larger and more granular than lymphocytes so
the relative FSC and SSC properties observed here are appropriate.
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3.3 Phagocyte-specific PKH dyes specifically taken up by
periteonal Mcp
The fluorescent PKH dyes (PKH-2 and PKH-26) can also be used to label peritoneal
Mq> in vivo (Melnicoff et al., 1988b). Fluorescent shifts of F4/80-HI M(p in the FL-1
and FL-2 channels are present 2 hours after the injection ofPKH-2 and PKH-26
respectively. Following excitation by a 488nm laser, PKH-2 emits light which is
detected in the FL-1 (green) channel. Emitted light from PKH-26 is detected in the
FL-2 channel.
Figure 11 below shows peritoneal lavage cells that were either pre-labeled in vivo
with PKH-2 (green fluorescence, FL-1 channel) or PKH-26 (red fluorescence, FL-2
channel). Peritoneal Mcp were then labeled with F4/80-PE/Cy5 (far-red, FL-4
channel). 99% of the cells which took up the fluorescent PKH dyes were F4/80-HI
Mcp. The remaining 1% were F4/80-LO cells and were probably immature
monocyte-Mcp.
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Figure 11. Peritoneal M<p specifically take up PKH-2 and
PKH-26 fluorescent dyes
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Peritoneal cells from control mice not receiving PKH-2 or PKH-26 have a clear F4/80-H1 population
(Y-axis) of M(p with FL-1 and FL-2 fluorescence less that 101 units (X-axis) (Panels A and C). The
F4/80-HI population acquires FL-1 fluorescence in animals that have received PKH-2 dye (Panel B)
and FL-2 fluorescence in those receiving PKH-26 (Panel D). Less than 1% of the PKH+ cells are
F4/80-LO.
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3.4 Identification of Flowcheck™ microspheres by flow cytometry
Flowcheck microspheres are polystyrene beads of 3 pm diameter that carry
fluorophore dyes emitting light detectable in multiple flow cytometer channels.
They form a population with very uniform FSC, SSC and fluorescent properties.
Their uniform size and fluorescence qualities make these beads ideally suited to the
calibration of flow cytometers. They are easy to separate from both the viable and
apoptotic cells used in this study.
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The small degree of variation in the size and shape of Flow-Check® microspheres means that they
form a very tight FSC/SSC population (left hand plot). They are polyfluorescent with a very narrow
range of emission intensity (right hand panels). These characteristics make it easy to distinguish
Flow-Check® microspheres from peritoneal cells by flow cytometry.
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3.5 Comparison between single and dual platform enumeration of
apoptotic cells
Obtaining the absolute number of cells in a sample by flow cytometry requires the
addition of a reference sample of beads to each sample prior to flow cytometry; so-
called single-platform counting. By establishing the number of cells of interest per
bead, the absolute number of cells per sample can be determined. This method is
widely used to precisely define leukocyte subsets in peripheral blood samples
(BCSH, 1997). Both single platform and haemocytometer based enumeration of
apoptotic thymocytes within peritoneal lavage fluid samples gave extremely similar
results (Correlation coefficients.96). However, single platform analysis was
considerably faster and was unaffected by sample contamination with erythrocytes.
For these reasons, single platform analysis was adopted for all subsequent
experiments.
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Figure 13. Correlation between single and dual platform







1,000 10,000 100,000 1,000,000
Apoptotic cells/ml lavage (Haemocytometer/flow cytmetry)
Y-axis shows apoptotic thymocytes counted by the addition of 5xl04 Flowcheck™ microspheres into
0.4 mis of various samples of peritoneal lavage fluid. 12,000 events were counted and the number of
apoptotic cells/ml lavage fluid calculated as described in 'Methods'. X-axis shows apoptotic cells
enumerated by counting total cells/ml by haemocytometry (see methods) and then the number of
apoptotic cells within each sample determined by flow cytometry.
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3.6 Macrophages phagocytose apoptotic cells
Apoptotic cells are identified within peritoneal lavage samples by flow cytometry.
They have the similar FSC and SSC characteristics as lymphocytes. Apoptotic
thymocytes have a slightly lower FSC than viable thymocytes as demonstrated below
(Figure 14).
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In this sample of thymocytes, approximately half are apoptotic, as defined by annexin-V positivity.
The majority of the apoptotic thymocytes have a lower FSC than the non-apoptotic thymocytes. This
reflects the loss of cell volume associated with apoptosis.
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Figure 15. Flow cytometry plots ofperitoneal M<p
phagocytosing apoptotic cells





b) After apoptotic cells
CMFDA-green
Flow cytometry dot plots of peritoneal lavage cells. Y-axis is F4/80-PE (FL2) and X-axis is CMFDA-
Green (FL1). Region l (Rl) defines Mcp (red); R2 defines apoptotic thymocytes (green). Top panel
shows peritoneal lavage cells derived from a non manipulated peritoneum. Bottom panel shows
peritoneal lavage cells obtained 15 mins after IP CMFDA-labeled IP apoptotic thymocytes.
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Apoptotic thymocytes injected IP are rapidly phagocytosed by peritoneal Mcp. This
can be demonstrated by flow cytometry. Apoptotic thymocytes labeled with
CMFDA-green were injected IP. After 15 minutes, the peritoneal cells were
recovered by lavage. Figure 15 shows recovered peritoneal lavage cells labeled with
F4/80-PE (Y-axis, FL-2) from mice which had received CMFDA+ apoptotic
thymocytes (panel B) and control mice which received no cells. In control mice
receiving no apoptotic cells (panel A), the F4/80-HI Mcp have <10 units of FL-1
fluorescence (X-axis, FL-1). The Mcp are defined by region 1 (Rl). In mice
receiving apoptotic thymocytes (panel B), the apoptotic thymocytes form a FL-1 HI,
FL-2 LO population (R2). Furthermore, some of the FL-2 HI Mcp in Rl have also
become FL-1 HI, indicating phagocytosis of the fluorescent apoptotic cells by Mcp.
3.7 Quantifying the phagocytosis ofapoptotic cells in vivo by flow
cytometry
Taylor et al. established two methods for quantifying phagocytosis of apoptotic cells
within the murine peritoneum by flow cytometry (Taylor et al., 2000). These were to
measure (i) the acquisition of apoptotic cell fluorescent marker by peritoneal Mcp
phagocytosing labeled apoptotic cells and (ii) the loss of apoptotic cells from the
peritoneal cavity over time. Both methods demonstrated delayed peritoneal
clearance of apoptotic cells in the Clqa -/- mouse compared to Clq +/+ control
animals. However, interpretation of the data from the acquisition of apoptotic cell
bome fluorescent label by Mcp was not straightforward.
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Figure 16. Phagocytosis of apoptotic Jurkat cells in C1qa -/-




















































Kinetic assay of fluorescently labeled apoptotic cell (Jurkat cells) peritoneal phagocytosis. Empty
circles represent C1 qa -/- mice; filled circles represent Clq +/+ control animals. Reproduced from
The Journal ofExperimental Medicine, 2000, 192,359-66 by copyright permission of Rockerfeller
University Press (Taylor et al., 2000)
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Figure 16A uses the acquisition of fluorescence from phagocytosed apoptotic cells as
a surrogate for the percentage of Mcp phagocytosing apoptotic cells. Figure 16B
shows the number of apoptotic cells recovered from the peritoneal lavage fluid. In
both cases, defective phagocytosis of apoptotic cells within the peritoneal cavity is
apparent in Clq -/- mice. Furthermore, the supply of apoptotic cells for phagocytosis
appears to have been exhausted after 30 minutes in the wildtype mice (Figure 16B)
although the percentage ofphagocytic Mcp remains around 30%, significantly above
the baseline. If Figure 16A were interpreted in isolation then a misleading
conclusion might be reached - that phagocytosis of apoptotic cells continued. Figure
16B seems to give a more straightforward representation of the true state of the
system. Therefore the loss of labeled, recoverable apoptotic cells was adopted as the
principle quantitative measurement of intraperitoneal apoptotic cell phagocytosis.
3.8 Kinetics of the phagocytosis ofapoptotic cells instilled IP into
C57BU6 mice
5xl06 CMFDA-green labeled apoptotic thymocytes in 0.5 mis of PBS were injected
intraperitoneally into C57BL/6 mice aged between 8-12 weeks. Peritoneal lavage
was performed after 1,5, 10 and 30 minutes and the recovered cells labeled and
counted by flow cytometry as described. The experiment was repeated on 3
occasions with 4-6 animals per time point in each experiment.
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The recovery of cells at 1 minute was intended to indicate the proportion of apoptotic
cells lost by mechanisms other than phagocytosis; 72.9 ± 1.7 % of injected apoptotic
thymocytes were recoverable at this time point.
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Figure 17. Intraperitoneal phagocytosis of apoptotic















5 10 15 20 25
Time after IP apoptotic cells (mins)
30
Y-Axis= number ofCMFDA-labeled apoptotic thymocytes recovered from C57BL/6 mice at various
intervals following their intraperitoneal injection. X-axis = time peritoneal lavage performed
following IP injection. N=12 per group; data from 3 experiments.
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3.9 'Disappearance' ofperitoneal M(p occurs synchronously with
apoptotic cell phagocytosis
Single platform enumeration of apoptotic cells using Flowcheck beads also allowed
the quantification ofMcp. Casual observation suggested that the frequency of Mcp
'events' observed by flow cytometry was lower in peritoneal lavages from animals
that had received apoptotic thymocytes than those which had not. Formal analysis
confirmed that the number of recovered M(p fell dramatically after IP apoptotic
thymocytes (Figure 18).
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Figure 18. M<p disappearance from C57BL/6 peritoneal lavages















5 10 15 20 25
Time after IP apoptotic cells (mins)
30
Y-axis = Number of F4/80-labeled peritoneal Mcp recovered from C57BL/6 mice at various time
intervals following the IP injection of 5x106 CMFDA-labeled apoptotic cells. X-axis = time that
peritoneal lavage was performed following IP apoptotic cells. Time 0 is the 'in-out' lavage of M(p
immediately after the IP injection of apoptotic cells. N=12 per group; data from 3 experiments.
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Most striking of all was the high degree of synchronicity observed between the loss
of apoptotic cells and the disappearance of peritoneal Mcp. When plotted on the same
graph, the rate of apoptotic cell and M(p disappearance are almost identical (Fig. 20).
Analysis of the peritoneal phagocytosis assay data (excluding 1 minute lavages)
showed a correlation between Mcp and apoptotic thymocyte recovery of +0.95
(Spearman's Rank Correlation). No significant correlation was seen in lavages taken
1 minute after the instillation of apoptotic cells, supporting the notion that this was a
time-dependent phenomenon.
The striking synchronicity of apoptotic cell clearance and Mcp disappearance from
the peritoneal cavity raised the possibility of a link between these two processes,
meriting further investigation. Moreover the nature of the peritoneal Mcp
'disappearance' was unclear. Both phenomena merited further investigation.
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Figure 19. Correlation between apoptotic cell phagocytosis and
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Apoptotic thymocytes/ml lavage fluid
200.000
Upper figure -Y axis (left) - Mcp recovered per ml of lavage fluid; Y axis (right) - apoptotic cells
recovered per ml of lavage fluid. Values shown are means. X-axis is time after IP injection of
apoptotic cells at which peritoneal lavages were performed.
Lower figure - same data set shown as scatter plot. Line of best fit displayed illustrating high degree
of correlation between Mcp and apoptotic cell recovery. Spearman's rank correlation coefficient =
+0.95. N=12 per group; data from 3 experiments.
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3.10 Summary
• Intra-peritoneal cells can be recovered by lavage, identified by
immunofluorescent labelling and counted by flow cytometry.
• Peritoneal lavage cells can be counted using a single platform flow cytometry
technique with Flowcheck™ microspheres as an internal control.
• Apoptotic thymocytes are rapidly phagocytosed by peritoneal Mcp.
• A profound loss of recoverable peritoneal Mcp occurs in synchrony with the
phagocytosis of apoptotic cells - a 'Macrophage Disappearance Reaction
(MDR).
3.11 Questions
• Where do the apoptotic cells and Mcp go following the MDR?
• Is the MDR a consequence of the phagocytosis of apoptotic cells?
• Can other bioparticles induce a MDR?
• What is the mechanism or mechanisms that drive the apoptotic cell induced
MDR?
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4.1 M<p disappearance reaction is neither caused by sham injection
nor injection of PBS
It was necessary to establish that the disappearance of peritoneal Mcp that followed
the injection of apoptotic cells was due to the apoptotic cells rather than some other
aspect of intraperitoneal injection. To that end, various control experiments were
undertaken. The MDR is known to follow the injection of killed bacteria (Haskill
and Becker, 1985) and pro-inflammatory substances such as thioglycollate
(Melnicoff et al., 1989). The risk that bacteria within the fur of experimental mice
might be transferred to the peritoneal cavity and induce a MDR was a potential
confounding factor in our previous observations. This was addressed in a number of
ways. Firstly, all reagents used in experiments were sterile and manufactured free of
lipopolysaccharide (LPS). Secondly, all preparation of substances for intraperitoneal
injection was performed in a negative pressure sterile tissue culture hood. Thirdly,
polymyxin B, which binds and deactivates LPS was added to all substances for
intraperitoneal injection. Fourthly, fur was shaved from the peritoneal injection site
and the underlying skin cleaned with a sterile wipe prior to injection. Finally control
experiments were performed to determine whether the MDR observed following
apoptotic cell injection was caused by the apoptotic cells or some other factor in the
injection.
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Groups ofmice were injected with a variety of control substances to test the
specificity of apoptotic cells as a causative agent of the MDR. In the following
experiment, mice were divided into the following groups:
• No intraperitoneal injection,
• Sham injection (i.e. skin breeched but NO intraperitoneal injection),
• 0.5ml PBS/polymyxin B (50pg/ml),
• 5x106 thymocytes, 80% viable (PI negative), 20% apoptotic in 0.5 mis
PBS/polymyxin (50pg/ml)
• 5xl06 thymocytes, 20% viable, 80% apoptotic in 0.5 mis PBS/polymyxin
30 minutes after these intraperitoneal injections, mice were sacrificed and peritoneal
cells recovered by a 5ml lavage. Mcp were labeled with F4/80-PE and counted by
flow cytometry as previously described.
Neither a sham injection nor the injection of 0.5 mis PBS/polymyxin B induced a
MDR. However, IP cells exhibiting either a low or high level of apoptosis induced
the disappearance of 59.5% and 82.8% of peritoneal Mcp (p=0.00004 and
p=0.000002 respectively). The MDR induced by highly apoptotic cells was
significantly greater than that induced by cells exhibiting a low level of apoptosis
(p=0.01) (Figure 20).
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Y-axis = Number of peritoneal M(p recovered by peritoneal lavage 30 minutes after various
intraperitoneal injections. X-axis = nature of peritoneal lavage. N=5 per group; 2
experiments*=statistically significant reduction in the number of Mcp recovered after the injection of
either low or high apoptotic cells compared to no IP injection. **=statistically significant reduction in
the number of Mcp recovered after IP high % apoptotic cells compared to low % apoptotic cells. N=5
per group; 2 experiments.
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LPS is not mediating the apoptotic cell-induced MDR
Lipopolysaccharide (LPS) is a pro-inflammatory substance which may induce a
MDR, though this has not been proven. Furthermore, LPS is produced by a wide
variety of bacteria and contamination of experimental reagents is often hard to avoid.
Experiments were therefore performed to determine whether LPS was entirely or
partially mediating the MDR. These employed polymyxin B, a powerful antagonist
of LPS (Jacobs and Morrison, 1977), and CD-14 knockout mice which are resistant
to LPS (Haziot et al., 1995).
CMFDA-labeled apoptotic thymocytes were prepared using the standard method and
resuspended at a concentration of lxl07/ml. Half of the apoptotic cells were
resuspended in PBS containing 0.5mg/ml polymyxin B and the remainder in PBS
without polymyxin B. Groups ofC57BL/6 female mice (6 mice per group) received
IP injections of apoptotic cells in suspensions with or without polymyxin B. After 30
minutes, the animals were sacrificed, the peritoneal cells lavaged with 5 mis PBS and
M(p labeled with F4/80 as previously described. Female littermates aged less than 10
weeks were used in all experiments.
A MDR was observed in mice receiving apoptotic cells either with or without
polymyxin B (Figure 21). Furthermore, similar losses of apoptotic cells were
observed in both groups, indicating similar levels of phagocytosis. No statistically
significant difference in either the size of the MDR or the loss of apoptotic cells was
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seen in mice receiving polymyxin B or PBS control injections. This suggested that
LPS was not mediating the apoptotic cell induced MDR.
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■ Macrophages - With Polymyxin
• Apoptotic cells - With Polymyxin
□ Macrophages - No Polymyxin
O Apoptotic cells - No Polymyxin
0 minutes 30 minutes
Y-axis = cells (Mcp or apoptotic thymocytes as indicated) recovered by peritoneal lavage after IP
injection of apoptotic thymocytes with or without polymyxin. X-axis = time interval between IP
injection and peritoneal lavage. N=4 per group; 2 experiments.
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To further examine the possibility that LPS was involved in the MDR, CD-14
knockout mice were used. These mice are known to be 10,000 times less responsive
to LPS than control mice (Haziot et ah, 1995). CD-14 has also been reported to play
a role in the phagocytosis of apoptotic cells in vitro (Devitt et ah, 1998). No
significant difference was seen between CD-14 knockout and wildtype mice in either
the rate of apoptotic thymocyte phagocytosis or the rate ofMcp disappearance (Figure
22). No significant difference was observed in the clearance of apoptotic cells,
though there was a trend towards impaired clearance in the CD-14 KO group (WT
Vs KO mice 1.36xl05 ± 1.78xl03 cells/ml Vs 1.18x105 ± 2.38xl03 cells/ml, p=NS).
The similar MDR in CD-14 wildtype and knockout animals further suggests that the
apoptotic cell-induced MDR is not a merely a consequence of LPS contamination.
Ill





Figure 22. The MDR is equivalent in LPS-insensitive CD-14 -/-







Y-axis=mean number ofM(p recovered per ml lavage fluid. X-axis= time elapsed after the IP
injection of 5x106 CMFDA labeled apoptotic thymocytes. N=5 per group; 2 experiments.
50,000
0 30
Minutes after IP injection
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4.2 The intraperitoneal administration of apoptotic human cells
also cause a MDR
Thus far the MDR had only been observed following the injection of murine
apoptotic thymocytes. To determine the generality of the apoptotic cell induced
MDR, apoptotic human Jurkat T-cells were injected IP and the effect on the Mcp
population was observed. Then 5xl06 CMFDA labeled apoptotic Jurkat cells
(45.76% apoptotic) were injected IP into female C57/BL6 mice which were
sacrificed 30 minutes later. Recovered Mcp and non-phagocytosed Jurkat cells were
counted by flow cytometry as previously described.
A MDR was observed following the injection of apoptotic human thymocytes
resulting in the disappearance of approximately 60% of the resident Mcp population.
An almost identical reduction in the number of apoptotic cells was observed. The
magnitude of apoptotic Jurkat cell clearance and the MDR was somewhat less than
the equivalent phenomena induced by apoptotic murine thymocytes. This probably
was a consequence of the lower proportion of apoptotic cells in the Jurkat cell
population (all data - Figure 23).
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Figure 23.
MDR
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Time since IP apoptotic cells (minutes)
Top figure - Y-axis= mean M(p recovered/ml lavage fluid; X-axis time interval between apoptotic
cell injection and peritoneal lavage
Bottom figure - Y-axis = mean apoptotic Jurkat cells recovered/ml lavage fluid; X-axis same as top
figure. N=6 per group; 2 experiments.
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4.3 Viable, non-apoptotic jurkat cells do not cause a MDR
The previous experiment had demonstrated that the IP instillation apoptotic human
Jurkat T-cells could induce an MDR. The loss ofMcp was smaller than observed
with apoptotic murine thymocytes. One possible explanation for this was the
presence of a higher proportion of viable cells than was generally present in
preparations of apoptotic murine thymocytes. It was decided to determine whether a
pure population of viable human Jurkal T-cells would, when instilled IP, cause a
MDR.
Viable Jurkat T-cells were taken directly from culture, washed, labeled with CMFDA
green and respuspended in PBS at a concentration of 1x106 cells/ml. PI and Hoescht
33342 labelling showed 0.5% necrosis and 1.2% apoptosis respectively. Then 5x106
CMFDA labeled viable Jurkat cells were injected IP into female C57/BL6 mice
which were sacrificed 30 minutes later. Recovered Mcp and non-phagocytosed Jurkat
cells were counted by flow cytometry as previously described.
Neither a significant MDR nor loss of Jurkat cells was observed 30 minutes after the
IP instillation of labeled Jurkat cells (Figure 24). Furthermore, there was little
evidence of murine Mcp-jurkat cell interaction seen on flow cytometry (ie few F4/80+
CMDFA + cells). These data suggested that murine Mcp did not phagocytose viable
Jurkat T-cells nor did the presence of Jurkat T-cells induce a MDR.
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Top figure - Y-axis = mean Mcp recovered/ml lavage fluid; X-axis = time interval between viable cell
injection and peritoneal lavage.
Bottom figure - Y-axis = mean viable Jurkat cells recovered/ml lavage fluid; X-axis same as top
figure. N=5 per group; 2 experiments.
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4.4 Apoptotic human PMNs cause a MDR
Further proof of the generality of the apoptotic cell induced MDR, apoptotic human
PMNs were injected IP and the effect PMNs (91% apoptotic) were injected IP into
female C57/BL6 mice which were sacrificed 30 minutes later. Recovered Mcp and
non-phagocytosed apoptotic PMNs were counted by flow cytometry as previously
described.
A very large MDR was observed following the injection of apoptotic human PMNs
resulting in the disappearance of 89% of the resident Mcp population. A 91%
reduction in the number of recovered apoptotic PMNs was also observed. The
magnitude of apoptotic Jurkal cell clearance and the MDR was comparible to that
seen when apoptotic murine thymocytes were injected IP, probably reflecting similar
high numbers of apoptotic cells instilled (in contrast to the IP injection of apoptotic
Jurkat T-cells). This probably was a consequence of the lower proportion of
apoptotic cells in the Jurkat cell population. A highly significant MDR was observed
following the IP injection of apoptotic cells (0 Vs 30 mins 2.65xl05 ± 2.51xl04
cells/ml Vs 2.97xl04 ± 1,97xl03 cells/ml p=0.00003, N=8, data from 2 experiments).
A significant loss of apoptotic PMNs was also seen (0 Vs 30 mins 6.93x105 ±
9.60x104 cells/ml Vs 6.29x104 ± 7.00x103 cells/ml p=0.00001, N=8, data from 2
experiments).
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Top figure - Y-axis, mean Mcp recovered/ml lavage fluid; X-axis time interval following apoptotic
cell injection.
Bottom figure - Y-axis mean apoptotic human PMNs recovered/ml lavage fluid; X-axis same as top
figure. N=8 per group, data from 2 experiments.
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4.5 Apoptotic thymocytes induce a greater MDR than latex beads
It was unclear whether the MDR which followed the injection of apoptotic cells was
due to the presence of apoptotic cells per se or the phagocytosis of apoptotic cells by
M(p. To that end, phagocytosable synthetic beads were injected IP and the
subsequent MDR compared with that induced by apoptotic cells. 5x106 2pm
fluorescent polystyrene beads (2 pm latex beads, carboxylate-modified polystyrene,
fluorescent yellow-green - Sigma-Aldrich Co. Ltd, UK) were injected IP in 0.5 mis
PBS. These beads were known to be readily phagocytosed by M(p (personal
communication Simone Brown). A second group ofmice received 5xl06 CMFDA
labeled apoptotic thymocytes. Mice from both groups were sacrificed after 30 mins,
peritoneal lavage performed and the number of recovered M(p, labeled apoptotic
thymocytes or beads counted by flow cytometry. Peritoneal lavage was also
performed in a group of uninjected control mice.
The injection of latex beads did induce a significant MDR with a 68% reduction in
the number of recoverable Mcp (p=0.001). However, a larger MDR (85% M(p
disappearance) was observed following the IP injection of apoptotic thymocytes
(p=0.0001 - Figure 26). The MDR induced by apoptotic thymocytes was
significantly greater than that induced by latex beads (p=0.01). More than 98% of
beads and apoptotic cells were cleared from the peritoneum during the course of the
experiment with no significant difference in the clearance of either particle observed.
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Figure 26. Apoptotic thymocytes induce a greaterMDR than















Control Lavages Beads Apoptotic cells
Latex beads and apoptotic thymocytes both induce a significant decrease in the number of recoverable
peritoneal Mcp. *=M<p significantly lower from control (P<0.05). **=Mip significantly lower than
beads (p<0.05). N= 7 per group; 2 experiments.
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4.6 Decreased phagocytosis of apoptotic cells and a decreased
MDR are observed in C1qa -/- mice
It has been established that the phagocytic clearance of apoptotic cells is significantly
reduced in the Clqa -/- knockout mouse (see Chapter l) (Taylor et ah, 2000). This
was manifested most clearly in a delayed removal of fluorescently labeled apoptotic
cells from the peritoneal cavity. This previous study used a very similar peritoneal
lavage technique to recover and count leukocytes but the number of recovered Mtp
was not commented upon. I hypothesised that if the disappearance ofM(p was
causally linked to the phagocytosis of apoptotic cells, and this was delayed in the
Clqa -/- mouse, the MDR might also be delayed in the Clqa -/- mouse.
The published data suggested that a high number of apoptotic cells would be required
to unmask the phagocytosis defect in the Clqa -/- knockout mouse. With this in
mind, 107 CMFDA-labeled apoptotic thymocytes were injected IP into Clqa -/-
knockout mice and age and sex matched wild-type control animals (all females).
After 30 minutes, animals were sacrificed, peritoneal cells recovered by lavage,
labeled and counted by flow cytometry, as previously described. Lavages of both
Clqa -/- knockout and control animals were also performed to establish the number
of lavagable peritoneal Mcp for each genotype ofmouse.
Approximately four times as many IP apoptotic cells were recovered from the Clqa -
/- knockout mice than controls 30 mins after IP apoptotic thymocyte injection
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(p=0.007 - Figure 27A). This demonstrated the expected defect in phagocytosis of
apoptotic cells known to exist in Clqa -/- mice (Taylor et al., 2000). There was no
significant difference between Clqa -/- knockout and control mice in terms of the
baseline number ofMcp. However, whilst a MDR was observed in both the Clqa -/-
knockout and control mice 30 minutes after IP apoptotic cells, this was significantly
larger in the control mice than Clqa -/- knockout mice (p=0.0007 - Figure 27B).
This suggested that either Clq itself is actively involved in the MDR or that
defective phagocytosis of apoptotic cells is associated with a smaller MDR.
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Figure 27. Decreased phagocytosis of apoptotic cells and a








C1q Knockout mice C1q Wildtype mice
Mcp/ml lavage fluid
Top panel: non-phagocytosed apoptotic thymocytes remaining 30 minutes after IP injection into
either Clqa -/- or +/+ mice or matched controls. Bottom panel: peritoneal Mtp recovered from either
control non-manipulated Clqa -/- or +/+ mice (i.e. no IP injection) or Clqa -/- mice (hatched bars) and
control +/+ animals (solid bars) 30 minutes after the instillation of lOxlO7 apoptotic thymocytes
Marker A - significantly more apoptotic cells were phagocytosed by peritoneal Mcp in Clq +/+
compared with Clqa -/- mice (p=0.007). Marker B - no significant difference between the baseline
number ofmacrophages lavaged from Clqa -/- and +/+ mice at baseline. Marker C - significantly
larger MDR seen in Clq +/+ than Clqa -/- mice (p=0.0007). N=7 per group; 2 experiments.
123
CHAPTER 4 - RESULTS SECTION B
4.7 The effect of exogenous C1q opsonisation on the phagocytosis
of apoptotic thymocytes
The defective clearance of apoptotic cells observed in the Clqa knockout mouse is
believed to be due to the absence ofClq bridging the surface of apoptotic cells to the
M(p. It follows that fully competent phagocytosis of apoptotic cells could potentially
be restored by the opsonisation of apoptotic cells with Clq. To test this, CMFDA-
labeled apoptotic thymocytes from Clqa -/- mice were opsonised in either 50pg/ml
of human recombinant Clq or 50pg/ml BSA in RPMI 1640 plus 10% Clqa knockout
mouse serum. After thorough washing, the apoptotic thymocytes were resuspended
at lxlO7cells/ml in PBS and injected IP into female Clqa -/- mice (N=6 per group).
After 30 mins, peritoneal lavages were performed and M(p and apoptotic thymocytes
remaining were counted. The results were compared against control mice in which
no apoptotic cell injection was given.
A significant MDR was observed in mice receiving apoptotic thymocytes opsonised
with either Clq or BSA. The MDR was larger when Clq opsonised, rather than
BSA treated apoptotic thymocytes were injected. However, this difference did not
reach statistical significance (p=0.1 - Figure 28). Similarly, the clearance ofClq-
opsonised apoptotic cells was greater than that of BSA-opsonised apoptotic cells but
again this did not reach statistical significance (p=0.39). Unfortunately, no
information was available regarding the adequacy of opsonisation by this method.
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Figure 28. Opsonisation of apoptotic cells with C1q neither



























Top panel: Y-axis= M(p recovered 30 minutes after the injection of apoptotic thymocytes opsonised
with Clq, BSA or after no injection (control); X-axis= opsonising agant. Bottom panel: Y-axis=
apoptotic thymocytes recovered 30 minutes after IP injection. X-axis= opsonising agent. N=6 per
group; 1 experiment.
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4.8 The addition of EDTA, but not the absence of Ca2+ from IP
buffer solution, affects both the phagocytosis ofapoptotic cells
and the MDR
The question of the possible mechanisms underlying the MDR was then addressed.
Extracellular Ca2+ is an important modulator ofmany adhesion molecules including
• • 2~t~ • • • •
integrins. The effect of extracellular Ca was tested by injecting apoptotic
thymocytes in PBS either with or without Ca2+. For extra stringency, apoptotic cells
were suspended in 5mM EDTA in PBS without calcium and were also injected IP in
an attempt to chelate extracellular Ca2+ present within the abdomen. As in previous
experiments, 5xl06 apoptotic thymocytes were injected IP, peritoneal lavage was
performed after 30 minutes and labeled cells were counted by flow cytometry.
A significant MDR occurred after apoptotic thymocytes were injected in PBS with or
without Ca2+ and without Ca2+ but with 5mM EDTA. The absence of Ca2+ from PBS
made no difference to either the magnitude of the MDR or the clearance of apoptotic
• • • 2"b
thymocytes. However, the suspension of apoptotic thymocytes in PBS lacking Ca
and containing EDTA resulted in a greater MDR than when EDTA was absent which
only just failed to reach statistical significance (p=0.06). The clearance of apoptotic
• 2+cells was significantly lower when they were injected with PBS (without Ca )
containing EDTA than PBS (without Ca2+) alone (p=0.0002). These results
suggested that removing Ca2+ from the extracellular fluid inhibited the clearance of
apoptotic thymocytes but not the MDR (Figure 29).
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Figure 29. The effect of Ca2+ and EDTA containing solutions on










No injection PBS with Ca++ PBS minus PBS with
Ca++ EDTA







No injection PBS with Ca++ PBS minus PBS with
Ca++ EDTA
Top figure: Y-axis = Mtp recovered from peritoneal lavage 30 minutes after the IP injection of
apoptotic thymocytes in PBS with or without Ca2+ or without Ca2+ but containing 5mM EDTA; X-
axis= nature of vehicle solution for apoptotic cells. Bottom figure: Y-axis = apoptotic thymocyte
recovery from same experimental conditions. ^ Significantly more apoptotic cells were recovered
when injected with PBS (minus Ca2+) with EDTA compared with PBS (minus Ca++) - p=0.0002.
N=6 per group; 1 experiment.
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4.9 The addition ofArg-Gly-Asp (RGD) peptide reduces both the
MDR and the clearance of apoptotic cells
It has been shown that M(p emigration to regional lymph nodes is partially mediated
by (X4P1 and (X5P1 integrins (Bellingan et al., 2002). The peptide RGD (Arg-Gly-Asp)
blocks the binding of P integrins to their ligands. A role for Pi integrins in the MDR
was investigated by adding RGD peptide to apoptotic thymocyte suspensions prior to
their IP injection. The peptide RGE (Arg-Gly-Glu) acted as a non-blocking control
peptide. 5xl06 CMFDA-labeled apoptotic thymocytes were suspended in either
O.lmM RGD or O.lmM RGE in PBS. The thymocytes were injected IP and
peritoneal lavage performed after 15 minutes. It had become clear that the MDR was
a difficult reaction to modulate and previous experiments to completely block it had
proved unsuccessful. Focus was shifted to delaying, rather than stopping, the MDR
altogether. For this reason, the earlier 15 minute timepoint, midway through the
MDR, was chosen. Lavaged cells were labeled and counted by flow cytometry using
the standard method.
The MDR that followed the IP injection of apoptotic thymocytes was significantly
reduced when thymocytes were injected with RGD peptide than with the RGE
control (p=0.037). A similar reduction in apoptotic thymocyte clearance was also
observed when apoptotic thymocytes were injected with RGD peptide but this was
not statistically significant (p=0.151). The there was no significant difference in the
number ofM(p recovered 30 minutes after the IP injection of RGD or RGE peptide
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alone (RGD Vs RGE 6.72xl04 ± 8.98xl03 Vs 7.30xl04 ± 1.20xl04. p=NS, N=6 per
group, 1 experiment).
Although the difference in apoptotic cell clearance was not statistically significant,
these data strongly suggested that RGD was having an effect both on apoptotic
thymocyte phagocytosis and the MDR. It was impossible to say whether the RGD
effect on the MDR was due to direct inhibition of a Pi-mediated mechanism ofMcp
disappearance or due to the inhibition of apoptotic cell phagocytosis.
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Apoptotic cells & RGDS Apoptotic cells & RGES
Top figure: Y-axis= Mcp recovery after the IP injection of apoptotic thymocytes with either O.lmM
RGD or O.lmM RGE peptide X-axis= nature of IP apoptotic cell vehicle solution. (*p=0.037);
Bottom figure: Y-axis= Apoptotic cell recovery from same lavage fluid samples. X-axis= as top
figure. *p<0.05 when compared with RGES (no significant difference). N=5 per group; 2
experiments.
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4.10 Hyaluronidase increases the MDR but has no effect on the
phagocytosis of apoptotic cells
Various studies have highlighted a role for hyaluronic acid, a widely-distributed
component of the extracellular matrix, in the MDR induced by pro-inflammatory
stimuli. In particular, studies in 1980 showed that the MDR induced by IP BCG was
reduced by pre-conditioning the peritoneal cavity with IP hyaluronidase and
increased by pre-conditioning with IP hyaluronic acid itself (Shannon et al., 1980,
Shannon and Love, 1980). The conclusion of these studies was that hyaluronic acid
within peritoneal extracellular matrix was acting as a ligand for an unidentified M(p
receptor. Against this background, the effect of hyaluronidase on the MDR was
tested.
5xl06 CMFDA-labeled apoptotic thymocytes in 0.5mls PBS were injected IP one
hour after an IP injection of either 20 units of streptomyces hyaluronidase (in 0.1ml
PBS) or a control injection of 0.1 ml PBS. Previous control experiments had shown
that this dose of hyaluronidase would not in itself induce a MDR (1.23xl05±9.40xl03
Mcp/ml Vs 1.01x105±1.13x104 Mcp/ml; IP 0.2mg hyularonidase in lOOpl PBS Vs
lOOpl PBS only, lavages performed 30 minutes after injections, N=4 per group,
p=NS). Mice receiving no IP injections acted as a control group. The mice were
sacrificed 30 minutes after the second IP injection, the peritoneal cavities were
lavaged and cells counted by flow cytometry using the standard method.
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No difference in the clearance of apoptotic cells was seen following peritoneal pre¬
conditioning with either PBS or hyaluronic acid (p=0.65 - Figure 31). However, a
significantly lower number ofMcp were recovered from the mice that had received
hyaluronidase than those receiving PBS pre-treatment (p=0.04). A substantial MDR
nonetheless occurred in both groups ofmice.
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Figure 31. Hyaluronidase increases the MDR but has no effect




























Top panel: Y-axis = the number of M<p recovered 30 minutes after IP apoptotic thymocytes following
peritoneal pre-conditioning with either PBS or hyaluronidase; X-axis=nature of pre-conditioning.
Bottom panel: Y-axis = the number of apoptotic thymocytes recovered from the same groups ofmice;
X-axis= nature of peritoneal pre-conditioning. * p<0.05 compared with hyaluronidase. N=5 per
group; 1 experiment.
133
CHAPTER 4 - RESULTS SECTION B
4.11 Unfractionated heparin reduces the MDR but does not affect
the phagocytosis of apoptotic cells
Activation of the coagulation system had been shown to mediate the MDR that
follows the induction of pleurisy using a number of sterile irritants in rats (Sultan et
al., 1978). In these experiments, the coagulation cascade was inhibited in vivo by the
systemic administration of heparin and warfarin. The use of both these
anticoagulants delayed the pleural MDR when compared to controls.
It was decided to inhibit the local coagulation cascade by injecting unfractionated
heparin IP together with apoptotic cells and observing the effect on the MDR. 5x106
CMFDA-labeled apoptotic thymocytes were injected IP with either 4 units of
unfractionated heparin or PBS into groups of C57BL/6 mice. After 15 minutes, the
animals were sacrificed and peritoneal cells recovered by lavage. These cells were
labeled and counted by flow cytometry as previously described.
There was no significant difference in the number of apoptotic thymocytes recovered
from either the mice receiving PBS or heparin IP (p=0.81). A significant MDR was
observed after IP apoptotic thymocytes, either with or without heparin. However,
almost 3 times as many M(p were recovered from mice that had received IP heparin
with apoptotic cells than those receiving PBS (p=0.02 - Figure 32).
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Figure 32. Unfractionated heparin reduces the MDR but does










No Apoptotic cells After apoptotic cells
Grey bar= with heparin
Hashed bar= with PBS
Y-axis = maan number of M(p recovered from unmanipulated peritoneal cavity (black bar). Mean
number of Mcp recovered from peritoneal cavity following IP apoptotic cells either with heparin (grey
bar) or with PBS (hashed bar). * p<0.05 compared with control; ^ p<0.05 compared with apoptotic
cells and PBS. N=5 per group; 2 experiments.
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4.12 De-O-sulphated heparin, lacking anticoagulant activity, does
not reduce the MDR
The previous experiment had highlighted that heparin inhibited the MDR.
Nonetheless, this did not necessarily implicate the coagulation cascade in the
apoptotic cell induced MDR. Heparin has many effects on leukocytes that are
independent of inhibition of the coagulation system and, in particular, may affect
leukocyte migration and the complement system (Ekre et ah, 1992). To try and
establish whether the reduction in the MDR was due to inhibition of the coagulation
cascade, chemically modified heparin (N-Acetyl-de-O-sulfated heparin sodium salt -
'deactivated heparin') which has no anticoagulant properties (Moffat et al., 1991)
was compared to standard unfractionated heparin in its effect on the apoptotic cell
induced MDR. To that end, 5xl06 CMFDA-labeled apoptotic thymocytes in 0.5mls
of PBS were injected IP with either 4 units of heparin or 200pg of deactivated
heparin. The doses of heparin and its control were based on an approximate
equivalence ofmolarity (approximate as unfractionated heparin is a mixture of
different molecules). Control groups ofmice received injections of active or
deactivated heparin with 0.5 mis PBS only. The mice were sacrificed and peritoneal
lavage performed 15 minutes following IP injection. Peritoneal cells were labeled
and Mcp counted by the standard method previously described.
There was no difference in the clearance of apoptotic thymocytes between the groups
ofmice receiving active or deactivated heparin (heparin Vs deactivated heparin
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8.47xl05 ± 2.27xl04 cells/ml Vs 7.88xl05 ± 2.50xl04 cells/ml p=0.51). Neither was
an MDR observed following the IP injection of either active or deactivated heparin
with PBS. However, the injection of deactivated heparin with apoptotic thymocytes
resulted in a significant MDR with disappearance of 57% of the original M(p
population (p=0.0015). This MDR induced by apoptotic thymocytes and deactivated
heparin was significantly greater than that caused by the administration of apoptotic
thymocytes and active heparin (p=0.018). Furthermore, the co-injection of apoptotic
cells and 'active' heparin did not cause a significant MDR, reinforcing the previous
data showing an inhibitory effect of heparin on the apoptotic cell-induced MDR.
To summarise, the apoptotic cell induced MDR was significantly reduced by
administration of IP unfractionated active heparin but not N-Acetyl-de-O-sulfated
heparin sodium salt, which lacks anticoagulant properties. These data suggest that
the coagulation cascade participates in the apoptotic cell induced MDR.
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p=NS















No injection Heparin & Deactivated Heparin & Deactivated
ACs heparin & PBS heparin &
ACs PBS
Y-axis= number of Mcp recovered 15 minutes after IP injections of combinations of apoptotic cells,
heparin and de-O-sulphated heparin ('deactivated heparin') as indicated by X-axis. N=5 per group; 1
experiment.
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4.13 Summary
• The MDR observed following IP apoptotic cells is not caused by LPS
contamination
• The IP instillation of apoptotic but not viable human Jurkat T-cells also
induced a MDR.
• The IP instillation of apoptotic human PMNs also induced a MDR.
• Phagocytosable latex beads induce an MDR, though of a lesser magnitude
than the apoptotic cell induced MDR
• The absence ofClq from apoptotic cells results in both reduced phagocytosis
by M(p and a lesser MDR
• EDTA and the RGD peptide inhibit the phagocytosis of apoptotic cells and
the apoptotic cell-induced MDR
• Hyularonidase increases the magnitude of the MDR without affecting the
phagocytosis of apoptotic cells
• Unfractionated heparin reduces the magnitude of the MDR without affecting
the phagocytosis of apoptotic cells
4.14 Questions
• Where do the disappearing M(p go following the apoptotic cell-induced
MDR?
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5.1 Introduction
In the previous chapter, various characteristics of the apoptotic cell induced MDR
were established. This chapter will address a separate aspect of the MDR, namely
what happens to the Mcp following their 'disappearance'. It is worth mentioning that
the fate of the Mcp is likely to be intimately linked to the fate of the IP injected
apoptotic cells. It has been established in previous studies that Mcp are responsible
for the clearance of IP injected apoptotic cells from the peritoneal cavity (Taylor et
ah, 2000). Flow cytometry data has already been presented in this thesis to show that
apoptotic cells are recovered from the peritoneal cavity either in isolation or
associated with Mcp (Chapter 2 - Results Section A). Apoptotic cells do not appear to
associate with any other cell within the peritoneal cavity. As the IP injected
apoptotic cells are fluorescently labeled, it was decided to identify where they went
after IP injection. It seemed a reasonable deduction that the disappeared Mcp would
be located with the apoptotic cells.
5.2 IP instilled apoptotic cells are not found in the spleen or
circulating blood
It was first decided to look for evidence for the emigration of apoptotic cells beyond
the peritoneal cavity. 5x106 fluorescently labeled apoptotic thymocytes (labeled with
CMFDA green as previously described) in 0.5mls PBS were injected IP into
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C57BL/6 mice. Labeling was checked pre-injection and fluorescence was found to
be increased by 103 in the FL-1 channel when compared to unlabeled apoptotic cells.
0.5 mis of PBS was injected into a separate group of control animals. 30 minutes
after the IP injections, the mice were sacrificed by terminal anaesthesia and cardiac
puncture, peritoneal lavage and splenectomy performed. The spleen was
disaggregated using a combination of physical and enzymic degradation (see
methods). Both whole blood and the splenic cell suspension were subjected to
hypotonic saline to achieve erythrocyte lysis. The remaining cell suspension was
then analysed by flow cytometry to see if there was any evidence of a population of
FL-1 HI cells representing either the CMFDA labeled apoptotic cells or Mcp that had
phagocytosed these cells (Figure 34).
In fact, there was no evidence ofCMFDA Green"1" cells in either the blood or spleen.
The experiment was repeated including an F4/80-PE labeling step to identify the
monocyte-Mcp cell population but even with specific gating on this population, no
shift in FL-1 fluorescence was observed. Similarly, no green fluorescent cells were
visible by microscopy of the blood and splenocyte cell suspensions.
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Figure 34. No FL-1 fluorescent shift apparent in blood or spleen
after IP CMFDA Green+ apoptotic thymocytes
Spleen
CMGreen (FL-1)
Histograms of FL-1 fluorescence for ungated blood cells (top graph) and splenic cells (bottom graph).
In both panels, Y-Axis = number of collected events; X-axis = log measure of FL-1 fluoresence.
Black line=cells after IP PBS injection; green line=cells after IP CMFDA-labeled apoptotic
thymocytes. Sample of one data set. N=5; 1 experiment.
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5.3 IP injected apoptotic cells concentrate within the omental
lymphoid organ
Having failed to find the 'disappeared' apoptotic thymocytes in spleen or blood,
attention was turned to the peritoneal membrane itself. The majority of the
peritoneal membrane is a homogeneous layer ofmesothelial cells enclosing a
vascularised connective tissue layer. However, there are regions within the
peritoneal membrane where Mcp are concentrated in large numbers; the so-called
milky spots (see earlier). As previously discussed, the greatest concentration of
milky spots is found within the omentum, also a well-established site of peritoneal
leukocyte trafficking. For these reasons it was decided to look for apoptotic cell
localisation to different regions of the peritoneal membrane, including the omental
lymphoid organ, where milky spots are most abundant.
5x106 apoptotic thymocytes (CMFDA labeled) were injected IP into 6 female
C57BL/6 mice. The mice were sacrificed after 30 minutes and their omenta were
carefully dissected together with its associated peritoneal membrane. Intact
segments of peritoneal membrane were also removed from the anterior abdominal
wall and the diaphragm. These tissues were wet mounted on microscopy slides and
examined under transmitted or fluorescent microscopy. The number of apoptotic
thymocytes per high powered field was counted for all regions of peritoneal
membrane.
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It was immediately obvious that many more apoptotic thymocytes were present
within the omental lymphoid organ than the other regions of peritoneal membrane.
Approximately 28 times as many apoptotic cells were counted with the omental
lymphoid organ as the other regions of peritoneal membrane (p=0.00001 - Figure
35). No significant difference was seen in the number of apoptotic cells binding the
other regions of peritoneal membrane examined.
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Omentum Adjacent to Anterior Sub-
omentum abdominal wall diaphragmatic
Regions of the peritoneal membrane
Y-axis = mean number of apoptotic thymocytes counted per high power field. X-axis= sampled
region ofmurine peritoneal membrane (XI5 magnification). N=5; 1 experiment.
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5.4 IP instilled apoptotic cells concentrate with omental milky
spots
Having established a striking localisation of apoptotic cells to the omentum
following IP administration, the question of where these apoptotic cells were
localised was next addressed. As has been previously discussed, the omentum is an
unusual part of the peritoneal membrane in that it contains a very large number of
milky spots, specialised Mcp-rich components of the CALT system. It seemed likely
that these structures, with their abundance of phagocytic M(p were the site of
apoptotic cell localisation within the omentum.
A phagocyte-specific dye, PKH-26, was used to identify the M(p within omental
milky spots. This dye is known to almost exclusively label Mcp within the
uninflamed peritoneal cavity (Melnicoff et al., 1988b), a result confirmed in this
study (see Chapter 3 - Results Section A). 0.5 mis of PKH-26 dye in the
manufacturer's diluent will label the entire lavageable peritoneal M(p population
within 2-4 hours. When the omenta ofmice receiving PKH-26 were dissected and
examined under fluorescence microscopy, Mcp-rich milky spots were readily
discernable (Figure 36).
147
CHAPTER 5 - RESULTS SECTION C
Figure 36. PKH-26 (red) fluorescent M(p visible within omental
lymphoid organ milky spots
Composite of six transmitted-light fluorescence microscopy images of an omental lymphoid organ
following IP PKH-26 dye. Aggregations of red fluorescently-labeled Mq> can be seen along the lateral
aspects of the organ. A representative milky spot is highlighted with a blue circle. Magnification xl5.
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Although the PKH-26 dye readily identified the milky spots, it was also possible to
identify these structures by transmitted light microscopy (Figures 36 & 37). As their
name suggests, the milky spots have a milky white colour and finer texture than the
surrounding cells, which are predominantly adipocytes. The finer texture of the
milky spots is a consequence of the smaller size of the leukocytes within the milky
spot when compared to the larger surrounding adipocytes. This allowed milky spots
to be identified without necessitating the use of pre-labeling with PKH dyes.
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Figure 37. Unlabeled milky spot viewed under transmitted light
microscopy
Central area shows finer, more granular cells corresponding to a milky spot. Surrounding larger cells
are mostly adipocytes. Blood vessel entering milky spot at '2 o'clock' just visible (outlined with red
lines). Magnification x20.
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Figure 38. Unlabeled milky spot viewed under transmitted light
microscopy
Adipocytes are clearly seen in the top left quadrant. A blood vessel runs from the top left quadrant
and branches within a milky spot in the lower left quadrant. Note again the finer more granular
appearance of the cells within the milky spot. Magnification x20.
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The question ofwhether IP injected, CMFDA-labeled apoptotic cells were taken up
by the omental milky spot M(p was addressed next. Milky spots were highlighted by
pre-labeled peritoneal Mcp with PKH-26 dye, as previously discussed. Next, 107
apoptotic thymocytes, double labeled with CMFDA-green and Hoescht 33342 were
injected IP into C57BL/6 female mice. After 30 minutes, the mice were sacrificed
and the omenta removed and examined under transmitted fluorescent microscopy.
Fluorescent exposures were taken in both the blue and red transmitted channels and
composite photomicrographs made. Representative images are shown (Figures 38
& 39).
152
CHAPTER 5 - RESULTS SECTION C
Figure 39. Colocalisation of labeled apoptotic cells and M<p
within the omental milky spots (A)
Three representative composite (red & blue channels merged) transmitted fluorescence
photomicrographs of omental milky spots 30 minutes after the injection of Hoescht 333342 labeled
apoptotic thymocytes. Resident peritoneal Mcp had been pre-labeled with PKH-26 fluorescent tracker
dye (red). (xl5)
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Figure 40. Colocalisation of labeled apoptotic cells and M<p
within the omental milky spots (B)
Fluorescent photomicrographs ofmilky spot 30 minutes after the IP injection ofCMFDA green-
labeled apoptotic thymocytes. Again, Mcp pre-labeled with PKH-26 red fluorescent dye. Individual
red and green channel photos are shown (top and middle) plus composite image (bottom). The
colocalisation of red and green labels give a yellow colour in composite picture. Nonetheless, some
individual red and green labelled cells can be seen. (xl5)
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5.5 Omental Mq> phagocytose IP injected apoptotic cells
These observational studies strongly suggested that there was direct contact between
apoptotic cells and M(p and possibly phagocytosis of apoptotic thymocytes by Mcp.
To test this further, CMFDA-green labeled apoptotic thymocytes were injected IP
into groups ofmice. After 30 minutes, omentectomies were performed and the
omental lymphoid organs removed and digested as previously described. The
omental cell suspension was then labeled with rat anti-mouse F4/80-PE/Cy5 Ab.
The labeled cell suspension was then analysed by flow cytometry to assess firstly
whether there was direct contact between the peritoneal M(p and apoptotic cells and
secondly whether unattached 'free' apoptotic cells were present within the omental
lymphoid organ.
The FL-4 fluorescence was then analysed by flow cytometry and compared with
unlabeled cells (Figure 41). A population of cells displayed a significant increase in
FL4 fluorescence (red line). These fluorescent cells had the typical FSC/SSC
characteristics of peritoneal Mcp. No such shift was seen in cells labeled with the
isotype control (grey line) or unlabeled cells (black line).
The recovery process of omental Mcp was relatively inefficient and gating was quite
stringent so only a relatively small number of omental M(p were recovered.
However, it was apparent that a significant proportion of the omental Mcp acquired
FL-1 fluorescence following the injection of IP CMFDA-labeled apoptotic
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thymocytes (Figure 41). It was not possible to assess this quantitatively but it
appeared that the majority of omental Mcp had gained some FL-1 fluorescence after
the IP injection ofCMFDA-labeled apoptotic cells. Virtually no free FL-1+ cells
were seen, suggesting that most of the IP injected apoptotic cells were either bound
to or phagocytosed by omental Mcp.
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Y-axis= number of detected events; X-axis = log measurement of FLA fluorescence. Cell suspension
recovered from the digested omenta labeled with rat anti-mouse F4/80-PE/Cy5 (red line), PE-Cy5-
labeled isotype control antibody (grey line) unlabeled cells (black line). Representative image from
N=3; l experiment.
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Figure 42. Omental M<p phagocytose CMFDA-green labeled
apoptotic cells and acquire green fluorescence
101 10s 105
CMFDA Green (FL-1)
Red Line= M(ps after IP apoptotic thymocytes
Black Line= Mq>s after IP PBS
Flow cytometry FL-1 histogram of digested omental Mcp - identified by gating for F4/80-PE/Cy5-FlI
fluorescent cells (from figure 41). Red line represents FL-1 fluorescence of recovered omental Mcp 30
minutes after 5x106 CMFDA+ apoptotic thymocytes. Black line represents FL-1 fluorescence of
omental Mcp 30 minutes after IP PBS.
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5.6 Peritoneal lavage technique samples 'free' intraperitoneal M<p,
not those within milky spots
The power of the intraperitoneal injection/lavage technique of instilling and sampling
cells from the peritoneal cavity is that it is fast and minimally destructive. This
allows for kinetic observations of the movement of peritoneal Mcp to be made over
short and tightly-separated time intervals. However, a crucial problem is that it is
unclear whether a peritoneal lavage recovers cells from the entire peritoneum,
including the clusters of Mcp within omental milky spots or the non-milky spot
populations of Mcp. Intuitively, one might imagine that the omental milky spot Mcp,
being more organised, were less likely to be recovered by a lavage technique. This
question has relevance for the interpretation of the data presented within this chapter
and was addressed experimentally in the following way.
A group of 10 C57BL/6 mice were sacrificed and peritoneal lavage performed with a
modification to the standard method. A small - approximately 3mm - incision was
made in the peritoneal membrane in the left upper quadrant over the omental
lymphoid organ. Then in 5 animals, the omental lymphoid organ was carefully
externalised through this incision and the peritoneal membrane closed with a
mosquito clip. In the remaining 5 animals, the incision was closed with the omentum
remaining within the peritoneal cavity. With the clamp in place, all 10 animals then
underwent a standard peritoneal lavage. The Mcp were then labeled with F4/80-PE
and counted by flow cytometry using the standard method previously described.
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The number of recovered peritoneal Mcp was virtually identical whether the lavage
had been performed with the omentum inside or outside of the peritoneal cavity
(Figure 43). Peritoneal lavage does not appear to remove Mcp from the omental
lymphoid organ (omentum externalised Vs internalised - 6.29xl05 ± 4.43xl04
Mcp/ml Vs 6.19xl05 ± 8.90xl04 Mcp/ml, p=NS). This suggested that the peritoneal
lavage technique selectively recovered non-omental 'free' peritoneal Mcp. A
particularly interesting consequence of this result is that it suggests that during the
MDR, non-adherent Mcp actively attach themselves to a structure or structures within
the peritoneal cavity. The possibility that the MDR is merely omental Mcp becoming
more adherent as a consequence of encountering apoptotic cells, is made less likely
by this experiment.
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Figure 43. The cxternalisation of the omentum has no effect on










Externafized omentum Non-externafeed omentum
Condition of omentum during lavage
Y-axis = the number of peritoneal M(p per ml of peritoneal lavage fluid; X-axis shows whether the
omentum was within or outside the peritoneal cavity at the time the lavages were performed. N=5 per
group; 2 experiments.
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5.7 Peritoneal M<p enter the omental lymphoid organ following IP
apoptotic cells
It has already been shown that, following the IP administration of apoptotic cells, a
rapid fall in the number of recoverable peritoneal M(p was observed. The immediate
fate of these Mcp was unknown but, given the previously proven role ofmilky spots
in the emigration of inflammatory peritoneal M(p (Bellingan et al., 2002), the
possibility that these Mcp were attaching themselves to the omental lymphoid organ
was investigated. Whilst it is relatively straightforward to label peritoneal Mcp with
the PKH dyes (see Methods), there is no similar method to selectively label omental
versus other intraperitoneal Mcp. The fate of intraperitoneal Mcp was thus determined
by a combination of inferential and adoptive transfer experiments.
The first experiment aimed to see whether there was a change in the size of the
omental Mcp population allowing the IP administration of apoptotic cells. If an
increase in the number of omental Mcp was observed, then this could indicate that
Mcp were being recruited to the omental lymphoid organ. Furthermore, if the entire
peritoneal Mcp population was pre-labeled with PKH dye prior to the injection of
apoptotic cells, any newly-arrived Mcp within the omentum could be identified as
either intra- or extra-peritoneal in origin.
A further complication was the innate heterogeneity of omental lymphoid organs and
differences in the amount of tissue recovered during dissection. There was
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considerable variation in both of these parameters. This meant that in any
experiment, the variation in the absolute number of Mcp recovered was considerable.
Using the absolute number ofMcp as a means to measure relatively small changes in
the omental Mcp population would be impractical. However, the ratio ofB-
lymphocytes to Mcp within uninflamed milky spots had been previously published
(Dux et al., 1986, Goldsmith et al., 1990, Beelen et ah, 1980) and seemed likely to be
a more constant value than absolute numbers as far as comparisons between
individual animals was concerned.
Preliminary experiments showed this to be the case. A group ofC57BL/6 mice were
sacrificed and omental dissection and digestion was performed. The recovered cell
suspension was then labeled with rat-anti mouse B220-PE (to identify mature B-
lymphocytes) and rat-anti mouse F4/80-PE/Cy5 to identify mature peritoneal Mcp.
These cells were separately identified by flow cytometry and the number of B220-H1
B-lymphocytes and F4/80-HI Mcp identified in each sample. The relative proportion
ofMcp to B-lymphocytes was then calculated.
In a sample of 8 animals, the ratio ofMcp per B-lymphocyte recovered was 1.29 ±
0.20. This is a higher proportion of B-lymphocytes than was seen in previous
published studies (approximately 2 Mcp per B-lymphocyte) and approximately
opposite the ratio found within cells recovered from the peritoneal cavity. There
may be a number of factors to explain these discrepancies. The seminal studies by
Beelan and Dux (Beelen et al., 1980, Dux et al., 1986) relied upon electron
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microscopy to identify the M(p and lymphocyte populations within milky spots.
Their inclusion criteria for 'macrophages' certainly included immature monocyte-
derived M(p, which are F4/80-LO or negative and thus would have been excluded
from counting in this current study. Furthermore, the animals used in my experiment
were younger and of a different sex and genetic strain to the ones used by Beelen and
Dux. Whatever the discrepancies, the ratio of B-lymphocytes to M(p within the
omental lymphoid organs was quite constant and was used as the standard for
measuring quantitative changes within the omental Mcp population.
C57BL/6 mice received 0.5 mis ofPKH-26 red fluorescent dye as previously
described. Then a group of 7 animals received an IP injection of 5xl06 CMFDA
apoptotic thymocytes, made as previously described. A control group (N=7) of
animals received an injection of 0.5 mis PBS. A second control group (N=3)
received neither PKH-26 nor CMFDA green labeled apoptotic thymocytes and these
animals provided tissue for flow cytometry fluorescent calibration.
The mice were sacrificed 30 minutes after receiving their IP injection of apoptotic
thymocytes or PBS. Omental digestion and cell labeling was performed as previously
described. The omental Mcp, which had been pre-labeled with PKH-26 red
fluorescent dye were then labeled with rat anti-mouse F4/80-PE/Cy5 Ab and the B-
lymphocytes with rat-anti mouse B220-PE Ab. Although the B220-PE and PKH-26
dye both fluoresce within the FL2 channel, previously published work and work
done as part of this study had shown that a) the B-lymphocytes had clearly distinct
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light scattering properties compared to Mcp and b) intra-peritoneal B-lymphocytes do
not phagocytose the PKH dye in vivo. These facts made misidentification of either
B-lymphocytes for PKH+ Mcp or vice versa highly unlikely.
The group ofmice that received IP apoptotic thymocytes demonstrated a significant
increase in the ratio ofMcp:B-lymphocytes when compared to mice receiving PBS
only (1.87±0.21 Vs 1.13±0.12, p=0.02 - Figure 42). Furthermore, flow cytometry
dot plot analysis demonstrated that virtually all of the omental Mcp had taken up the
PKH-26 dye, confirming their origin as intraperitoneal rather than extraperitoneal
(Figure 43). Both of these observations supported the hypothesis that peritoneal Mcp
were associating with the omental lymphoid organ during the MDR.
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Figure 44. A proportional increase in Mq> within the omental





Y-axis = the ratio ofMcp:B-lymphocytes recovered by peritoneal lavage following IP injection; X-
axis= the nature of the IP injected material. *A significantly higher ratio ofMtp: B-lymphocytes was
seen in animals receiving IP apoptotic cells (p=0.02). N=6 per group; 2 experiments.
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Figure 45. Intra-peritoneal M<p enter the omental lymphoid






Flow cytometry plot of cells following enzymic dissociation of the omental lymphoid organ (B-
lymphocytes excluded by selective gating). Y-axis shows fluorescent labeling with the rat-anti mouse
F4/80-PE/Cy5 Ab in the FL4 channel. The X-axis shows fluorescent labeling with PKH-26 dye in the
FL2 channel. Almost all of the F4/80-H1 cells are also PKH-26 HI
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5.8 Adoptively transferred peritoneal M<p are selectively taken up
by omental milky spots
Further evidence for the emigration of peritoneal Mcp to the omental milky spots after
the IP injection of apoptotic cells was sought by means of adoptive transfer
experiments. Peritoneal M(p were labeled in situ within donor mice using the PKH-
26 dye as previously described. After washing, lxlO6 donor peritoneal cells (61.9%
Mcp) in 250pl of PBS were mixed at 4°C with 5xl06 Hoescht 333342 labeled
apoptotic thymocytes in an equal volume ofPBS. The mixture of apoptotic
thymocytes and donor peritoneal cells was then injected IP into age and gender
matched female C57BL/6 recipient animals. After 30 minutes the recipient animals
were sacrificed and peritoneal lavage and omentectomy performed. Control animals
received an IP injection of donor lavage cells mixed with 250pl of PBS. The
recovered donor peritoneal Mcp were enumerated by flow cytometry using the
previously described single platform flow cytometry counting method. The Mcp
adherent to omental milky spots were counted manually using transmitted
fluorescent microscopy to identify the red fluorescent adoptively transferred Mcp.
Milky spots were identified by their characteristic appearance under transmitted
white light microscopy (see earlier).
A significantly higher number ofMcp bound to the omental lymphoid organ milky
spots when adoptively transferred with apoptotic cells compared to Mcp transferred
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alone (46.3±7.54 M(p/high power field Vs 9.65±1.89 Mcp/high power field, p=0.009 -
Figure 46).
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Figure 46. Apoptotic cells enhance the attachment of resident
peritoneal M<p to omental milky spots








Mcp + Apoptotic cells Mcp + PBS
Cells adoptively transfered
Y-axis = the number of adoptively transferred resident Mcp counted per field within milky spots. X-
axis shows the nature of the adoptively transferred cells - Mcp transferred with or without apoptotic
thymocytes. N=6 per group; 3 exeriments.
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The experiment was repeated with inflammatory peritoneal Mcp harvested 4 days
after an IP injection of 1ml of 3% brewers thioglycollate rather than resident non¬
inflammatory peritoneal M(p. In a similar pattern to the resident Mcp, a significantly
higher number of inflammatory Mcp adoptively transferred with apoptotic cells bound
to the omental lymphoid organ milky spots compared to Mcp transferred alone
(12.24±1.27 Mcp/field Vs 2.06±0.50 Mcp/field, p=0.003 - Figure 47).
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Figure 47. Apoptotic cells enhance the attachment of
inflammatory peritoneal Mq> to omentalmilky spots




MO & apoptotic cells M0 & PBS
Cells adoptively transfered
Y-axis = the mean number of adoptively transferred inflammatory M(p counted per field within milky
spots. X-axis shows the nature of the adoptively transferred cells - Mcp transferred with or without
apoptotic thymocytes. N=5 per group; 2 experiments.
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Figure 48. Representative images of adoptively transferred M<p
and labeled apoptotic cells binding to omental milky spots
Four representative images of PKH-26 labeled adoptively transferred Mcp (red) and apoptotic
thymocytes (blue) bound to omental milky spots. Magnification = xl5.
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5.9 The IP injection of apoptotic thymocytes promotes peritoneal
M<p emigration to parathymic lymph nodes
Bellingan has previously shown that, during the resolution phase of acute peritonitis,
M(p leave the peritoneal cavity and subsequently emigrate to draining lymph nodes
(Bellingan et al., 1996). He focused on the intrathoracic parathymic lymph nodes,
through which lymph from the peritoneal cavity passes en route to the thoracic duct.
These lymph nodes are relatively easy to identify and dissect, particularly in the
inflamed state (G Bellingan - personal communication). However, in his seminal
paper in which he tracked the progress of inflammatory Mcp out of the peritoneal
cavity over a 7 day period, he observed an abundance of Mcp within the omentum at a
much earlier stage (4 hours) than they became apparent within the parathymic lymph
nodes (24 - 72 hours) (Bellingan et al., 1996). Bellingan later identified milky spots
as portals of emigration of peritoneal Mcp from the peritoneal cavity to the
parathymic lymph nodes (Bellingan et al., 2002).
Bellingan used the sterile thioglycollate model of peritonitis for his Mcp emigration
work and it is known that the IP injection of thioglycollate causes a very similar
MDR to that which follows the injection of apoptotic thymocytes (Melnicoff et al.,
1989). Taken together, these observations suggested that the MDR might be the first
stage of a process of Mcp emigration from the peritoneal cavity to regional lymph
nodes. It was therefore decided to test the hypothesis that the IP injection of
174
CHAPTER 5 - RESULTS SECTION C
apoptotic cells would not only induce a rapid MDR but would also promote
peritoneal Mcp emigration to regional lymph nodes.
12 C57BL/6 mice received an injection ofPKH-26 dye as previously described.
Four hours later, 6 mice received a further injection of 5x106 CMFDA-labeled
apoptotic thymocytes in 500pl PBS; the remaining 6 control animals received 500pl
ofPBS only. After 4 days, all the animals were sacrificed and the parathymic lymph
nodes were recovered by careful dissection. The tissue was examined under
fluorescent microscopy to confirm the presence of labeled peritoneal Mcp and then
disaggregated and digested to liberate the Mcp within. The cell suspensions were
examined by flow cytometry and the PKH-26 labeled Mcp were quantified as a
percentage of all recovered cells.
A fairly small proportion of the cells recovered from the lymph node digestions were
PKH-26+ peritoneal Mcp. Nonetheless, a significantly greater proportion ofMcp was
recovered from animals that had received an IP injection of apoptotic thymocytes
compared to the group receiving IP PBS only (3.58±0.51% Vs. 1.12±0.38%, N=6 per
group, p=0.02 - Figure 49).
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Figure 49. The IP injection of apoptotic thymocytes promotes
resident M<p emigration to parathymic lymph nodes
Apoptotic cells PBS
Intraperitoneal injection
Y-axis = the proportion of PKH-26+ M(p as a percentage of the total cell population recovered from
the lymph node digestion. X-axis represents the IP injection received (either IP apoptotic thymocytes
or IP PBS). *p~0.02. N=5 per group; 2 experiments.
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5.10 Summary
• IP injected apoptotic cells rapidly concentrate within milky spots in the
omental lymphoid organ
• Apoptotic cells within the omental milky spots have been phagocytosed by
Mcp
• Peritoneal lavage samples extra-omental 'free' peritoneal M(p, not those
bound to milky spots
• Extra-omental Mcp enter the omental milky spots following the apoptotic cell
induced MDR
• Both resident and inflammatory peritoneal M(p enter omental milky spots
when adoptively transferred with apoptotic cells
• Apoptotic cells promote the emigration of peritoneal M(p to parathymic
lymph nodes
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6.1 Introduction
The role of the omentum in the capture of free particles within the peritoneum in vivo
was discussed in the Introduction. This activity is mediated by peritoneal Mcp of
which there exists a 'free' population outside milky spots and a 'bound' population
within milky spots. Evidence has been shown that some 'free' intraperitoneal M(p
bind to milky spots after interaction with apoptotic cells. Milky spots probably play
a role in the initiation of secondary immune and inflammatory responses. The work
presented in previous chapters has highlighted the consequences of interaction
between instilled apoptotic cells and M(p within the murine peritoneal cavity. There
is considerable interest in in vivo assays of phagocytosis. The arrangement of the
omentum, with 'naked' Mcp in direct contact with the peritoneal fluid is highly
adapted for the phagocytosis of intraperitoneal particulate matter. Furthermore, it
readily allows the passage of either white or fluorescent light, making it very
amenable to microscopic study. In this chapter, specific mechanisms of apoptotic
cell uptake by the omentum are investigated. The interactions of other particles (e.g.
viable, non-apoptotic cells and fixed killed bacteria) with the omentum are also
investigated.
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6.2 Free intraperitoneal apoptotic cells, rather than viable non-
apoptotic cells, are preferentially bound to M<p within the
omental milky spots
The omental lymphoid organ is ideally suited for the removal of particulate matter
from within the peritoneal cavity. This has been shown clearly by the speed,
efficiency and specificity of peritoneal apoptotic cell clearance. However, it is
possible that the capture and subsequent phagocytosis of IP injected thymocytes was
not a consequence of their being apoptotic. Thymocytes are, after all, immature T-
lymphocytes which have the capacity to interact with Mcp in the context of antigen
presentation within the immune response.
To ensure that omental Mcp were selectively binding to IP apoptotic cells I set up a
competition assay. Equal numbers of apoptotic and non-apoptotic viable thymocytes
were made using protocols described in the Methods section. The viable (5%
apoptotic cells) and apoptotic thymocytes (85% apoptotic cells) were differentially
labeled with CMFDA green and Hoescht 333342. Prior to labeling, the percentage
apoptosis was measured in representative samples of cells using Hoescht 333342 and
• 7 • •
assessing nuclear morphology. A 50:50 mixture of 1x10 viable and apoptotic cells
(5x106 cells of each type) was injected IP into 5 C57BL/6 mice. After 30 minutes
the mice were sacrificed and the omental lymphoid organs dissected and examined
under light microscopy. 6 images from different regions of the omental lymphoid
organ were taken in both the green, blue and orange channels allowing the apoptotic
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and viable cells to be identified. The number of viable and apoptotic cells bound to
omental milky spots within each image were then quantified.
The overwhelming majority of thymocytes which bound to the omental milky spots
were apoptotic rather than viable (93.89 ± 1.74% Vs 6.11 ± 1.73%, apoptotic
thymocytes Vs viable thymocytes, p=0.000006 - Figure 50). This data strongly
supported the hypothesis that the apoptotic thymocytes are captured within the
peritoneal cavity in preference to viable cells and thence taken up by milky spots.
Apoptosis, or more probably the presence of'eat me' signals on the cell surface,
seemed to be a requirement for cell capture and phagocytosis by the omental milky
spots.
There are important caveats to this data, which implies that a small number of viable,
non-apoptotic cells may be captured. In vivo, potentially autoreactive thymocytes are
deleted by apoptosis to prevent their development into mature T-cells. Furthermore,
the extraction process requires the application of mechanical stress which is likely to
induce apoptosis in some thymocytes. As a result, approximately 5% of the so-called
'viable' thymocytes instilled IP may in fact have been apoptotic and this may
account for some of the 'viable' cells tethering to milky spots.
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Figure 50. Apoptotic, rather than viable cells, preferentially








Top panel - Y-axis shows the percentage of thymocytes that bound to the milky spots that were either
from the viable or apoptotic cell preparation. X-axis shows the nature of the bound cell - either an
apoptotic thymocyte or viable thymocyte. N=4; 1 experiment.
Bottom panel - representative image showing green viable cells and blue Hoescht 333342 labeled
apoptotic cells (magnification x50)
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6.3 Apoptotic thymocytes prepared from C1q +/+ mice
preferentially localise to milky spots compared with apoptotic
thymocytes from C1qa -/- donors
A number of receptor-ligand pairings are known to mediate the recognition and
phagocytosis of apoptotic cells by phagocytes (see Introduction). The relevance of
these pairings in vivo in mammals is less well understood and is the subject of much
scientific interest. Clq is known to be an important bridging molecule between the
apoptotic cell and Mxp and its absence is associated with defective phagocytosis of
apoptotic cells in vivo and autoimmunity (Botto et ah, 1998, Taylor et ah, 2000). It
was therefore decided to see whether apoptotic cells opsonised in serum containing
Clq would localise to the OLO in preference to those not opsonised with Clq.
Apoptotic murine thymocytes, derived from Clqa -/- mice, labeled with either
CMFDA green or CMFDA red cell tracker dye, were prepared as previously
outlined. The red apoptotic thymocytes were then incubated in serum from C57BL/6
mice whilst the green thymocytes were incubated in serum from age and sex matched
Clqa -/- mice, which completely lacked Clq. After appropriate washing steps to
remove any residual serum, an equal '50:50' suspension of green and red apoptotic
thymocytes was prepared at a final concentration of lxl07cells/ml in PBS. 0.5 mis of
this suspension was injected IP into recipient Clqa -/- mice. After 30 minutes the
OLOs were recovered by careful dissection and the number of red and green
183
CHAPTER 6 - RESULTS SECTION D
apoptotic thymocytes attached to milky spots was counted by fluorescence
microscopy.
Apoptotic thymocytes opsonised in Clq replete C57BL/6 serum localised to OLO
milky spots in clear preference to those opsonised in Clq deficient serum from Clqa
-/- mice. 78.48 ± 1.3 % of captured apoptotic thymocytes had been opsonised in
C57BL/6 serum whilst the remaining 28.52 ± 1.3% had been opsonised in Clqa -/-
serum (p=0.0000054, N=4 - Figure 51). This result was repeated when the cell
tracker dyes were used in the opposite combination. This suggested that, not only
was the localisation of cells to OLO milky spots the result of the cells being
apoptotic, but the presence ofClq on the surface of the apoptotic cells further
enhanced the localisation to OLO milky spots.
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Figure 51. Opsonisation with C1q replete serum preferentially

















Serum used for opsonisation
Y-axis = the percentage of differentially labeled cells counted on the OLO; X-axis indicates the nature
of the opsonising serum used for each cell type. N=5; 1 experiment.
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6.4 Viable thymocytes lacking CD31 localise to omental milky spot
more readily than those expressing CD31
It has been shown previously that the antibody mediated blockade ofCD31 inhibits
the detachment of viable cells from phagocytes in vitro (Brown et al., 2002). This
phenomenon has not, however, been demonstrated in vivo. CD31 is expressed by
thymocytes and thymocytes completely lacking CD31 are available in the form of
tissue harvested from CD31 knockout mice (CD31 A variant of the competition
assays described above was used to determine whether the presence ofCD31
influenced the proportion of viable thymocytes captured by intraperitoneal Mcp.
Viable, non-apoptotic thymocytes were extracted from CD31 -/- and CD31 +/+
controls (all females, less than 12 weeks old) as previously described. The CD31 -/-
and +/+ thymocytes were then labeled with CMFDA green and red respectively and
after appropriate washing to avoid contamination, a 50:50 mixture of green and red
labeled cells was made at a final concentration of lxl 07 cells/ml. 0.5mls of this
mixture was then injected IP into recipient CD31 +/+ mice. 30 minutes after the IP
injection, the mice were sacrificed, OLOs recovered by careful dissection and the
labeled cells that were attached to the OLO counted by fluorescence microscopy.
The number of viable thymocytes attached to the OLO was considerably lower than
would have expected for IP injected apoptotic thymocytes. Nonetheless, it was clear
that CD31 -/- viable thymocytes were preferentially bound to the OLO milky spots in
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place ofCD31 +/+ cells (percentage of CD31 -/- Vs CD31 +/+ thymocytes attached
to the OLO respectively 69.48 ± 1.07% Vs 31.52 ± 1.07%, p= 0.00056, N=5 - Figure
52). This result was repeated when the cell tracker dyes were used in the opposite
combination. These data supported the previous observation ofBrown et al. that
CD31 has a role in mediating the detachment of viable cells from phagocytes.
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Figure 52. CD31 -/- viable thymocytes preferentially bind to















CD-31-/- thymcocytes CD-31 +/+ thymocytes
Genotype of viable thymocyte
Y-axis = the percentage of differentially labeled cells counted on the OLO; X-axis = the genotype of
the IP injected apoptotic cells. N=6 per group; l experiment.
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6.5 The M(p phagocytosis of killed and fixed Staphylococcal aureus
bacteria and their transportation to the omental milky spots
Mcp are known to phagocytose bacteria in vivo, thus aiding the resolution of bacterial
infection. Specific interactions between bacterial surface molecules and receptors on
Mcp mediate the phagocytosis of bacteria in a similar way to the phagocytosis of
apoptotic cells (see chapter 1). The possibility of using the omentum to study the
mechanisms and consequences of the phagocytosis of bacteria in vivo was explored
in some preliminary experiments discussed below.
The bacteria used for the following experiment were heat killed Staphylococcus
aureus, Wood strain without protein A, labeled with Alexa 488 green cell tracker
dye. These were bought commercially (Molecular Probes Catalog # S23371) and
resuspended in PBS to a concentration of 5x106 bacteria/ml according to the
manufacturer's instructions, lxl 06 bacteria were injected IP into recipient C57BL/6
mice which were sacrificed after 30 minutes. Their omenta were dissected and
examined under fluorescent microscopy as previously described. Many fluorescent
bacteria were seen within milky spots. The omenta were then mechanically
disaggregated and digested using the previously described methods. The resultant
cell suspensions were then washed twice in PBS, labeled with F4/80-PE cell tracker
dye as outlined previously. When examined by flow cytometry and fluorescent
microscopy, it was apparent that the IP injected bacteria had been phagocytosed by
omental Mcp (figures 52 and 53).
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Figure 53. Phagocytosed fluorescently labeled S. aureus
bacteria within M<p recovered from omental milky spots (A)
Fluorescence photomicrograph of omental Mcp (F4/80-PE - red) recovered 30 minutes after the IP
injection of heat-killed S. aureus bactera (Alexa 488 - green). Green fluorescent bacteria may be
clearly seen within M(p phagolysosomes. Magnification x 400
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Figure 54. Phagocytosed fluorescently labeled S. aureus




Flow cytometry dot plot. Y-axis = F4/80-PE (FL2); X-axis = Alexa 488 (FL1). F4/80-HI Mcp
population has acquired FL1 labeling indicating that Mcp have phagocytosed FL1+ bacteria.
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6.6 IP injection of S. aureus, but not apoptotic cells, causes PMN
recruitment to the omentum
The omentum is thought to be the major site of PMN recruitment during peritonitis.
Significant recruitment of PMNs following the IP injection ofAC had not been seen
but it seemed likely that this would follow IP bacteria. To compare the relative
potential for omental PMN recruitment of bacteria and AC, the following experiment
was performed. C57BL/6 mice received an IP injection of either a) lxlO6 heat killed
S. aureus (Alexa 488 labeled), b) 5x106 apoptotic thymocytes or c) 0.5ml PBS.
Animals from each group were sacrificed at 24 and 48 hours and their omenta
digested. PMNs within the cell suspension were identified by labeling with rat-anti-
mouse GR1. The labeled samples were analysed by flow cytometry and the number
ofGR1-HI PMNs expressed as a percentage of total recoverable cells.
A very large recruitment ofPMNs to the omentum was apparent 24 hours after IP S.
aureus injection (Figure 55). This was still apparent after 48 hours but to a lesser
degree. Neither the injection ofAC or PBS caused a significant recruitment of
PMNs to the omentum.
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□ 1 Day post injection




Y-axis = GR1-HI PMNs recovered from digested omenta expressed as the percentage of total omental
cells within the cell suspension. X-axis= IP injection given to groups of mice
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6.7 Summary
• Omental milky spots preferentially bound apoptotic, rather than viable
thymocytes
• Omental milky spots prefertially bound apoptotic cells opsonised in Clqa +/+
serum, rather than Clqa -/- serum
• Viable, non-apoptotic thymocytes lacking CD31 localised to omental milky
spots more readily than those expressing CD31
• IP injected heat-killed and fixed S. aureus bacteria also localize to omental
milky spots
• IP injection ofheat-killed and fixed S. aureus bacteria causes PMN
recruitment to the omental lymphoid organ; apoptotic cells do not
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7 CHAPTER 7 - DISCUSSION
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7.1 IP injected apoptotic cells cause a MDR
The M(p disappearance reaction (MDR) was first described over 40 years ago
(Nelson, 1963) but remains something of an immunological mystery to this day. The
MDR typically follows injurious, pro-inflammatory insults to the peritoneal cavity.
This study reports that IP instilled apoptotic cells can induce a MDR.
There are several pieces of evidence indicating that apoptotic cells trigger a MDR
involving resident peritoneal M(p. IP injected apoptotic thymocytes induce a
profound and rapid loss of lavageable resident peritoneal Mcp. This occurs
simultaneously with the loss of apoptotic cells due to their clearance by phagocytic
resident M(p. The MDR is seen following IP administration of apoptotic murine
thymocytes and apoptotic Jurkat cells. Control injections in which the peritoneal
membrane was merely breached or PBS was injected IP did not induce a MDR. The
MDR induced by apoptotic thymocytes is not confined to the C57BL/6 strain (in
which most experiments were performed) but was also seen in Balb/c mice. The co-
injection of polymyxin B with apoptotic cells had no effect on the MDR, suggesting
that contaminating LPS was not causing the MDR. Furthermore, the MDR seen in
LPS-resistant CD14 -/- mice after IP apoptotic cells was of identical size to that seen
in LPS-sensitive control Balb/c mice.
Unexpectedly, IP injected Flowcheck beads also induced a MDR, albeit one of
smaller magnitude than that induced by apoptotic cells. The only published data
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regarding IP synthetic beads on the size of the resident M(p population was by
Haskill and Becker who used tiny fluorescent spheres to label the resident peritoneal
M(p population prior to the induction of a MDR (Haskill and Becker, 1985). These
beads were phagocytosed by M(p but did not induce a MDR, though one did
subsequently occur after IP administration of C. parvum bacteria. Nonetheless, the
induction of a MDR and other inflammatory responses by inorganic material is not
unprecedented. A pleural leukocyte disappearance reaction followed the intrapleural
instillation of ground glass (Sultan et ah, 1978). Inorganic particulate matter such as
carbon particles or titanium dioxide is phagocytosed by alveolar Mcp causing their
activation (Renwick et al., 2004). Furthermore, urate crystals, when phagocytosed
by M(p with subtly different maturation states, induce different inflammatory
responses from the phagocytosing Mcp (Yagnik et al., 2000). It is impossible to
properly compare the spheres used by Haskill and Becker and Flowcheck
microspheres but it is almost certain that they will differ significantly. Haskill and
Becker's work suggests that phagocytosis of beads does not always induce a MDR.
They did not examine their peritoneal lavages until 96 hours after IP beads during
which time Mcp may have disappeared and then reappeared. However, the presence
of a similar number ofMcp at the 96 hour time point suggests that a MDR did not
occur.
The same authors identified clumps of Mcp held together by fibrinous strands
following the MDR (Haskill and Becker, 1985). Three days later, resident Mcp began
to reappear in the peritoneal fluid and elevated levels of plasminogen activating
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factor (PAF) were also noted within the peritoneal cavity, suggesting that fibrin
degradation was occurring (Haskill and Becker, 1985). Leak et al. also observed that
resident Mcp reappeared 72 hours post-MDR together with evidence of fibrinolysis in
peritoneal lavage fluid (Leak, 1983). A MDR directly induced by thrombin has also
been reported (Jokay and Karczag, 1973). These data, taken as a whole, suggest that
activation of the coagulation cascade and fibrin deposition can account for some
descriptions of the MDR.
The MDR induced by apoptotic cells appears to be faster than others reported
elsewhere. Melnicoff reported a MDR induced by the IP injection of brewers
thioglycollate (Melnicoff et al., 1989). A MDR was observed in 20% ofmice at 30
minutes and in all mice by 60 minutes. This seems to be slower than the MDR
induced by IP administration ofAC. No other published report of the MDR
examined time points below 30 minutes. However, a complete disappearance ofMcp
was almost always observed in other published studies.
The rapidity and magnitude of the MDR suggests that direct contact with the
provoking agent may not be necessary to trigger an MDR. Secondary amplification
mechanisms may trigger the disappearance after an initial contact with the primary
agent. Such signals could be mediated by cells other than M(p, such as peritoneal
mesothelial cells, known to mediate peritoneal inflammation by cytokine secretion
(Topley, 1995). Peritoneal lavage supernatant transfer experiments from donor
animals receiving apoptotic cells to naive recipients might shed light upon this.
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There have been no reported studies showing a MDR following the instillation of
noxious material in humans though one observational study provides indirect
evidence for this (personal communication, Professor Simon Davies, Keele
University). A longitudinal study ofperitonitis in patients on peritoneal dialysis
involved patients retaining daily samples of peritoneal dialysis fluid. The study
aimed to examine the microbiological and leukocyte profiles of the peritoneal
dialysis fluid immediately before and after the clinical manifestation of peritonitis.
The investigators were surprised to observe a fall in the number of resident peritoneal
M(p in the hours before peritonitis became clinically apparent.
This observation was not explained but, in retrospect, it is tempting to conclude that
a MDR involving resident peritoneal Mcp occurred.
Another possibility worthy of consideration is that apoptotic cells may have played a
significant role in previous published reports ofMDRs. It should be remembered
that many reports ofMDRs were published in the period 1960-90. Apopsosis was
only discovered in 1972 (Kerr et al., 1972) and its fundamental and wide-reaching
importance as a biological processes only truly appreciated in the late 1980s.
Furthermore, practical, straightforward tests to identify apoptotic cells were not
available during the period in which much of the pioneering work on the MDR was
published. It is entirely possible that previous investigators were either unaware of
or unable to identify apoptotic cells as part of their investigations of the MDR.
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There is certainly reason to believe that many of the agents historically used to
induce MDRs could have themselves lead to apoptosis of cells within the peritoneal
cavity. Firstly, apoptosis is now recognized to be the predominant mode of death for
PMNs after the first phase of acute inflammation (Haslett, 1999, Haslett et al., 1994,
Haslett et al., 1991) and it is generally accepted that these cells are removed from
inflamed tissue by phagocytic Mcp (Savill, 1992, Savill and Fadok, 2000). It is
possible that these apoptotic PMNs induce a MDR; it is certainly clear that the period
in which these cells are dying is associated with rapid trafficking ofM(p (Melnicoff
et al., 1989). However infectious pathogens can themselves induce apoptosis in host
cells and these too could stimulate a MDR. Mycobacterium bovis is known to
induce the MDR in Guinea pigs (Gillissen and Bubenzer, 1970) and it also induces
apoptosis ofMcp as part of its pathogenic behaviour (Fratazzi et al., 2000). Similar
behaviour has been described in other Mycobacteria including Mycobacterium avium
(Allen et al., 2001). Group B streptococci also induce M(p apoptosis (Ullet and
Adderson, 2003) and a MDR (Bultmann et al., 1971).
Non-leukocyte cells within the peritoneal cavity are also prone to inflammation-
dependent apoptosis. Peritoneal mesothelial cells become susceptible to Fas-
mediated apoptosis in the presence of high levels of TNF-a (Chen et al., 2003). It is
entirely possible that apoptosis of peritoneal mesothelial cells occurs during
peritonitis and that these may induce a secondary MDR. However, such a possibility
has not yet been investigated.
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7.2 Mechanism of the AC-induced MDR
This present study also investigated possible mechanisms mediating an apoptotic cell
induced MDR. The MDR was initially observed in apoptotic cells injected in PBS
0-i- 0-i- 0-t- *7 I
lacking Ca and Mg . When apoptotic cells were injected in a Ca and Mg
containing PBS solution, no difference in the magnitude of the MDR was seen.
However, apoptotic cells injected in PBS containing EDTA triggered a significantly
larger MDR than EDTA-free controls. A lesser degree of apoptotic cell phagocytosis
was also observed in those mice receiving EDTA. EDTA has been added to
peritoneal lavage solutions, the purpose being to increase the recovery of Mq> by
• 9+ •
disabling Ca -dependent Mcp adhesion mechanisms (Taylor et ah, 2000). It seems
likely that EDTA induced a large reduction in the cation concentration within the
peritoneal fluid which may have disrupted integrin-mediated phagocytosis of
apoptotic cells. Nonetheless, these data suggest that the MDR is not critically
dependent on the presence of extracellular divalent cations.
The Arg-Gly-Asp (RGD) motifmediates cell adhesion to several extracellular matrix
components (including those involving integrins) as well as cell-cell interactions
(Yamada, 1997). The addition ofRGD peptide to IP injected suspension of apoptotic
thymocytes reduced the apoptotic cell-induced MDR. However a proportionate
decrease in the clearance of the apoptotic cells was also observed. Integrins bearing
the RGD motif are known to be involved in the phagocytosis of apoptotic cells
(Savill et ah, 1990). Bellingan has shown that thioglycollate-elicited M(p binding to
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milky spots was inhibited by the action ofRGDS and antibodies blocking VLA-4
and VLA-5 integrins (Bellingan et ah, 2002). Furthermore, the action of
phagocytosing apoptotic cells modulates the expression of integrins on the
phagocytic Mcp (albeit to decrease their expression) (Erwig et ah, 1998). For his
binding experiments to milky spots, Bellingan used a ring clamp system to minimise
the volume of distribution of his antibodies (Bellingan et ah, 2002). In this present
study, the phagocytosis of apoptotic cells was believed to be a prerequisite for the
binding ofMcp to milky spots. IP injection of bulk antibody had been shown to
modulate Mcp emigration to parathymic lymph nodes (Bellingan et ah, 2002) and
future work may use this strategy to examine M(p behaviour following the uptake of
apoptotic cells including the interaction with the omentum.
IP hyaluronidase reduced the apoptotic cell-induced MDR without affecting the
phagocytosis of apoptotic cells. Hyaluronic acid is a disaccharide polymer
composed of D-glucuronic acid and D-N-acetylglucosamine (Alberts, 1994). It is an
important component of extracellular matrix with roles in solute and water
movement across the peritoneal membrane and in cell migration (Wright and Day,
2005, Edward et ah, 2005). Mcp and other cells bear CD44 which has hyaluronic
acid as its main ligand. CD44 is also known to be involved in the phagocytosis of
apoptotic human PMNs (Hart et ah, 1997). IP injected hyaluronidase is known to
break down intraperitoneal hyaluronic acid (Shannon and Love, 1980). Furthermore
hyaluronic acid has previously been shown to play a role in the MDR. The BCG-
induced MDR observed in mice was almost completely abolished by the IP co-
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administration of hyaluronidase (Shannon et al., 1980). Moreover, when M(p
reappeared following the BCG-induced MDR, peritoneal hyaluronic acid levels fell
compared to the time ofMDR induction (Shannon et al., 1980). There is also some
evidence to suggest that peritoneal Mcp from C3H/Hej mice, which do not undergo a
BCG-induced MDR, have a lower capacity to bind hyaluronic acid than the C57BL/6
strain, in which an MDR is seen (Shannon and Love, 1980). No data has previously
been published linking CD44 to the MDR.
This present study also demonstrated that unfractionated heparin reduced the
apoptotic cell induced MDR without reducing the phagocytosis of apoptotic cells.
The coagulation cascade has been implicated in other examples of the MDR. The
first instance of this is the intrapleural MDR induced by the injection of ground glass
(Sultan et al., 1978). As previously discussed, the pleural and peritoneal cavities
have many similarities and Mcp disappearance reactions occur in both. The MDR
observed by Sultan et al. was inhibited by both heparin and warfarin. The
coincidence of a reduced MDR in two structurally unrelated anticoagulant agents
strongly implicated the coagulation cascade in the ground glass MDR. Mcp clumps
encased in fibrin were also observed following a MDR (Sultan et al., 1978), a finding
reported in other examples of the MDR (Nelson and Boyden, 1963, Haskill and
Becker, 1985).
Heparin may also disrupt the MDR independently of its actions on coagulation.
Heparin is known to disrupt the diapedesis of extravasating T-lymphocytes, probably
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by binding to polysaccharide receptors (Gorski et al., 1991). Furthermore, heparin is
known to bind to Mcp-borne receptors for L-Selectin, a molecule which again might
conceivably be involved in the MDR (Nelson et al., 1995).
The role of other types of leukocytes in the MDR was investigated by Barth (Barth et
al., 1995). Leukocyte precursors in murine bone marrow were selectively depleted
using Sr89. Barth et al showed that the MDR induced by P. acnes could still occur,
even in the absence of significantly reduced numbers of circulating monocytes,
lymphocytes or leukocytes. However, it would be a mistake to take this as evidence
that the MDR is never mediated by other leukocytes. Sonoszaki and Ochiya
showed that T-lymphocytes, depleted of Mcp, from sensitised donors could passively
transfer the MDR to naive recipient mice (Sonozaki and Cohen, 1971, Ochiya et al.,
1982). Furthermore, cyclosporine inhibits the MDR induced by muramyl dipeptide
(Matsushima and Baba, 1990). This finding might now be reinterpreted as not
necessarily implicating T-cells in the MDR.
7.3 Fate of the 'disappeared' Mcp
In these studies IP apoptotic cells triggers a MDR followed by a specific binding of
Mcp to omental milky spots. The evidence for this came from three key observations.
Firstly, 'free' apoptotic cells bind to and are phagocytosed by Mcp within peritoneal
fluid. After the MDR, these apoptotic cells are seen in high concentrations and are,
once again, bound to or phagocytosed by Mcp. Secondly, the omentum appeared to
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become 'enriched' with Mcp following the MDR. Thirdly, adoptively transferred Mcp
(resident or inflammatory Mcp) bound to omental milky spots when transferred with
apoptotic cells. It was not possible to determine what proportion of the 'disappeared'
peritoneal Mcp bound to omental milky spots. The peritoneal membrane has a
relatively high surface area. Its strong adherence to underlying structures and
tendency to fold when dissected meant that examination of the entire peritoneal
membrane was practically impossible. However, few if any Mcp were seen away
from milky spots following the MDR.
Bellingan identified milky spots as sites to which inflammatory peritoneal Mcp
selectively attach themselves (Bellingan et al., 2002, Bellingan et ah, 1996).
Thioglycollate-elicited Mcp labeled with PKH-26 dye left the peritoneal cavity during
the resolution phase of inflammation and migrated to the parathymic lymph nodes
(Bellingan et ah, 1996). A thorough survey of the abdominal contents identified the
milky spots as sites in which peritoneal Mcp congregated. The highest concentration
of Mcp was found in the omentum and, though not published in the original paper, the
author has confirmed that the locality of these Mcp was within the omental milky
spots (G. Bellingan - personal communication).
Other reports suggest a different fate for the disappeared Mcp, not necessarily
involving the milky spots. The first report of the MDR described the finding of
clumps ofMcp within peritoneal lavage fluid (Nelson and Boyden, 1963). Electron
microscopy showed Mcp in very close association without obvious fibrinous material
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holding them together. From the modern perspective, this suggests the involvement
of cell-membrane adhesion molecules, such as integrins and their ligands. Other
authors also found M(p clumped within peritoneal fluid. Sultan et al. studied the
MDR that occurs in the pleural cavity of rats (a structure which shares many features
with the peritoneal cavity, including milky spots) (Sultan et al., 1978). Clumps of
Mcp encased in fibrin were recovered following a MDR induced by intrapleural
ground glass. Haskill and Becker also observed clumping ofMcp on the peritoneal
membrane following a MDR and also the reappearance of 'disappeared' Mcp after
approximately 3 days (Haskill and Becker, 1985).
It was not possible to track the Mcp that disappeared after IP apoptotic cell injection
for a time period beyond 24 hours for several reasons. Firstly, phagocytosed
microspheres would have allowed prolonged tracking but may have compromised
the phagocytic ability of Mcp and possibly induced a MDR themselves. Secondly,
phagocytosed apoptotic cells and their associated CMFDA marker are rapidly
degraded within the Mcp phagolysosome and hence cannot be identified after 5-7
hours (personal communication - J Gilmore). Another possibility was to label
apoptotic cells with a pH sensitive dye that would signal the entry of an apoptotic
cell into an acidic phagolysosome. Preliminary enquiries to appropriate suppliers
suggested that such dyes would not persist for the period of time required for a more
lengthy study. This, plus time and resource constraints, meant that studies on pH-
sensitive dyes were not undertaken.
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It may be that several variations of the MDR exist, some involving the milky spots
and others not. The production of fibrin is a well-recognised and frequent
complication of peritonitis is clinical practice (Dunn et ah, 1984, Hau and Simmons,
1978, Muntean, 1987, Nadig et ah, 1997). Even here the milky spots may be playing
a role by encouraging the extravasation of coagulation factors during peritonitis
(Cranshaw and Leak, 1990).
7.4 Link between phagocytosis and the MDR
This study showed that the phagocytosis of apoptotic thymocytes, injected IP, was
very rapid and resulted in a simultaneous disappearance of resident peritoneal Mcp.
Flow cytometry of recovered peritoneal lavage cells clearly showed that apoptotic
cells were being phagocytosed. Apoptotic cells were concentrated within omental
milky spots. When Mcp were digested from the omentum after the apoptotic cell-
induced MDR, it was clear that these Mcp had also phagocytosed apoptotic cells.
The question of whether the apoptotic cell-induced MDR actually required
phagocytosis of apoptotic cells was addressed by examining the MDR in Clqa -/-
mice. These mice have a well-characterised defect in the phagocytosis of apoptotic
cells (Taylor et al., 2000). Clq is not thought to play a direct role in Mcp adhesion or
emigration. Both the phagocytosis of apoptotic cells and the MDR were both




The MDR is no doubt mediated by molecules involved in Mcp adhesion, as discussed
earlier. Many adhesion molecules including integrins and ICAMs are involved in
both phagocytosis of apoptotic cells and Mcp adhesion (Gregory et ah, 1998, Moffatt
et ah, 1999, Savill et ah, 1990). Indeed, it is known that alterations in the
extracellular matrix environment can decrease the ability of Mcp to phagocytose
apoptotic cells, probably by sequestrating M(p receptors that would normally engage
the apoptotic cell on ECM proteins (Kirkham et ah, 2004, McCutcheon et ah, 1998).
The ligation of integrin receptors downregulates M(p phagocytic ability (Erwig et al.,
1999). The phagocytosis of Mycobacterium tuberculosis is known to increase the
adhesiveness of human Mcp via the increased expression of LFA-1 and ICAM-1
(DesJardin et al., 2002). However, there appears to have been no specific studies of
changes in M(p adhesion following the phagocytosis of apoptotic cells.
7.5 M<p may emigrate to lymph nodes following the MDR
Resident peritoneal Mcp appeared to emigrate to parathymic lymph nodes following
the IP administration of apoptotic cells. PKH-26 labeled cells, of peritoneal origin,
appeared in parathymic lymph nodes several days after the IP injection of apoptotic
cells (unlabeled). In this study, and previously published work (Melnicoff et al.,
1988b) 99% ofPKH-HI cells within the peritoneal cavity are resident Mcp. It is
possible that the PKH-26 dye was carried to parathymic lymph nodes by peritoneal
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dendritic cells, rather than Mcp. However, few if any CD1 lc+ dendritic cells are
identified within the quiescent peritoneal cavity. In control animals receiving PKH-
26 but no apoptotic cells, PKH-26 fluorescence was nonetheless identified within
parathymic lymph nodes. This probably indicates that resident peritoneal Mcp
migrate to regional lymph nodes as part of their normal life cycle, though this has not
been shown definitively. Nonetheless, a significantly greater proportion ofPKH-26+
cells were found in the parathymic lymph nodes after IP apoptotic cells.
Bellingan found that the attachment of inflammatory peritoneal Mcp to milky spots
was partially mediated by VLA-4 and VLA-5 integrins (Bellingan et al., 2002).
Furthermore, these same anti-VLA-4 and anti-VLA-5 blocking antibodies also
inhibited emigration of peritoneal Mcp to parathymic lymph nodes (Bellingan et al.,
2002). These data suggested that the emigration ofMcp from the peritoneal cavity
involved an initial binding ofMcp to milky spots followed by emigration to lymph
nodes. Blocking this initial binding to milky spots appeared to delay the entire
emigratory process. Mandache et al. made similar observations in rats (Mandache et
al., 1985). They injected rats with C. parvum, excised their omenta at a variety of
time points and examined the milky spots by electron microscopy. Within 30
minutes, layers ofMcp were seen overlying the surface ofmilky spots. After 24
hours, resident Mcp were found in the deeper layers of the milky spot and after four
days within regional lymph nodes.
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There is no published evidence that the phagocytosis of apoptotic cells promotes the
emigration ofM(p to draining lymph nodes though circumstantial evidence suggests
that it might. Huynh demonstrated that the instillation of intra-tracheal apoptotic
cells enhanced the resolution of experimental pneumonia via the release of TGF-P
(Huynh et al., 2002). A dramatic decrease in the number of inflammatory M(p was
observed during this resolution phase. It could be that the production of anti¬
inflammatory cytokines mediated the emigration of resident peritoneal Mcp to lymph
nodes, though TGF-P production following the phagocytosis of apoptotic cells by
quiescent M(p is not well established.
Dendritic cell (DC) migration to lymph nodes is an important part of their function as
antigen presenting cells (Janeway, 2001a). Hirao and colleagues showed that
dendritic cells co-cultured with apoptotic tumour cells altered their expression of
chemokine receptors, upregulating CCR7 and downregulating CCR1 (Hirao et al.,
2000). The presence of the CCR7 ligands, macrophage inflammatory protein 3b and
secondary lymphoid-tissue chemokine significantly increased the migration ofDCs
co-cultured with apoptotic cells in an in vitro migration assay. Furthermore,
increased expression of CCR7 in vivo resulted in increased emigration of DCs to
lymph nodes in vivo (in the presence of apoptotic tumour cells). Similar studies on
M(p have not been published.
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7.6 Novel uses for the omentum to explore M<p behaviour and
function
IP injected apoptotic cells are rapidly taken up by the murine omental milky spots
partly by free peritoneal Mcp which phagocytose apoptotic cells before themselves
attaching to milky spots. However, M(p already resident within the milky spots will
almost certainly capture and phagocytose passing free apoptotic cells within the
peritoneal cavity. The architecture of the milky spot places fully mature resident
peritoneal Mcp, with the greatest capacity for phagocytosis, at the outermost layer in
direct contact with the peritoneal fluid. This allows mature Mcp to constantly sample
peritoneal fluid and capture passing particulate matter, including apoptotic cells and
bacteria.
These features were exploited in various competition assays. In these assays, a 50:50
mixtures of differentially labeled cells with differing properties were injected and the
number of each cell type that ultimately became attached to milky spots was counted
by fluorescence microscopy. The power of injecting a mixture of cells was that
uncontrollable variables - cell leakage, size and cellularity of the omental lymphoid
organ, cell pooling within the peritoneal cavity etc.- were identical for both types of
injected cell. This vastly reduced the errors in comparative measurements compared
with injecting homgenous pools of cells into separate groups of recipients.
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As proofof this principle, a 50:50 mixture of differentially labeled apoptotic and
viable thymocytes was injected IP. The hypothesis was that both peritoneal and
omental milky spot Mcp would preferentially bind apoptotic, rather than viable,
thymocytes. This was indeed the case. However, the difference was large - about
20 fold - and highly statistically significant despite injections only being given to 3
animals. The reason for this highly significant result was the extremely consistent
ratio of viabledive cells attached to milky spots.
The next test for this system was to inject a mixture of apoptotic thymocytes derived
from Clqa -/- mice; 50% were opsonised in serum from Clq +/+ mice and 50% were
opsonised in Clqa -/- serum. Thus, 50% of the administered apoptotic thymocytes
would have Clq bound to their cell surface. The hypothesis was that Clq-opsonised
thymocytes would have a greater probability of being phagocytosed by peritoneal
and milky spot Mcp and this indeed was the case. As with viable and apoptotic cells,
the difference was large - about 4 fold in favour ofClq opsonised cells - and highly
significant.
Although the issue of whether the milky spot Mcp had actually phagocytosed
apoptotic cells in this particular experiment was not directly assessed, previous
experiments had shown that apoptotic cells injected IP are phagocytosed by Mcp
within this time interval. This type of competition experiment could therefore be
considered a 'phagocytosis assay', notwithstanding the absence of direct observation
of phagocytosed apoptotic cells within milky spot Mcp. Various in vivo other
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phagocytosis assays do not include the direct observation of apoptotic cells within
Mcp, in particular those which rely on the persistence of apoptotic cells as evidence
for defective phagocytosis (Scott et ah, 2001, Robson et ah, 2001, Piatt et ah, 1996).
This system is potentially a very powerful one for identifying factors on the apoptotic
cell surface that are thought to mediate the phagocytosis of the cell by Mcp. The
production of paired data and reduction in uncontrolled variability offers far more
robust data than injecting cells into different groups of animals. 'Refinement and
reduction' are key principles in the development of in vivo experiments, especially
given concern amongst the lay public about the use of animals in experimentation.
The final application of the competition assay in this study switched from apoptotic
to viable cells. Brown et al. had shown that CD31 mediates the repulsion ofMcp and
viable cells in vitro. Using a flow cell system to apply shear stress, at room
temperature viable leukocytes became attached to M(p but detached at 37°C. When
CD31 was either blocked with antibody or not expressed, this detachment was
inhibited. This observation suggested that, in vivo, CD31 may act as a 'badge' to
inform Mcp to disregard them as a possible 'phagocytic meal'. This hypothesis had
not been tested in vivo and the paired competition assay was an ideal tool for this
purpose. The observation that viable thymocytes from CD31 -/- mice were
significantly more likely to be captured by omental milky spots than CD31 +/+
thymocytes supported Brown's in vitro observation.
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7.7 Why should apoptotic cells induce a MDR?
The consensus view is that the MDR is an immune response to injurious stimuli
(Barth et al., 1995). This raises the question ofwhy might the immune system regard
apoptotic cells as a potentially injurious stimulus? The first danger posed by
apoptotic cells is the possibility of triggering autoimmunity. During the process of
apoptosis, many intra-cellular components, normally invisible to the immune system
- proteins, DNA, phospholipids etc. - are expressed at the cell surface (Savill and
Fadok, 2000). In some cases - e.g. phosphatidylserine - these substances have a
clear role in allowing the phagocyte to recognise, attach to and ultimately
phagocytose the apoptotic cell (Fadok et al., 1992b). The proteins and nucleic acids
expressed on the surface during apoptosis are usually modified by enzymic
degradation during the apoptotic programme. This processing produces 'altered self
which can provoke autoantibody production (Kinoshita et al., 1999, Cline and Radic,
2004, Rosen and Casciola-Rosen, 1999).
It is not only the potential for autoantibody production that gives apoptotic cells their
injurious potential. Apoptotic cells can secrete chemokines that recruit both M(p and
PMNs. This was demonstrated most elegantly in experiments utilising a vascular
smooth muscle cell line designed to undergo apoptosis via the over-expression of
FADD under a Tet-off control (Schaub et al., 2000, Bowen-Pope and Schaub, 2001).
The apoptotic smooth muscle cells expressed high levels of IL-8 (neutrophil
chemokine) and MCP-1, a M(p chemokine in vitro. When seeded within the
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vasculature of rats, the mass apoptosis of these cells resulted in significant local
inflammation and Mtp recruitment.
More recent work has identified other chemoattractants produced during apoptosis.
In vivo, tumours such as Burkitt's lymphoma are characterized by large numbers of
infiltrating Mcp which clear apoptotic tumour cells. It has been shown in vitro that
apoptosis of Burkitt's lymphoma cells leads to the chemotaxis of Mcp (Truman et al.,
2004). Recently a chemoattractant has been identified that is produced during
apoptosis which might explain how professional phagocytes find distant apoptotic
cells (Lauber et al., 2003). Lauber induced apoptosis in a variety of different tumour
cell lines in vitro and showed that this lead to the chemoattraction of various types of
monocyte-Mcp cells (Lauber et al., 2003). Furthermore, the supernatant from these
cultured apoptotic cells also induced transmigration ofmonocyte-Mcps. Whilst the
phenomenon was not restricted to apoptosis induced in a single cell type, it was
notably not seen in MCF7 cells (Lauber et al., 2003).
Unlike the other apoptotic cell types tested by Lauber, the MCF7 cell line did not
express caspase-3. Lauber showed that restoring the production of caspase-3 in
MCF7 cells also restored their ability to produce a chemoattractant supernatant
during apoptosis (Lauber et al., 2003). Further investigations showed that the
chemotactic agent within this supernatant was lysophosphatidylcholine, produced by
an as-yet imperfectly understood mechanism involving the activation of caspase-3
and calcium-independent phospholipase A2 (Lauber et al., 2003).
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Lysophosphatidylcholine has also been identified as a membrane bound 'eat me'
signal on apoptotic cells (Kim et al., 2002). Kim et al. also showed that membrane-
bound lysophosphatidylcholine on apoptotic cells is recognized by IgM natural
antibodies which recruit Clq, a molecule known to mediate the phagocytosis of
apoptotic cells (Kim et ah, 2002, Taylor et ah, 2000). Whether the same mechanisms
are responsible for the production of bound and secreted lysophosphatidylcholine is
unknown as are the inflammatory consequences of lysophosphatidylcholine
secretion.
7.8 Apoptotic cells and bacteria - amplification of the 'danger
signal'?
Despite triggering a MDR, IP apoptotic cells do not appear to promote acute
inflammation, as judged by the recruitment ofPMNs. Mcp play a pivotal role in the
recruitment of PMNs to the peritoneum through the induction ofCXC chemokine
production (Cailhier et ah, 2005). It is not clear whether the omentum produces
these chemokines, and this would be an interesting area for future study. It seems
highly likely that one purpose of the MDR is to allow activated Mcp the opportunity
to present danger signals to the site of peritoneal leukocyte trafficking - i.e. omental
milky spots. Although the phagocytosis of apoptotic cells itself is generally deemed
a non-inflammatory process, there is some evidence that the phagocytosis of
apoptotic cells can, in certain circumstances, augment an inflammatory response
(Lucas et ah, 2003). It would be interesting to study the effects of co-administration
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of apoptotic cells and bacteria, on both the MDR and inflammatory cell trafficking.
The presence of apoptotic cells and large number of bacteria may result in an
amplification of the 'danger signal'. On the other hand, the phagocytosis of
apoptotic cells may reprogram some Mcp from a pro- to anti-inflammatory phenotype
and reduce the subsequent level of peritoneal inflammation. The ratio of apoptotic
cells: bacteria is likely to be critical to the outcome of such experiments.
7.9 Further definition of the mechanism driving the MDR
This study offered some insights into the mechanism driving the apoptotic cell
induced MDR but did not fully define it. The MDR has been shown to be enhanced
by hyaluronidase and inhibited by EDTA and unfractionated heparin. Both the MDR
and apoptotic cell clearance were inhibited by RGDS peptide, which blocks the
activity of certain integrins.
CD44 is the major receptor on Mcp for hyaluronic acid and a possible role in the
MDR merits further investigation, possibly utilising CD44 knockout mice. One of
the problems with knockout animals in general is the uncertainty as to what
compensatory phenotypical changes may have occurred in the genetically modified




The role of integrins should be more fully explored. IP RGD inhibited both
phagocytosis and the MDR. However, this shone little light on the exact mechanism
governing the MDR as RGD block a wide variety of integrins. It might be possible
to define integrins involved in phagocytosis from others involved in the adhesion and
disappearance ofMcp by the use of specific antibodies or Fab fragments.
Alternatively, adoptive transfer of Mcp lacking specific integrins from genetically
modified mice or cell lines could be used. Other molecules involved in cell
adhesion, including members of the ICAM and VCAM families, which are again
highly expressed in milky spots (Cui et al., 2002), could be included in such a study.
The role of chemokines was not examined in this study. The omentum is known to
secrete large amounts of chemokines, including SDF-la (Pinho Mde et al., 2002),
and it is conceivable that these play a role in the MDR. Again, this could be studied
by testing the MDR in knockout mice lacking genes encoding chemokines or
chemokine receptors. Again, antibody blocking strategies could also be considered.
Such materials were not available to me during the period of this study. However, a
simple test screening test could be performed using IP instilled pertussis toxin, a
general inhibitor of the action of chemokines.
The effect of heparin on the MDR is both intriguing and challenging. It is well-
recognised clinically that peritonitis is complicated by the production of fibrin and
hence intraperitoneal heparin is often used to prevent this (Johnson and Feehally,
2003). The coagulation cascade is complex with many components. An initial first
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step to identifying clotting factors that might be involved in the MDR could include a
comparative trial ofwarfarin and heparin to see whether the MDR was mediated by
the intrinsic or extrinsic coagulation pathway. However, as previously mentioned,
heparin has effects other than those on coagulation which might be of relevance to
the MDR, including inhibition of selectins (Nelson et al., 1995). Selectins are
another possible family ofmolecules that may play a role in the MDR and would be
candidates for investigation. Recently-published work has also demonstrated that
chemerin, an agonist ofCMKLR1 which is activated by the coagulation cascade, can
direct the migration of dendritic cells to sites of injury in which bleeding has
occurred (Zabel et ah, 2005a). It may be that this, or other chemokine pathways
associated with haemorrhage, are being disabled by heparin and chemerin is another
interesting candidate as a mediator of the apoptotic cell-induced MDR.
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7.10 Further definition of the role of CD31 in M<p-viable cell
interactions
The observation that viable non-apoptotic thymocytes lacking CD31 were more
likely to become attached to milky spots that viable non-apoptotic CD31 +/+
thymocytes was interesting and novel. CD31 is not expressed on all cell types and it
was assumed that binding occurred in a homophilic manner between the thymocyte
and milky spot Mcp. This could be proven by either confocal microscopy or by flow
cytometry of digested omental cells.
Brown and colleagues showed that certain cytoplasmic tail mutations in CD31
removed the ability ofMcp and viable leukocytes to detach under shear stress e.g. a
double tyrosine to phenylalanine mutant of the ITIM motifwithin the cytoplasmic
tail ofCD31 (Brown et al., 2002). This region is known to be involved in
intracellular signalling pathways (Reedquist et al., 2000) and integrin activation
(Newton et al., 1997). A number of cell lines expressing CD31 molecules with
various tail mutations have been produced (S. Brown - personal communication).
The competition assay described within this thesis could be used to determine
whether some or all play a role in the detachment of viable cells from Mcp.
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7.11 The omentum for investigation of leukocyte trafficking in vivo
The murine omentum is in many ways an ideal organ for examining the trafficking of
leukocytes in vivo. Milky spots are well established as the sites of leukocyte
recruitment to the omentum and, in the case ofM(p, the site of emigration too. Milky
spots have a clear morphology that allows them to be identified with light
microscopy or by simple staining, such as PKH-26 or even intraperitoneal carbon
particles. They are highly reactive to intraperitoneal inflammatory stimuli with the
number and cellularity ofmilky spots increasing dramatically during inflammation.
Furthermore, the position of the omentum within the abdominal cavity allows it to be
readily accessed and externalised. Whilst this study only attempted to do this post-
mortum, it is quite possible that intravital microscopy could be performed on the
omentum using similar technology to that applied to the murine mesentery (Little et
al„ 2005).
Furthermore, the presence of lymphatic vessels within omental milky spots makes
the omentum an attractive target for studying leukocyte emigration from the
peritoneal cavity, again using intravital microscopy. An intriguing if highly
speculative possible consequence of the MDR is the relationship with
lymphangiogenesis. Twenty years ago, a study of the behaviour ofmurine omental
milky spots following stimulation with sheep erythrocytes noted that Mcp bound to
milky spots and nearby peritoneal membrane formed clumps similar to those
described in other studies (Dux et al., 1986). Several days later, tubular structures
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were seen in association with these clumps and it was speculated that these might be
newly developing lymphatic vessels whose production was stimulated by the
attached peritoneal Mcp. At the time, the technology to identify these as lymphatic
vessels within the peritoneal membrane did not exist. However, it has recently been
shown that M(p can themselves transdifferentiate into lymphatic endothelial cells
during corneal inflammation (Maruyama et ah, 2005). Furthermore, in vitro
peritoneal M(p can form tube like structures and express markers typically found on
lymphatic endothelial cells including Prox-1 and LYVE-1 (Maruyama et al., 2005).
Once again, the accessibility of the omentum for intra-vital microscopy makes it an
ideal place to study lymphangiogenesis. Indeed, generations of surgeons have
exploited the omentum for its apparent ability to encourage revascularisation
following surgery, including procedures beyond the abdominal cavity (Shrager et ah,
2003, Goldsmith, 2004) Indeed, a novel if controversial therapy for Alzheimers
dementia involving transplantation of omentum within the brain is currently the
subject of clinical trials within the USA (Goldsmith, 2004). It is known that the
omentum contains high levels of VEGF (Zhang et ah, 1997, Sigrist et ah, 2003,
Williams et ah, 1989) and the mechanisms governing its action within the omentum




The data presented within this thesis identifies a novel process by which apoptotic
cells within the peritoneal cavity induce a MDR. This MDR is not induced by live
cells and is not restricted to particular type of apoptotic cell. Resident and
inflammatory M(p localize to the milky spots of the omentum and may then migrate
to regional lymph nodes. Future work arising from this thesis should focus on three
main areas. Firstly, the mechanism by which apoptotic cells induce the attachment
ofM(p to milky spots, secondly the mechanism governing the emigration ofM(p from
the peritoneal cavity to regional lymph nodes and thirdly the generalisability of the
the apoptotic cell-induced MDR.
This mechanism governing the binding ofM(p to milky spots is clearly one that can
be rapidly activated given the short time interval between the IP injection of
apoptotic cells and the MDR. Attachment and recognition molecules on the M(p and
target sites ofmilky spots are unlikely to be synthesized de novo during the MDR but
are far more likely to be pre-formed and activated at the initiation of the MDR.
Integrins are attractive candidate molecules for such a mechanism and should be
investigated. Data presented in this thesis demonstrates that RGD peptide does
indeed inhibit the MDR but this could have been explained by RGD-dependent
inhibition of phagocytosis of apoptotic cells. Further work should focus on more
precise interuption of integrin function that avoids inhibition of phagocytosis. Such a
experiments could involve the adoptive transfer of genetically modified Mcp (either
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mature peritoneal M(p or via bone marrow transplant) that fail to express defined
integrins. A good starting candidate would be Pi integrins such as VLA-4 or VLA-5
already implicated in inflammatory M(p adhesion to milky spots (Bellingan et ah,
2002). Another strategy could be to employ blocking antibodies or fAb fragments
against target integrins though the large quantity of antibody needed for effective
blockade of the whole peritoneal cavity could be a significant practical problem.
The role of the coagulation system in the apoptotic cell-induced MDR also merits
further investigation. The coagulation cascade is rapidly activated during injury -
physical and inflammatory - and certainly is capable of inducing the apoptotic cell-
induced MDR. Further evidence for a role for the coagulation system in the
apoptotic cell induced MDR could be obtained by using warfarin to disable
coagulation. Then more defined experiments could be performed to investigate the
role of individual components of the coagulation cascade in the apoptotic cell-
induced MDR. Potential candidates for investigation could include factor Xlla and
plasmin, serine proteases that activate both the coagulation cascade and chemerin, a
ligand for the G-protein-coupled receptor CMKLR1 present on dendritic cells and
M(p. Chemerin recruits circulating antigen presenting cells to sites of injury
following activation by the coagulation cascade (Zabel et ah, 2005b, Zabel et al.,
2005a). Inhibitors of chemerin and genetic knockout mice are available and could be
tested as inhibitors of the apoptotic cell-induced MDR.
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The process by which Mcp leave the omentum and emigrate to regional lymph nodes
appears to be slower than the immediate Mcp disappearance reaction but nevertheless
there could still be shared mechanistic elements. For example, Bellingan
demonstrated that Pi integrins were involved in both the initial rapid binding ofMcp
to peritoneal milky spots and their subsequent emigration, despite the fact that the
first process occurred over minutes and the second over days (Bellingan et al., 2002).
Therefore future work should examine a role for integrins not only in the immediate
MDR but also in subsequent emigration of peritoneal Mcp to draining lymph nodes.
Chemokines are likely to play a role in the emigration ofMcp to draining lymph
nodes. Recent work showed that the expression of CCR7 on dendritic cells was
increased following contact with apoptotic tumour cells resulting in emigration of
dendritic cells to draining lymph nodes (Hirao et al., 2000). It is quite possible that a
similar mechanism governs the emigration of Mcp from the peritoneal cavity
following the MDR. The hypothesis that chemokines were involved in the
emigration of peritoneal Mcp by using pertussis toxin as a general inhibitor of
chemokines. The specific role ofCCR7 could be investigated by measuring its
expression on Mcp that have phagocytosed apoptotic cells. CCR7 knockout mice do
exist and these might be used in experiments to determine the role of CCR7 in Mcp
emigration to lymph nodes in vivo.
It is important to determine whether the MDR and subsequent Mcp emigration to
lymph nodes are peculiar to the peritoneal cavity or more generalisable phenomena.
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To determine which is the case, it should first be established whether the apoptotic
cell-induced MDR occurs other coelomic cavities. This could be done by recreating
the apoptotic cell transfer experiments described in this thesis. Further work could
investigate whether apoptotic cells induce a MDR in solid organs. In such cases in
would not be practical to directly inject apoptotic but these could be generated in situ
for example by ultraviolet irradiation of the skin or systemic administration of
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